

Table S1 Percentages of epidemiological and clinical characteristics among the confirmed patients: In/ outside of former epicenter (median, IQR)	3
Table S2 Details of hospital(s), city/cities, province(s), admission period and number of patients in each study	6
Table S3 Epidemiological characteristics of the confirmed patients in former epicenter a.....	12
Table S4 Epidemiological characteristics of the confirmed patients in former epicenter b	13
Table S5 Epidemiological characteristics of the confirmed patients outside former epicenter/ nationwide a.....	14
Table S6 Epidemiological characteristics of the confirmed patients outside former epicenter b	16
Table S7 Epidemiological characteristics of the confirmed patients outside former epicenter/ nationwide c	17
Table S8 Epidemiological characteristics of the confirmed patients outside former epicenter d	18
Table S9 Comorbidities of the confirmed patients in former epicenter a	19
Table S10 Comorbidities of the confirmed patients in former epicenter b	20
Table S11 Comorbidities of the confirmed patients outside former epicenter a.....	21
Table S12 Comorbidities of the confirmed patients outside former epicenter b	22
Table S13 Comorbidities of the confirmed patients outside former epicenter c	23
Table S14 Comorbidities of the confirmed patients outside former epicenter d	24
Table S15 Signs and symptoms on admission of the confirmed patients in former epicenter a	25
Table S16 Signs and symptoms on admission of the confirmed patients in former epicenter b.....	27
Table S17 Signs and symptoms of the confirmed patients outside of former epicenter/ nationwide a.....	28
Table S18 Signs and symptoms of the confirmed patients on admission outside of former epicenter/ nationwide b	30
Table S19 Signs and symptoms of the confirmed patients outside of former epicenter c.....	32
Table S20 Signs and symptoms on admission of the confirmed patients outside of former epicenter d	34
Table S21 Complications of the confirmed patients in/ outside of former epicenter/ nationwide	36
Table S22 Radiologic findings of the confirmed patients in former epicenter a.....	37
Table S23 Radiologic findings of the confirmed patients in former epicenter b	38
Table S24 Radiologic findings of the confirmed patients outside of former epicenter/ nationwide a.....	39
Table S25 Radiologic findings of the confirmed patients outside of former epicenter b	40
Table S26 Radiologic findings of the confirmed patients outside of former epicenter c.....	42
Table S27 Radiologic findings of the confirmed patients outside of former epicenter d	44
Table S28 Laboratory findings of the confirmed patients in former epicenter a	45
Table S29 Laboratory findings of the confirmed patients in former epicenter b.....	49
Table S30 Laboratory findings of the confirmed patients outside of former epicenter/ nationwide a	53
Table S31 Laboratory findings of the confirmed patients outside of former epicenter/ nationwide b.....	56

Table S32 Laboratory findings of the confirmed patients outside of former epicenter c.....	60
Table S33 Laboratory findings of the confirmed patients outside of former epicenter d	64
Table S34 Treatment of the confirmed patients in former epicenter.....	67
Table S35 Treatment of the confirmed patients outside of former epicenter a.....	68
Table S36 Treatment of the confirmed patients outside of former epicenter/ nationwide b.....	69
Table S37 Percentages of epidemiological and clinical characteristics among the confirmed patients: Non-severe/severe (median, IQR).....	70
Table S38 Epidemiological and clinical characteristics of the confirmed patients with severe condition or not	73
Table S39 Summary table of univariable risk factors significantly ($p < 0.05$)associated with severe condition/ICU admission	104
Table S40 Univariable risk factors significantly ($p < 0.05$) associated with severe condition.....	108
Table S41 Epidemiological and clinical characteristics of the confirmed patients with ICU admission or not.....	115
Table S42 Univariable risk factors significantly ($p < 0.05$)associated with ICU admission	120

Table S1 Percentages of epidemiological and clinical characteristics among the confirmed patients: In/ outside of former epicenter (median, IQR)

Subject	Total, %	In former epicenter, %	Outside former epicenter, %	P
Epidemiological characteristics and comorbidities				
Male	53.45(48.48-58.03)	51.45(47.93-56.05)	54.15(48.94-58.15)	0.394
Age>45-60, y	51.60(34.65-62.00)	61.50(52.95-68.50)	34.65(29.03-48.53)	0.001
Smoking history	7.00(6.55-24.00)	7.00(6.55-22.75)	14.29(6.40-26.50)	1
Exposure to confirmed patients	31.00(18.20-43.96)	/	31.00(18.20-43.96)	/
Exposure B*	51.80(30.57-66.52)	7.90(1.75-39.00)	57.97(46.03-77.90)	0.001
Severe condition	18.00(9.60-32.20)	48.30(36.00-56.20)	15.70(7.95-26.55)	0.007
Death	0.75(0-9.53)	10.70(3.68-15.43)	0(0-0.73)	0.001
Any comorbidities	48.00(31.08-58.08)	46.75(37.10-53.20)	28.60(18.10-47.50)	0.031
Hypertension	13.70(6.70-27.50)	27.50(15.00-30.00)	8.80(5.23-17.92)	0.003
Cardiovascular disease	5.20(2.68-12.25)	7.30(5.20-15.00)	2.93(2.10-6.45)	0.01
Cerebrovascular disease	2.80(2.03-4.73)	4.10(2.35-5.70)	2.25(1.40-3.33)	0.2
COPD	3.70(1.50-5.90)	2.45(1.48-9.43)	4.00(1.50-5.96)	0.864
Diabetes	9.60(5.86-12.00)	12.05(10.35-16.25)	6.70(5.00-9.80)	<0.001
Digestive disease	5.10(3.91-5.77)	5.10(4.55-9.55)	4.56(3.64-5.77)	0.686
Chronic liver disease	2.90(1.96-6.00)	2.90(2.00-5.70)	2.82(1.62-10.03)	0.694
Immunodeficiency/HIV	1.40(0.10-4.45)	3.65(1.40-5.90)	0.20(0-3.00)	0.4
Malignancy	2.00(1.00-5.28)	2.50(1.00-6.38)	1.67(0.99-4.50)	0.46
Chronic kidney disease	2.00(1.33-2.85)	2.80(1.20-3.40)	1.98(1.43-2.30)	0.556
Signs, symptoms and complications				
Fever	83.15(76.13-92.15)	91.10(81.40-96.00)	79.38(75.60-87.55)	0.073
Highest temperature > 39°C	10.00(4.10-15.72)	17.70(9.60-34.00)	7.55(3.85-13.33)	0.112
Chills	11.30(9.10-14.79)	/	11.30(9.10-14.79)	/
Cough	62.60(50.00-75.38)	65.25(50.00-75.25)	62.55(49.05-75.75)	0.708
Sputum production	18.10(13.00-34.69)	25.15(7.03-30.10)	17.90(14.00-38.80)	0.733

Dyspnea	14.30(7.70-28.00)	31.10(17.93-56.00)	10.70(6.90-21.40)	0.003
Chest tightness	15.99(8.35-31.39)	31.25(23.70-59.00)	10.74(8.10-28.22)	0.146
Fatigue	31.70(15.68-53.93)	54.90(27.95-72.30)	28.00(15.65-44.90)	0.157
Myalgia	16.00(10.85-29.00)	14.06(10.85-34.55)	16.00(9.55-27.25)	0.974
Headache	8.57(6.60-12.80)	8.00(6.20-11.30)	9.36(6.90-14.00)	0.295
Sore throat	9.00(6.30-14.50)	5.30(3.28-15.95)	9.25(6.63-14.79)	0.29
Diarrhea	7.70(3.60-12.20)	10.10(3.00-14.00)	6.69(3.95-10.00)	0.779
Inappetence	14.67(6.43-28.50)	31.80(12.20-39.90)	7.20(4.40-25.27)	0.117
Asymptomatic infection	4.10(2.08-6.78)	3.60(1.80-5.40)	4.45(2.23-7.75)	0.429
ARDS	3.20(0-18.30)	19.60(17.00-29.00)	1.00(0-6.30)	0.024
Acute cardiac injury	7.20(0-9.70)	9.60(7.20-12.00)	0(0-7.40)	0.4
Other acute respiratory injury	0(0-8.00)	8.00(8.00-8.00)	0	0.667
Acute kidney injury	3.30(0-4.53)	3.60(3.00-7.00)	0(0-3.70)	0.4
Shock	2.35(0-7.43)	7.00(4.00-8.70)	0(0-0.70)	0.1
Secondary infection	13.75(10.00-17.50)	10.00(10.00-10.00)	17.50(17.50-17.50)	1
Radiological and laboratory findings				
Bilateral involvement	81.85(68.81-92.85)	91.15(78.30-95.45)	80.65(60.00-84.30)	0.028
Local patchy opacity	24.38(8.43-30.70)	8.80(4.90-27.20)	30.00(19.73-47.14)	0.014
Ground glass opacity	75.00(29.37-92.15)	37.35(16.70-81.25)	80.30(50.90-93.30)	0.216
Consolidation	41.80(19.45-49.73)	24.45(21.60-27.30)	43.70(19.75-58.58)	0.4
Pleural effusion	5.05(4.00-12.85)	/	5.05(4.00-12.85)	/
Pleural thickening	53.80(12.30-66.80)	/	53.80(12.30-66.80)	/
Interlobular septal thickening	60.85(45.25-77.33)	/	60.85(45.25-77.33)	/
Crazy-paving pattern	36.10(20.50-41.10)	/	36.10(20.50-41.10)	/
Air bronchogram	34.10(13.68-72.38)	/	34.10(13.68-72.38)	/
Lymph node enlargement	10.70(1.00-20.00)	/	10.70(1.00-20.00)	/
No abnormality	5.00(1.35-11.42)	0.70(0-2.75)	6.15(2.58-11.43)	0.019
White blood cell count > 10 × 10 ⁹ /L	10.00(2.80-20.00)	19.00(12.05-27.00)	5.98(1.93-9.58)	0.007
White blood cell count < 4 × 10 ⁹ /L	23.60(17.60-33.18)	23.60(19.10-33.91)	23.33(16.35-35.10)	0.826
Neutrophil count > 5.8-7 × 10 ⁹ /L	4.03(2.40-20.00)	6.68(1.56-11.80)	4.03(2.85-22.50)	0.571

Neutrophil count < 1.8-2×10 ⁹ /L	11.40(7.53-24.46)	25.00(25.00-25.00)	10.99(6.70-22.82)	0.5
Lymphocyte count < 0.8-1.5×10 ⁹ /L	50.20(33.60-62.45)	58.90(35.00-72.30)	43.00(32.90-59.52)	0.168
Hemoglobin < 110-130 g/L	37.23(29.21-43.50)	41.00(38.20-51.00)	36.25(8.10-36.25)	0.1
Platelet count < 100-150×10 ⁹ /L	12.00(7.69-17.00)	14.50(6.75-24.13)	10.99(7.69-15.38)	0.604
D-dimer > 0.5 mg/L	20.80(14.09-44.00)	36.00(17.75-45.44)	10.00(5.90-14.09)	0.095
Alanine aminotransferase > 40-50 U/L	17.00(7.90-25.65)	24.15(18.63-27.20)	8.10(5.72-21.60)	0.111
Aspartate aminotransferase >40-50 U/L	19.36(12.28-22.20)	24.00(20.60-37.00)	16.10(10.85-21.80)	0.064
LDH > 240-250 U/L	38.15(25.56-63.25)	73.00(52.00-76.00)	30.20(21.25-43.00)	0.033
Total bilirubin > 21-26 mmol/L	7.20(2.92-13.43)	8.80(3.00-18.00)	5.60(2.68-11.90)	0.7
Prothrombin time > 13.5-17 s	11.41(5.00-50.00)	27.50(5.00-50.00)	11.41(11.41-11.41)	1
Prothrombin time < 10-10.5 s	3.33(2.74-23.44)	16.45(2.90-30.00)	3.22(2.68-3.75)	0.667
Creatine kinase >185-200 U/L	8.05(7.20-10.90)	8.30(6.70-33.00)	8.03(7.30-10.45)	0.905
Serum creatinine > 73-87 μmol/L	16.30(2.25-23.23)	17.60(17.60-17.60)	9.80(1.73-25.72)	0.8
Serum creatinine >111-133 μmol/L	5.00(2.75-13.80)	10.00(3.00-17.60)	3.75(2.50-5.00)	0.4
Procalcitonin > 0.5 ng/mL	21.75(4.63-41.43)	21.75(6.50-40.30)	22.09(1.57-49.75)	0.886
Blood urea nitrogen > 8-10 mmol/L	12.00(4.25-15.65)	13.15(7.50-16.33)	2.50(2.50-2.50)	0.4
C-reactive protein > 3-6 mg/L	62.86(52.00-83.90)	83.90(64.00-91.90)	54.44(47.50-62.20)	0.021
C-reactive protein > 8-10 mg/L	60.70(52.00-75.20)	78.25(67.20-82.85)	55.00(46.00-62.86)	0.006
Treatment				
Oxygen therapy	66.70(43.75-76.00)	74.00(65.00-76.20)	43.75(21.25-78.32)	0.247
Invasive mechanical ventilation	0.70(0-8.80)	6.90(3.00-12.67)	0(0-0.35)	0.03
Non-invasive mechanical ventilation	5.40(0.34-12.48)	11.95(5.65-24.20)	0.67(0-5.30)	0.009
CRRT	5.90(2.58-8.00)	6.45(2.56-8.50)	3.70(3.70-3.70)	0.8
ECMO	2.90(0-3.00)	2.90(1.45-4.00)	0	0.19
Antibiotic treatment	71.00(47.70-95.13)	91.20(78.95-99.50)	56.45(44.03-84.76)	0.065
Antiviral treatment	98.00(89.45-100.00)	93.00(76.60-98.00)	100.00(92.72-100.00)	0.109
Corticosteroid therapy	26.35(14.63-41.40)	30.90(22.00-50.00)	15.00(8.95-28.35)	0.055
Intravenous immunoglobulin therapy	20.00(12.75-32.10)	27.00(10.80-32.10)	17.25(13.19-41.75)	1
Antifungal treatment	0(0-15)	15.00(15.00-15.00)	0	0.667
TCM	84.65(3.54-93.85)	43.25(2.90-83.60)	88.75(24.24-97.95)	0.267

ICU	13.75(1.50-24.15)	23.50(20.30-29.05)	2.00(0-9.35)	0.008
Percentage of patients in severe condition or not of each subject is in median and interquartile ranges (IQR). Exposure B*: Exposure to the Huanan Seafood Market for studies conducted in former epicenter, and exposure to former epicenter for studies outside of former epicenter. COPD: Chronic obstructive pulmonary disease; ARDS: Acute respiratory distress syndrome; LDH: Lactate dehydrogenase; CRRT: Continuous renal replacement therapy; ECMO: Extracorporeal membrane oxygenation; TCM: Traditional Chinese medicine; ICU: Intensive unit care.				

Table S2 Details of hospital(s), city/cities, province(s), admission period and number of patients in each study

	Study	Hospital	City	Province	Admission period	Number
In former epicenter	Huang 2020 A	Jinyintan Hospital	Wuhan	Hubei	Dec 16 th , 2019- Jan 2 th , 2020	41
	Chen 2020 A	Jinyintan Hospital	Wuhan	Hubei	Jan 1 th , 2020- Jan 20 th , 2020	99
	Wang 2020 A	Wuhan University Zhongnan Hospital	Wuhan	Hubei	Jan 1 th , 2020- Jan 28 th , 2020	138
	Huang 2020 B	Wuhan University Zhongnan Hospital	Wuhan	Hubei	Dec 21 th , 2020- Jan 28 th , 2020	34
	Chen	Tongji Hospital affiliated to Tongji Medical College of	Wuhan	Hubei	Jan, 2020	29

	2020 B	Huazhong University of Science and Technology				
Zhang 2020 B		No. 7 Hospital of Wuhan	Wuhan	Hubei	Jan 16 th , 2020- Feb 3 th , 2020	140
Mao 2020 A		Main District, West Branch, and Tumor Center of the Union Hospital of Huazhong University of Science and Technology	Wuhan	Hubei	Jan 16 th , 2020- Feb 19 th , 2020	214
Cao 2020		Wuhan University Zhongnan Hospital	Wuhan	Hubei	Jan 3 th , 2020-Feb 1 th , 2020	102
Li 2020 A		the Department of Thoracic Surgery of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei	Jan 1 th , 2020-Feb 20 th , 2020	25
Liu 2020 A		Nine tertiary hospitals in Hubei province	Wuhan, Shiyan, Jingzhou, Yichang, Xiaogan and Enshi	Hubei	Dec 30 th , 2020- Jan 24 th , 2020	137
Wang 2020 B		Xiaogan Hospital	Xiaogan	Hubei	Jan 25 th , 2020- Feb 9 th , 2020	114
Bin 2020		Wuhan Huangpi district hospital of traditional Chinese medicine	Wuhan	Hubei	Jan 29 th , 2020- Feb 16 th , 2020	55
Chen 2020 D		Wuhan east lake district people's hospital	Wuhan	Hubei	Jan 3 th , 2020-Feb 7 th , 2020	64
Wang 2020 C		Yangtze river shipping general hospital	Wuhan	Hubei	Jan 20 th , 2020- Feb 14 th , 2020	96
Din 2020		Wuhan central hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei	Jan 1 th , 2020-Feb 3 th , 2020	56
One province outside of former epicenter	Chang 2020	1. Beijing Tsinghua Changgung Hospital; 2. Beijing Anzhen Hospital; 3.Chinese PLA General Hospital	Beijing		Jan 16 th , 2020- Jan 29 th , 2020	13
	Tian 2020	Beijing Emergency Medical Service (EMS)			Jan 20 th , 2020- Feb 10 th , 2020	262
	Yu 2020	The fifth medical center of PLA general hospital			Jan 21 th , 2020-	25

	A				Feb 2 th , 2020	
Chen 2020 C	Shanghai Public Health Clinical Center (SPHCC)	Shanghai			Jan 20 th , 2020- Feb 6 th , 2020	249
Peng 2020	Zhoupu Hospital				Jan 23 th , 2020- Feb 16 th , 2020	11
Dai 2020	13 tertiary hospitals in Jiangsu Province	Not reported	Jiangsu Province		Jan 10 th , 2020- Feb 7 th , 2020	234
Wu 2020 A	1. the First People's Hospital of Yancheng City; 2. the second People's Hospital of Yancheng City; 3. the Fifth People's Hospital of Wuxi	Yancheng, Wuxi			Jan 22 th , 2020- Feb 14 th , 2020	80
Xu 2020 D	the Third Hospital of Changzhou	Changzhou			Jan 22 th , 2020- Feb 18 th , 2020	51
Huang 2020 C	The second people's hospital of Guangdong province	Guangzhou	Guangdong		Jan 23 th , 2020- Feb 14 th , 2020	35
Xu 2020 C	Guangzhou Eighth People's Hospital				Jan 23 th , 2020- Feb 4 th , 2020	90
Liu 2020 C	Six tertiary hospitals in Anhui Province	Not reported	Anhui		Jan 21 th , 2020- Feb 3 th , 2020	73
Li 2020 C	Fuyang second people's hospital	Fuyang			Feb 5 th , 2020- Feb 27 th , 2020	49
Xu 2020 E	The first affiliated hospital of Bengbu medical college	Bengbu			Jan 21 th , 2020- Feb 8 th , 2020	32
Liu 2020 D	Wenzhou sixth people's hospital	Wenzhou	Zhejiang		Jan 17 th , 2020- Feb 19 th , 2020	42
Qian 2020	Five tertiary hospitals in Anhui Province	Not reported			Jan 20 th , 2020- Feb 11 th , 2020	91
Xu 2020 A	1. First Affiliated Hospital, Zhejiang University; 2. Wenzhou Central Hospital; 3. Enze Medical Center(Group) Enze Hospital; 4. First People's Hospital of Wenling;	Hangzhou, Wenzhou, Taizhou, Wenling, Zhoushan and Ningbo			Jan 10 th , 2020- Jan 26 th , 2020	62

		5. Affiliated Zhoushan Hospital, Wenzhou Medical University; 6. Affiliated Yinzhou Hospital, Ningbo University; 7. TaiZhou Hospital				
Yang 2020	1. Wenzhou central hospital; 2. Ruian people's hospital; 3. Yueqing people's hospital	Wenzhou		Jan 17 th , 2020- Feb 10 th , 2020	149	
Wang 2020 D	Jinhua city central hospital	Jinhua		Jan 22 th , 2020- Feb 7 th , 2020	17	
Yu 2020 B	Hangzhou xixi hospital	Hangzhou		Jan 20 th , 2020- Feb 12 th , 2020	87	
Lo 2020	the Centro Hospitalar Conde de São Januário (CHCSJ)	Macau	Macau	Jan 21 th , 2020- Feb 16 th , 2020	10	
Tang 2020	Chongqing public health medical treatment center	Chongqing		Jan 24 th , 2020- Feb 4 th , 2020	83	
Wan 2020	the Chongqing University Three Gorges Hospital			Jan 23 th , 2020- Feb 8 th , 2020	135	
Wu 2020 B	1. Chongqing Three Gorges Central Hospital; 2. The Second Affiliated Hospital of Chongqing Medical University			Jan 2020-Feb 2020	80	
Zhao 2020	The database of the Radiology Quality Control Center, Hunan	Changsha, YueYang, ChangDe and Xiang-Tan	Hu'nan	Not reported	101	
Zheng 2020	the North Hospital of Changsha First Hospital (Changsha Public Health Center)	Changsha		Jan 17 th , 2020- Feb 7 th , 2020	161	
Diao 2020	West China Hospital of Sichuan University	Chengdu	Sichuan	Jan 17 th , 2020- Feb 26 th , 2020	15	
Liang 2020 B	To the first affiliated hospital of He'nan university of science and technology	Luoyang	He'nan	From Jan 22 th	28	
Lv 2020	1. Tianjin third central hospital; 2. Tianjin fourth central hospital;	Tianjin		Jan 20 th , 2020- Feb 12 th , 2020	17	

		3. The second hospital of Tianjin medical university				
	Mao 2020 B	Ankang hospital of infectious diseases	Ankang	Shaanxi	As of Feb 18 th , 2020	24
	Xiang 2020	The first affiliated hospital of Nanchang university	Nanchang	Jiangxi	Jan 21 th , 2020-Jan 27 th , 2020	49
>1 and <30 provinces	Feng 2020	Three hospitals in Wuhan, Shanghai and Anhui	Wuhan, Shanghai and Tongling	Hubei, Shanghai and Anhui	Jan 1 th , 2020-Feb 15 th , 2020	476
	Li 2020 B	1. The second affiliated hospital of Chongqing medical university; 2. Chongqing Three Gorges Central Hospital; 3. Yanzhuang Central Hospital of Gangcheng District	Chongqing, Ji'nan	Chongqing, Shandong	Jan 2020-Feb 2020	83
	Liu 2020 B	1. The first hospital of lanzhou university; 2. Shenyang sixth people's hospital; 3. Ankang city central hospital; 4. Lishui city central hospital; 5. Zhenjiang third people's hospital; 6. Baoding people's hospital; 7. Linxia state people's hospital	Lanzhou, Shenyang, Ankang, Lishui, Zhenjiang, Baoding and Linxia	Gansu, Liaoning, Shaanxi, Zhejiang, Jiangsu, Hebei	Jan 23 th , 2020-Feb 8 th , 2020	32
	Xu 2020 B	1. The Fifth Medical Center of Chinese PLA General Hospital; 2. Affiliated Hospital of Hebei University; 3. Baoding people's hospital	Beijing, Baoding	Beijing, Hebei	Jan 2020-Feb 2020	41
	Gao 2020	1. Hospital of infectious diseases, Xianyang city central hospital; 2. Liaocheng infectious disease hospital	Xianyang, Liaocheng	Shaanxi, Shandong	1. Jan 21 th , 2020-Feb 16 th , 2020; 2. Jan 30 th , 2020-Feb 16 th , 2020	40
	Guan 2020	30 provinces in China	Nationwide		Dec 11 th , 2019-Jan 29 th , 2020	1099
30-31 provinces (nationwide)	Zhang 2020 A	31 provinces in China			As of Feb 11 th , 2020	44672

	Liang 2020 A	31 provinces in China		Nov 21 th , 2019- Jan 31 th , 2020	1590
--	-----------------	-----------------------	--	---	------

Table S3 Epidemiological characteristics of the confirmed patients in former epicenter a

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020 A	Huang 2020 B	Chen 2020 B	Zhang 2020 B	Mao 2020 A
Total	41	99	137	138	34	29	140	214
Male	30 (73%)	67 (68%)	61 (44.5%)	75 (54.3%)	14 (41.2%)	21 (72%)	71 (50.7%)	87 (40.7%)
Female	11 (27%)	32 (32%)	76 (55.5%)	63 (45.7%)	20 (58.8%)	8 (28%)	69 (49.3%)	127 (59.3%)
Median (IQR)	49 (41-58)	NR	57	56 (42-68)	NR	56	57	NR
Range	NR	21-82	20-83	22-92	26-88	26-79	25-87	NR
Age, y								
≥50	A*	67 (67%)	NR	NR	≥58: 16 (47%)	NR	98 (70%)	124 (57.9%)
< 50	A*	32 (32%)	NR	NR	< 58: 18 (53%)	NR	42 (30%)	90 (42.1%)
Mean (SD)	NR	55.5 (13.1)	55 (16)	NR	56.24 (17.14)	NR	NR	52.7 (15.5)
Huanan seafood market exposure	27 (66%)	49 (49%)	0	12 (8.7%)	NR	2 (7%)	0	NR
Smoking history	3 (7%)	B*	NR	NR	NR	2 (7%)	9 (6.4%)	NR
Time from onset of symptoms to first hospital admission	7.0(4.0-8.0)	NR	NR	7.0 (4.0-8.0)	NR	NR	8 (6-11)	NR
Incubation period	NR	NR	NR	NR	NR	NR	NR	NR
Medical staff infection	NR	0	NR	40 (29%)	NR	NR	3 (2.1%)	NR
Severe condition	NR	NR	NR	NR	NR	14 (48.3%)	NR	NR
Discharge	28 (68%)	31 (31%)	44 (32.1%)	47 (34.1%)	D*	E*	NR	NR
Hospitalization	7 (17%)	57 (58%)	77 (56.2%)	85 (61.6%)	33 (97.1%)	NR	NR	NR
Death	6 (15%)	11 (11%)	16 (11.7%)	6 (4.3%)	NR	2 (6.9%)	NR	NR

Continuous data are median (IQR) or mean (SD); Categorical data are n (N%). NR: not reported. A*: 20 (49%) of the patients were 25–49, and 14 (34%) were 50–64; B*: Two cases of old male death with a long history of smoking but no previous chronic underlying disease; C*: Mean (95th percentile): 5.2 (12.5) for all 425 cases; D*: Home isolation was reported in 1 (2.9%), and unknown in 23 (67.6%); E*: Nine cases reported as alleviated.

Table S4 Epidemiological characteristics of the confirmed patients in former epicenter b

	Cao 2020	Li 2020 A	Wang 2020 B	Bin 2020	Chen 2020 D	Din 2020	Wang 2020 C
Total	102	25	114	55	64	56	96
Male	53 (52%)	12 (48%)	58 (50.9%)	31 (56.4%)	31 (48.4%)	30 (53.6%)	46 (47.9%)
Female	49 (48%)	13 (52%)	56 (49.1%)	24 (43.6%)	33 (51.6%)	26 (46.4%)	50 (52.1%)
Median (IQR)	54 (37-67)	NR	53	NR	NR	NR	NR
Range	NR	NR	23-78	NR	28-84	24-86	NR
Age, y							
≥ 50	NR	> 51: 12 (48%)	70 (61.4%)	NR	40 (62.5%)	NR	> 60: 59 (61.5%)
< 50	NR	≤ 51 : 13 (52%)	46 (40.4%)	NR	24 (37.5%)	NR	≤ 60 : 37 (38.5%)
Mean (SD)	NR	A*	NR	53.9 (17.1)	54.55±14.04	54.6±15.5	NR
Exposure to the Huanan Seafood Market				NR	NR	4 (7.1%)	NR
Exposure to confirmed patients	47 (46.1%)	19 (76%)	90 (78.9%)	NR	NR	NR	NR
Smoking history	NR	7 (28%)	NR	NR	NR	NR	NR
Time from onset of symptoms to first hospital admission	6 (3-7)	NR	NR	NR	NR	NR	NR
Incubation period	3 (2-6)	NR	NR	NR	NR	NR	NR
Medical staff infection	24 (23.5%)	12 (48%)	NR	NR	NR	NR	NR
Hospitalized patients or outpatients	10 (9.8%)	13 (52%)	NR	NR	NR	NR	NR
Severe condition	NR	9 (36%)	NR	NR	NR	NR	54 (56.2%)
Discharge	85 (83.3%)	20 (80%)	NR	10 (18.2%)	NR	11 (19.6%)	86 (89.6%)
Hospitalization	0	NR	NR	NR	45 (80.4%)	0	NR
Death	17 (16.7%)	5 (20%)	NR	1 (1.8%)	NR	0	10 (10.4%)
Others	BMI, kg/m ² : 24.4 (21.8-26.0)						

Continuous data are median (IQR) or mean (SD); Categorical data are n (N%). NR: not reported. A*: 60.2 (5.6%) for hospitalized patients and 35.8 (9.2%) for health care staff.

Table S5 Epidemiological characteristics of the confirmed patients outside former epicenter/ nationwide a

	Xu 2020 A	Chang 2020	Guan 2020	Liu 2020 B	Yang 2020	Tian 2020	Wu 2020	Xu 2020 B	Zhang 2020 A
Total	62	13	1099	32	149	262	80	50	44672
Male	35(56%)	10(77%)	640(58.2%)	20(62.50%)	81(54%)	127(48.5%)	39(48.75%)	29(58%)	22981(51.4%)
Female	27(44%)	3(23%)	459/1096(41.9%)	12(37.50%)	68(46%)	135(51.5%)	41(51.25%)	21(42%)	21691(48.6%)
Median(IQR)	41(32-52)	34(34-48)	47.0(35.0-58.0)	38.50(26.25-45.75)	NR	47.5(1-94)	46.1(30.7-61.5)	NR	NR
Range	NR	NR	NR	NR	NR	1-94	NR	3-85	NR
Age, y	≥50	>40: 27(43%)	NR	445/1011(44%)	NR	NR	≥45: 139(53.1%)	28(35%)	>50: 15(30%)
	≤40:								
	<50	35(56%)	NR	566/1011(56%)	NR	NR	<45: 123(46.9%)	52(65%)	≤50: 35(70%)
Mean(SD)	NR	NR	NR	NR	45.11(13.35)	NR	46.10(15.42)	43.9(16.8)	NR
Exposure to confirmed patients	NR	NR	NR	NR		NR	NR	NR	NR
Exposure to the former epicenter	23(37%)	12(92.3%) A*	193/616(31.3%)	NR	80(53.69%) B*	53(20.2%)	100% C*	30(60%)	7753/ 11302(68.6%) D*
Smoking history	NR	NR	158/1085(14.6%)	NR	NR	NR	NR	NR	NR
Time from onset of symptoms to first hospital admission	2.0(1.0-4.3)	NR	NR	NR	6.8(5.0)	4.5(3.7)	NR	NR	NR
Incubation period	4(3-5)(n=56)	NR	4.0(2.0-7.0)	NR	NR	6.7(5.2)	NR	NR	NR
Medical staff infection	NR	NR	23(2.09%)	NR	0	NR	0	NR	1716(3.8%)
Severe condition	NR	NR	173(15.74%)	NR	0	46(17.6%)	3(3.75%)	NR	8255/ 44415(18.5%)
Discharge	1(2%)	13(100%) E*	55(5%)	NR	73(48.99%)	45(17.2%)	61(76.25%)	NR	NR
Hospitalization	61(98%)	0	1029(93.7%)	NR	76(51.01%)	214(81.7%)	21(23.75%)	NR	NR
Death	0	0	15(1.37%)	NR	0	3/342(0.9%)	0	NR	1023(2.3%)

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported; A*: Either visited or had family members visited Wuhan; B*: With stayed in Hubei Province except Wuhan for 5(3.36%), contacted with people from Hubei Province for 49(32.89%) and no relation with Hubei Province for 15(10.06%); C*: All with a history of epidemic in Wuhan.

D*: Patients who had contacted with people from Wuhan were included; E*: All the 13 patients were recovered, but 12 were still being quarantined in hospital.

Table S6 Epidemiological characteristics of the confirmed patients outside former epicenter b

	Huang 2020 C	Xu2020 C	Liu2020 D	Qian 2020	Chen 2020 C	Peng 2020	Liu 2020 C	Dai 2020	Xu 2020 D	Wan 2020
Total	35	90	42	91	249	11	73	234	51	135
Male	19(54.3%)	39(43%)	23(54.8%)	37(40.66%)	126(50.6%)	5(45.5%)	41(56.2%)	136(58.1%)	25(49%)	72(53.3%)
Female	16(45.7%)	51(57%)	19(45.2%)	54(59.34%)	123(49.4%)	6(54.5%)	32(43.8%)	98(41.9%)	26(51%)	63(46.7%)
Median(IQR)	41(32-52)	50	NR	50(36.5-57)	51(36-64)	NR	NR	NR	A*	47(36-55)
Range	12-74	18-86	NR	NR	NR	NR	NR	7-82	NR	3-85
Age, y										
≥50	NR	NR	NR	47(51.6%)	NR	NR	NR	92(39.3%)	NR	NR
<50	NR	NR	NR	44(48.4%)	NR	NR	NR	142(60.7%)	NR	NR
Mean(SD)	44(15.17)	NR	42.5	NR	NR	40.73(11.32)	B*	NR	NR	NR
Exposure to confirmed patients	15(42.86%)		13(31%)	40(43.96%)	NR	2(18.2%)	16(21.9%)	78(33.3%)	NR	23(17.0%) C*
Exposure to the former epicenter	20(57.14%)	86(96%)	20(47.6%)	31(34.07%) D*	NR	7(63.6%)	54(74%)	133(56.8%)	15(29.4%)	71(52.6%)
Smoking history	5(14.29%)	NR	NR	NR	NR	NR	NR	NR	NR	9(6.7%) E*
Time from onset of symptoms to first hospital admission	NR	NR	1-14(mean=7.02)	NR	4(2-7)	NR	NR	NR	NR	NR
Incubation period	NR	NR	NR	6(3-8)	NR	NR	NR	NR	NR	NR
Medical staff infection	NR	NR	NR	0	NR	NR	NR	3(1.3%)	NR	NR
Severe condition	NR	NR	4(9.5%)	9(9.9%)	NR	NR	24(32.9%)	15(6.4%)	0	40(29.6%)
Discharge	NR	NR	42(100%)	31(34.07%)	215(86.3%)	NR	Recovered: 12(16.4%)	NR	NR	120(88.9%)
Hospitalization	NR	NR	NR	60(65.93%)	32(12.9%)	NR	NR	NR	NR	NR
Death	NR	NR	0	0	2(0.8%)	NR	NR	NR	0	1(0.7%)

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported; A*: 35.0(29.0-51.0) for imported cases(n=15), 37.0(24.0-47.5) for secondary cases(n=17) and 53.0(35.0-65.0) for tertiary cases(n=19). B*: 29.2 ± 10.9 in mild type(n=6), 33.4 ± 12.2 in common type(n=43), 44.2 ± 12.0 in severe type(n=21), 63.0 ± 21.2 in critical type(n=3). C*: Contact with suspected patients in epidemic area 19(14.1%). D*: And vehicle exposure(e.g. airplane, coach, ship): 11(12.09%), contact with Wuhan personnel: 8(8.79%). E*: Current smoking 9(6.7%).

Table S7 Epidemiological characteristics of the confirmed patients outside former epicenter/ nationwide c

	Li 2020 B	Wu 2020 B	Tang 2020	Zheng 2020	Zhao 2020	Lo 2020	Feng 2020	Liang 2020 A	Diao 2020	Gao 2020
Total	83	80	83	161	101	10	476	1590	15	40
Male	44(53%)	42(52%)	44(53%)	80(49.7%)	56(55.4%)	3(30%)	271(56.9%)	904/1578(57.3%)	8(53.3%)	19(47.5%)
Female	39(47%)	38(48%)	39(47%)	81(50.3%)	45(44.6%)	7(70%)	205(43.1%)	674/1578(42.7%)	7(46.7%)	21(52.5%)
Median(IQR)	NR	50	NR	45(33.5-57)	NR	54(27-64)	53(40-64)	NR	NR	NR
Range	NR	15-79	10-77	NR	17-75	NR	NR	NR	NR	NR
Age, y	≥50	NR	NR	NR	NR	> 50: 29(28.7%)	> 60: 3(30%)	≥65: 118(24.8%)	NR	NR
	<50	NR	NR	NR	NR	≤50: 72(71.3%)	≤60: 7(70%)	< 65: 358(75.2%)	NR	NR
Mean(SD)	45.5(12.3)	44(11)	44.9(15.8)	NR	44.44	40.73(11.32)	NR	48.9(16.3)	NR	41±16.4
Exposure to confirmed patients	NR	NR	39(47%)	NR	12(11.9%)		NR	NR	B*	NR
Exposure to the former epicenter	NR	NR	38(45.8%)	104(64.6%)	84(83.2%)	A*	425(89.3%)	1334(83.9%)	7(46.7%)	16(40%)
Smoking history	NR	26(33%)	NR	NR	NR	C*	44/454(9.7%)	111(7.0%)	NR	NR
Time from onset of symptoms to first hospital admission	7(4.75-9)	7(4)	NR	6(3-8)	NR	5(1-11)	6(4-10)	NR	NR	(1-13, range),(4.9 ±3.5)
Medical staff infection	NR	NR	NR	NR	NR	0	NR	NR	NR	NR
Severe condition	25(30.1%)	NR	13(15.7%)	30(18.6%)	14(13.9%)	4(40%)	124(26.1%)	131(8.24%)	NR	1(2.5%)
Discharge	NR	NR	NR	NR	NR	5(50%)	287/300(95.7%)	NR	NR	14(35%)
Hospitalization	NR	NR	NR	NR	NR	5(50%)	11/300(3.7%)	NR	NR	26(65%)
Death	NR	NR	NR	NR	NR	0	2/300(0.7%)	50(3.14%)	NR	0

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported; A*: Visited local hospital in Wuhan, China 2(20%), visited local hospital in Zhuhai, China 1(10%). B*: Close contact with people from Wuhan or confirmed patients 5(33.3%). C*: Ex-smoker 2(20%), current smoker 0.

Table S8 Epidemiological characteristics of the confirmed patients outside former epicenter d

	Liang 2020 B	Lv 2020	Mao 2020 B	Wang 2020 D	Xiang 2020	Xu 2020 E	Yu 2020 A	Yu 2020 B	Li 2020 C
Total	28	17	24	17	49	32	25	87	49
Male	16(57.1%)	12(70.6%)	14(58.3%)	10(58.8%)	33(67.3%)	19(59.4%)	16(64%)	40(46%)	28(57.1%)
Female	12(42.9%)	5(29.4%)	10(41.7%)	7(41.2%)	16(32.7%)	13(40.6%)	9(36%)	47(54%)	21(42.9%)
Median(IQR)	NR	NR	NR	NR	NR	NR	NR	NR	45(32-60)
Range	24-87	28-75	4-83	19-86	18-78	NR	3-79	4-88	14-82
Age, y	≥50	> 60: 11(39.3%)	NR	NR	NR	NR	> 45: 8(22%)	NR	NR
	<50	≤60: 17(60.7%)	NR	NR	NR	NR	≤45: 17(68%)	NR	NR
Mean(SD)	51.75(19.74)	52.6(11.6)	43.1	42.1(16.6)	42.9	52(31)	37.9(17.1)	42.89±17.02	NR
Exposure to confirmed patients	3(10.7%)	NR	5(20.8%)	7(41.2%)	NR	21(65.6%)	2(8%)	17(19.5%)	34(69.4%)
Exposure to the former epicenter	10(35.7%)	NR	19(79.2%)	10(58.8%)	46(93.9%)	NR	23(92%)	58(66.7%)	25(51%)
Smoking history	NR	NR	NR	NR	3(6.1%)	NR	NR	NR	NR
Incubation period	NR	NR	NR	1-11(5.5 ± 3.1)	4.7(1-13, range)	NR	5.5±3(3-13,range)	6.30±3.99,(range, 1~26)	6(2-11, range)
Severe condition	4(14.3%)	4(23.5%)	NR	2(11.8%)	9(18.4%)	6(18.8%)	NR	5(5.7%)	27(55.1%)
Discharge	NR	NR	NR	11(64.7%)	NR	NR	1(4%)	NR	49(100%)
Hospitalization	NR	NR	NR	NR	NR	NR	23(92%)	NR	0
Death	NR	NR	NR	NR	NR	NR	1(4%)	NR	0

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported; A*: Close contact with family members from Wuhan to Luoyang 3(10.7%), close contact with family members in fever 1(3.6%).

Table S9 Comorbidities of the confirmed patients in former epicenter a

	Huang 2020 A	Chen 2020 A	Liu 2020 A Hubei	Wang 2020 A	Huang 2020 B	Chen 2020 B	Zhang 2020 C	Mao 2020 A
Any comorbidity	13(32%)	50(51%)	27(19.7%)	64(46.4%)	16(47.1%)	16(55%)	90(64.3%)	83(38.8%)
Hypertension	6(15%)	NR	13(9.5%)	43(31.2%)	8(23.5%)	8(28%)	42(30.0%)	51(23.8%)
Diabetes	8(20%)	12(12%)	14(10.2%)	14(10.1%)	4(11.8%)	5(17%)	17(12.1%)	30(14.0%)
Cardiovascular disease	6(15%)		10(7.3%)	20(14.5%)	6(17.6%)	NR	B*	15(7.0%)
Cerebrovascular disease	NR	40(40%) A*	NR	7(5.1%)	NR	NR	3(2.1%)	A*
COPD	1(2%)	NR	2(1.5%)	4(2.9%)	2(5.9%)	NR	2(1.4%)	NR
Malignancy	1(2%)	1(1%)	2(1.5%)	10(7.2%)	3(8.8%)	1(3%)	NR	13(6.1%)
Chronic liver disease	1(2%)	NR	NR	4(2.9%)	1(2.9%)	2(6%)	8(5.7%)	NR
Chronic kidney disease	NR	NR	NR	4(2.9%)	NR	NR	2(1.4%)	6(2.8%)
Immunodeficiency/HIV	NR	NR	NR	2(1.4%)	2(5.9%)	NR	NR	NR
Others	NR	Digestive system disease 11(11%)	Other chronic diseases: 24(17.5%)	NR	Hyperuricemia: 1(2.9%); Hypothyroidism: 2(5.9%)	After lung cancer surgery: 1(3%)	Hyperlipidemia: 7(5.0%); Cholelithiasis: 6(4.3%); Arrhythmia: 5(3.6%); Thyroid diseases: 5(3.6%); Electrolyte imbalance: 4(2.9%); Urolithiasis: 3(2.1%); Secondary pulmonary tuberculosis: 2(1.4%); Chronic gastritis and gastric ulcer: 7(5.0%)	NR

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; A*: Cardiovascular and cerebrovascular diseases; B*: Reported as aorta sclerosis 2(1.4%) and coronary heart disease 7(5.0%).

Table S10 Comorbidities of the confirmed patients in former epicenter b

	Cai 2020	Li 2020 A	Wang 2020 B	Wang 2020 C
Any comorbidity	47(46.1%)	NR	60(52.6%)	NR
Hypertension	28(27.5%)	2(8%)	33(28.9%)	50(52.1%)
Diabetes	11(10.8%)	1(4%)	15(13.2%) A*	25(26.1%)
Cardiovascular disease	5(4.9%)	B*	7(6.1%)	5(5.2%)
Cerebrovascular disease	6(5.9%)	NR	NR	3(3.1%)
COPD	NR	5(20%)	NR	Chronic bronchitis or COPD: 15(15.6%)
Other respiratory diseases	10(9.8%)		5(4.4%)	
Digestive diseases			5(4.4%)	Gastritis: 5(5.2%)
Malignancy	4(3.9%)	NR	1(0.9%)	1(1%)
Chronic liver disease	2(2%)	NR	NR	1(1%)
Chronic kidney disease	4(3.9%)	NR	NR	1(1%)
Others		NR	Neural system diseases:1(0.9%).	Hyperthyroidism: 2(2.1%); Phlebothrombosis: 2(2.1%).

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; A*:Endocrine system diseases. B*: Coronary heart disease: 4(16%).

Table S11 Comorbidities of the confirmed patients outside former epicenter a

	Xu 2020 A	Guan 2020	Liu 2020 B	Yang 2020	Wu 2020 A	Zhang 2020 A
Any comorbidity	20(32%)	261(23.7%)	NR	52(34.9%)	38(47.50%)	5446/20982(26%)
Hypertension	5(8%)	165(15.0%)	1(3.13%)	NR	NR	2683/20982(12.8%)
Diabetes	1(2%)	81(7.4%)	NR	9(6.04%) A*	5(6.25%) A*	1102/20982(5.3%)
Cardiovascular disease	NR	NR	1(3.13%)	28(18.79%) B*	25(31.25%) B*	873/20982(4.2%)
Cerebrovascular disease	1(2%)	15(1.4%)	NR			NR
COPD	1(2%)	12(1.1%)	NR	NR	0	NR
Malignancy	NR	10(0.9%)	2(6.25%)	2(1.34%)	1(1.25%)	107/20982(0.5%)
Respiratory system diseases	NR	NR	1(3.13%)	1(0.67%)	1(1.25%)	511/20982(2.4%)
Chronic liver disease	7(11%) C*	NR	1(3.13%)	NR	1(1.25%)	NR
Chronic kidney disease	1(2%) E*	8(0.7%)	NR	NR	1(1.25%)	NR
Immunodeficiency/HIV	NR	2(0.2%)	NR	NR	0	NR
Others	NR	Hepatitis B infection: 23(2.1%)	NR	Digestive system diseases: 8(5.37%); Neural system diseases: 0(0%); Others: 4(2.68%)	Digestive system disease: 3(3.75%); Nervous system diseases: 1(1.25%)	NR

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; A*: Endocrine diseases. B*: Cardiovascular and cerebrovascular diseases; C*: Reported as liver disease; D*: Alcoholic hepatitis; E*: Reported as renal disease.

Table S12 Comorbidities of the confirmed patients outside former epicenter b

	Huang 2020 C	Xu 2020 C	Liu 2020 D	Qian 2020	Chen 2020 C	Xu 2020 D	Wan 2020	Li 2020 B
Any comorbidity	4(11.43%)	45(50%)	NR	NR	90(36.1%)	12(23.5%)	43(31.9%)	15(18.1%)
Hypertension	1(2.86%)	17(19%)	9(21.4%)	15(16.48%)	1(5.9%)	NR	13(9.6%)	5(6%)
Diabetes	2(5.71%)	5(6%)	2(5%)	8(8.79%)	25(10.0%) A*	4(7.8%)	12(8.9%)	7(7.8%)
Cardiovascular disease	1(2.86%) B*	3(3%)	NR	3(3.30%) C*	55(21.7%) C*	NR	7(5.2%)	1(1.2%)
Cerebrovascular disease	NR	NR	NR			NR	NR	NR
COPD	2(5.71%)	1(1%)	NR	NR	NR	NR	4(10%)	5(6%)
Malignancy	NR	10(0.9%)	NR	NR	1(0.4%)	NR	4(3.0%)	NR
Respiratory system diseases	NR	Tuberculosis: 2(2%)	NR	NR	5(2.0%)	1(1.96%)	1(0.7%)	NR
Chronic liver disease	NR	NR	3(7.1%)	NR	NR	1(1.96%)	2(1.5%)	NR
Chronic kidney disease	NR	NR	1(2.4%)	NR	NR	1(1.96%)	NR	NR
Others	Others: 15(17%)		Digestive system diseases: 9(3.6%); Chronic hepatitis B virus infection: 2(0.8%)					

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; A*: Endocrine diseases. B*: Coronary heart disease. C*: Cardiovascular and cerebrovascular diseases.

Table S13 Comorbidities of the confirmed patients outside former epicenter c

	Wu 2020 B	Tang 2020	Zheng 2020	Zhao 2020	Lo 2020	Feng 2020	Liang 2020 A	Diao 2020	Gao 2020
Any comorbidity	15(18%)	16(19.3%)	33(20.5%)	40(69.7%)	5(50%)	205(43.1%)	399(25.1%)	2(13.3%)	14(35%)
Hypertension	4(5%)	6(7.2%)	22(13.7%)	NR	3(30%)	113(23.7%)	269(16.9%)	1(6.7%)	2(5%)
Diabetes	4(5%)	8(9.6%)	7(4.3%)	3(3.0%) A*	NR	49(10.3%)	130(8.2%)	1(6.7%)	4(10%)
Cardiovascular disease	1(1%)	2(2.4%)	4(2.5%)	16(15.8%) B*	NR	38(8%)	59(3.7%)	NR	NR
Cerebrovascular disease	NR	1(1.2%)	4(2.5%)		NR	17(3.6%)	30(1.9%)	NR	NR
COPD	3(4%)	NR	6(3.7%)	NR	NR	22(4.6%)	24(1.5%)	NR	NR
Malignancy	NR	NR	NR	NR	NR	12(2.5%)	18(1.1%)	NR	2(5%)
Respiratory system diseases	0	3(3.6%)	NR	5(4.9%)	NR	NR	NR	NR	NR
Chronic liver disease	NR	NR	4(2.5%)	NR	NR	NR	NR	NR	NR
Hepatitis B infection	NR	2(2.4%)	NR	NR	Past: 1(10%)	NR	28(1.8%)	NR	2(5%)
Chronic kidney disease	NR	NR	NR	NR	NR	4(0.8%)	21(1.3%)	NR	NR
Immunodeficiency/HIV	Immunosuppression: 3(3%)	NR	NR	NR	NR	Immunosuppression: 7(1.5%)	3(0.2%)	NR	NR
Others	Hyperlipidemia: 1(1.2%); Gout: 2(2.4%);		Surgical history: 7(6.9%); Digestive system disease: 6(5.9%);	Dyslipidemia: 2(20%).	Others: 103(21.6%)			Surgical history: 2(5%).	

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; A*: Endocrine diseases. B*: Cardiovascular and cerebrovascular diseases.

Table S14 Comorbidities of the confirmed patients outside former epicenter d

	Li 2020 C	Liang 2020 B	Mao 2020 B	Wang 2020 D	Xiang 2020	Yu 2020 A
Any comorbidity	NR	18(64.3%)	3(12.5%)	NR	14(28.6%)	NR
Hypertension	9(18.4%)	9(32.1%)	NR	2(11.8%)	6(12.2%)	1(4%)
Diabetes	11(11.4%)	7(25%)	NR	NR	2(4.1%)	3(12%)
Cardiovascular disease	5(10.2%)	4(14.3%)	1(4.2%)	NR	NR	NR
Cerebrovascular disease	NR	1(3.6%)	NR	NR	NR	NR
COPD	2(4%)	NR	NR	NR	NR	NR
Malignancy	1(2%)	NR	NR	NR	NR	NR
Respiratory system diseases	0	1(3.6%)	NR	NR	NR	NR
Chronic liver disease	NR	NR	NR	NR	6(12.2%)	NR
Hepatitis B infection	3(6.1%)	NR	NR	NR	NR	NR
Chronic kidney disease	NR	NR	NR	NR	NR	NR
Immunodeficiency/HIV	NR	NR	NR	NR	NR	NR
Others	Autoimmune diseases: 1(3.6%); Surgical history: 1(3.6%). Tonsillitis: 1(4.2%); A/H1N1 influenza: 1(4.2%). Hyperlipidemia: 1(5.9%)					

Categorical data are n(N%). NR: not reported. COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus.

Table S15 Signs and symptoms on admission of the confirmed patients in former epicenter a

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020 A	Huang 2020 B	Chen 2020 B	Zhang 2020 B	Mao 2020 A
Fever	40(98%)	82(83%)	112(81.8%)	136(98.6%)	32(94.1%)	28(97%)	110/120(91.7%)	132(61.7%)
Highest temperature > 39°C	14(34%)	NR	20(17.7%)	NR	NR	NR	NR	NR
Highest temperature < 37.5°C	< 37.3°C: 1(2%)	NR	< 37.3°C: 28(25.0%)	NR	NR	NR	NR	NR
Cough	31(76%) A*	81(82%)	66(48.2%)	82(59.4%) A*	17(50.0%)	Cough and sputum production: 21(72%);	90/120(75.0%)	107(50.0%) A*
Sputum production	11/39(28%)	NR	6(4.4%)	37(26.8%)	8(23.5%)		NR	NR
Dyspnea	22/40(55%)	31(31%)	26(19.0%)	43(31.2%)	5(14.7%)	17(59%) B*	44/120(36.7%) B*	NR
Fatigue		9(9%)		96(69.6%)	Myalgia or fatigue: 22(64.7%)		90/120(75.0%)	NR
Myalgia	Myalgia or fatigue: 18(44%)	11(11%)	Myalgia or fatigue: 44(32.1%)	48(34.8%)		Myalgia or fatigue: 12(41%)	NR	23(10.7%)
Headache	3/38(8%)	8(8%)	13(9.5%)	9(6.5%)	2(5.9%)	2(7%)	NR	28(13.1%)
Hemoptysis	2/39(5%)	NR	7(5.1%)	NR	NR	NR	NR	NR
Diarrhea	1/38(3%)	2(2%)	11(8.0%)	14(10.1%)	5(14.7%)	4(14%)	18/139(12.9%)	41(19.2%)
Time from onset of symptoms to shortness of breath, d	8.0(5.0-13.0)	NR	7(1-20)	5.0(1.0-10.0)	NR	NR	NR	NR
Time from onset of symptoms to ARDS, d	9.0(8.0-14.0)	NR	NR	8.0(6.0-12.0)	NR	NR	NR	NR
Time from onset of symptoms to ICU admission, d	10.5(8.0-17.0)	NR	NR	10(6-12)	NR	NR	NR	NR
Respiratory rate	12(29%) > 24/min	NR	NR	20(19-21)	NR	6(21%) > 24/min	NR	NR
Sore throat	NR	5(5%)	NR	24(17.4%)	NR	NR	NR	31(14.5%)
Nausea or vomiting	NR	1(1%)	NR	Nausea: 14(10.1%); Vomit: 5(3.6%)	NR	NR	Nausea: 24/139(17.3%); Vomiting: 7/139(5.0%)	NR
Dizziness	NR	NR	NR	13(9.4%)	NR	NR	NR	36(16.8%)

Anorexia	NR	NR	NR	55(39.9%)	NR	NR	17/139(12.2%)	68(31.8%)
Abdominal pain	NR	NR	NR	3(2.2%)	NR	NR	8/139(5.8%)	10(4.7%)
Others	Time from onset of symptoms to mechanical ventilation, d: 10.5(7.0-14.0)	Chest pain: 2(2%); Rhinorrhea: 4(4%);	Heart palpitations: 10(7.3%);	Time from hospital admission to ICU admission, d: 1(0-3);	NR	NR	Belching: 7/139(5.0%);	C*

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. ARDS: acute respiratory distress syndrome ICU, intensive care unit. A*: Most patients with cough were dry cough in Huang 2020 A and Mao 2020, and were all dry cough in Wang 2020; B*: Chest tightness and dyspnea. C*: Impaired consciousness: 16(7.5%); Acute cerebrovascular disease: 6(2.8%); Ataxia: 1(0.5%); Seizure: 1(0.5%); Taste impairment: 12(5.6%); Smell impairment: 11(5.1%); Vision impairment: 3(1.4%); Nerve pain: 5(2.3%).

Table S16 Signs and symptoms on admission of the confirmed patients in former epicenter b

	Cao 2020	Li 2020 A	Wang 2020 B	Bin 2020	Chen 2020 D	Din 2020	Wang 2020 C
Fever	83(81.4%)	24(96%)	107(93.9%)	39(70.9%)	54(84.37%)	51(91.1%)	71(74%)
Highest temperature > 39°C	NR	NR	11(9.6%)	NR	NR	NR	NR
Highest temperature < 37.5°C	NR	< 37.3°C: 1(4%)	< 37.3°C: 5(4.4%)	NR	NR	NR	NR
Cough	Dry cough: 50(49%)	17(68%)	91(79.8%)	31(56.4%)	45(70.31%)	35(62.5%)	70(72.9%)
Sputum production	NR	NR	9(7.9%)	20(36.4%)	NR	NR	NR
Dyspnea	NR	20(80%)	27(23.7%)	3(5.5%)	NR	NR	NR
Chest tightness	NR	NR	27(23.7%)	NR	20(31.25%)	NR	NR
Fatigue	56(54.9%)	Fatigue or muscular soreness:	Myalgia or fatigue:	NR	NR	Myalgia or fatigue:	45(46.9%)
Myalgia	35(34.3%)	17(68%)	44(32.1%)	NR	9(14.06%)	29(51.8%)	NR
Headache	NR	NR	NR	NR	14(21.87%)	NR	2(2.1%)
Diarrhea	11(10.8%)	5(20%)	3(2.7%)	1(1.8%)	2(3.12%)	2(3.6%)	11(11.5%)
Sore throat	NR	NR	6(5.3%)	NR	1(1.56%)	NR	NR
Abdominal pain	NR	NR	NR	NR	NR	1(1.8%)	NR
Asymptomatic infection	NR	NR	NR	1(1.8%)	NR	3(5.4%)	NR
Others	Multiple symptom: 92(90.2%)	Surgical history: 13(52%)		Shortness of breath: 15(27.3%).			

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported.

Table S17 Signs and symptoms of the confirmed patients outside of former epicenter/ nationwide a

	Xu 2020 A	Chang 2020	Guan 2020	Liu 2020 B	Yang 2020	Tian 2020	Li 2020 B	Wu 2020 A	Xu 2020 B
Fever	48(77%)	12(92.3%)	473/1081(43.8%) A*	25(78.13%)	114(76.51%)	215(82.1%)	12(70.6%)	63(78.75%)	34(86%)
Highest temperature	8(13%)	NR	38/1081(3.5%) B*	NR	NR	9(3.4%)	NR	NR	5(10%)
>39°C									
Highest temperature <37.5°C	< 37.3°C: 14(23%)	NR	608/1081(56.2%) C*	NR	NR	< 37.3°C: 47(17.9%)	NR	NR	7(14%)
Cough	50(81%)	6(46.2%)	745(67.8%)	22(68.72%)	87(58.39%)	120(45.8%)	13(76.5%) D*	51(63.75%)	20(40%)
Sputum production	35(56%)	2(15.4%)	370(33.7))	NR	48(32.21%)	NR	3(17.6%)	NR	7(14%)
Dyspnea	NR	NR	205(18.7%)	NR	2(1.34%)	18(6.9%)	NR	30(37.50%)	4(8%) E*
Fatigue	Myalgia or fatigue:	NR	419(38.1%)	NR	NR	69(26.3%)	8(47.1%)	NR	8(16%)
Myalgia	32(52%)	3(23.1%)	Myalgia or arthralgia: 164(14.9%)	NR	5(3.36%)	NR	4(23.5%)	18(22.50%)	8(16%)
Headache	21(34%)	3(23.1%)	150(13.6%)	NR	13(8.72%)	17(6.5%)	NR	13(16.25%) F*	5(10%)
Hemoptysis	2(3%)	NR	10(0.9%)	NR	21(14.09%)	NR	NR	NR	NR
Chills	NR	NR	126(11.5%)	NR	NR	NR	NR	NR	NR
Chest pain	NR	NR	NR	NR	5(3.36%)	NR	NR	3(3.75%)	NR
Diarrhea	3(8%)	1(7.7%)	42(3.8%)	NR	11(7.38%)	NR	2(11.8%)	1(1.25%)	NR
Respiratory rate	2(3%) > 24/min	NR	NR	NR	NR	124.5(14.8%)	NR	NR	NR
Sore throat	NR	NR	153(13.9%)	NR	21(14.09%)	NR	NR	11(13.75%)	4(8%)
Rhinorrhea	NR	1(7.7%)	NR	NR	5(3.36%)	NR	2(11.8%)	5(6.10%)	NR
Nausea or vomiting	NR	NR	55(5.0%)	NR	2(1.34%)	NR	NR	1(1.25%)	NR
Throat congestion	NR	NR	19(1.7%)	NR	NR	NR	NR	NR	NR

	Oxygenation index: 379(292-448)(n=51);	Conjunctival congestion: 9(0.8%); Nasal congestion: 53(4.8); Rash: 2(0.2%); Enlargement of lymph nodes: 2(0.2%); Tonsil swelling: 23(2.1%);	Chest NR	tightness: 16(10.74%);	NR	Dizziness: 2(11.8%)	More than one sign or symptom: 66(82.50%); Time from onset of symptoms to shortness of breath, d: 8.0(5.0-13.0)	Gastrointestinal Reaction: 1(2%);
Others	Arterial oxygen pressure(mm Hg): 90(80-105)(n=51)	Upper airway congestion: 8(61.5%)						

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. A*: Fever during hospitalization: 975/1099(88.7%). B*: Highest temperature > 39°C during hospitalization:114/926(12.3%). C*: Highest temperature < 37.5°C during hospitalization:92/926(9.9%). D*: Including dry cough 7(41.2%); E*: Dyspnea and chest tightness. F*: Headache and mental disorder symptoms.

Table S18 Signs and symptoms of the confirmed patients on admission outside of former epicenter/ nationwide b

	Huang 2020 C	Xu 2020 C	Liu 2020 D	Qian 2020	Chen 2020 C	Peng 2020	Liu 2020 C	Dai 2020	Yu 2020 B	Liang 2020 A
Fever	30(85.71%)	70(78%)	35(83.3%)	65(71.43%)	217(87.1%)	10(91%)	68(93.2%)	170(72.6%)	62(71.3%)	1351/1536(88%)
Highest temperature > 39°C	6(17.14%)	NR	NR	≥ 39.1°C: 3(3.3%)	NR	NR	NR	5(10%)	NR	NR
Highest temperature < 37.5°C	NR	NR	NR	< 37.3°C: 26(28.57%)	NR	NR	NR	7(14%)	NR	NR
Cough	28(80%)	57(63%)	26(61.9%)	55(60.44%)	91(36.5%)	6(55%)	60(82.2%)	150(64.1%)	45(51.7%)	Dry cough: 1052/1498 (70.2%)
Sputum production	A*	11(12%)	NR	30(32.97%)	NR	NR	39(53.4%)	NR	NR	513/1424 (36.0%)
Dyspnea	7(20%)	NR	9(21.4%)	3(3.3%)	19(7.6%)	0	NR	7(3%)	NR	331 (20.8%)
Shortness of breath	8(22.86%)	NR	NR	10(10.99%)	NR	NR	NR	5(2.1%)	NR	NR
Fatigue	14(40%)	19(21%)	14(33.3%)	40(43.96%)	39(15.7%)	NR	55(75.3%)	31(13.2%)	6(6.9%)	584/1365 (42.8%)
Myalgia	15(42.86%)	25(28%)	5(11.9%)	5(5.49%)	NR	Systemic soreness: 7(64%)	NR	21(9%)	NR	Myalgia or arthralgia: 234/1338 (17.5%)
Headache	3(8.57%)	4(4%)	2(4.7%)	7(7.69%)	28(11.2%) B*	NR	NR	NR	NR	205/1328 (15.4%)
Hemoptysis	NR	NR	NR	NR	NR	NR	NR	NR	NR	16/1315(1.2%)
Chills	5(14.29%)	6(7%)	NR	NR	NR	NR	NR	23(9.8%)	NR	163/1333 (12.2%)
Chest pain	NR	NR	NR	NR	NR	NR	NR	8(3.4%)	NR	NR
Chest distress	11(31.43%)	NR		17(18.68)	NR	NR	NR	13(5.6%)	6(6.9%)	NR
Diarrhea	9(25.71%)	5(6%)	6(14.2%)	21(23.08%)	8(3.2%)	NR	NR	9(3.8%)	4(4.6%)	57/1359 (4.2%)
Inappetence	6(17.14%)	NR	NR	Anorexia: 23(25.27%)	8(3.2%)	NR	20(27.4%)	NR	NR	NR

Abdominal pain	NR	NR	1(2.3%)	NR	NR	NR	NR	NR	distention/pain: 3(3.5%)	NR
Sore throat	10(28.57%)	23(26%)	4(9.5%)	NR	16(6.4%)	1(9%)	NR	NR	6(6.9%)	194/1317 (14.7%)
Rhinorrhea	NR	NR	NR	NR	17(6.8%)	0	NR	13(5.6%)	3(3.5%)	NR
Nausea or vomiting	NR	Nausea: 5(6%); Vomiting: 2(2%)	Nausea: 4(9.5%)	11(12.09%); Vomiting: 6(6.59%)	NR	NR	NR	Nausea and vomiting: 5(2.1%)	NR	80/1371 (5.8%)
Asymptomatic infection	NR	6(7%)	NR	NR	7(2.8%)	NR	NR	NR	2(2.3%)	73(4.6%)
Others	Constipation: 2(5.71%); Bitter taste: 4(11.43%); Thirst: 2(5.71%).		Back discomfort: 3(3.3)			pharyngeal discomfort: 35(15%).	Dry throat: 6(6.9%).	Unconsciousness: 20/1421 (1.4%); Conjunctival congestion: 10/1345 (0.7%); Tonsil swelling: 31/1376 (2.3%); Lymphadenectomy: 2/1375 (0.1%); Rash: 3/1378 (0.2%); Throat congestion: 21/1286 (1.6%).		

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. A*: White phlegm 8(22.86%), yellow sputum 9(25.71%). B*: Dizziness and headache.

Table S19 Signs and symptoms of the confirmed patients outside of former epicenter c

	Feng 2020	Xu 2020 D	Wan 2020	Li 2020 B	Wu 2020 B	Tang 2020	Zheng 2020	Zhao 2020	Lo 2020	Yu 2020 A
Fever	390/454(85.9%)	34(66.7%)	120(88.9%)	72(86.7%)	61(76%)	72(86.7%)	122(75.8%)	79(78.2%)	8(80%)	18(72%)
Highest temperature >39°C	NR	NR	7(5.1%)	NR	3(4%)	NR	NR	NR	NR	NR
Highest temperature <37.5°C	NR	< 38°C: 18(35.3%)	< 37.3°C: 16(11.9%)	NR	< 37.3°C: 19(24%)	NR	NR	NR	NR	NR
Cough	Dry cough: 269/453(59.4%)	23(45.1%)	102(76.5%)	65(78.3%)	58(73%)	60(72.3)	101(62.7%)	63(62.4%)	5(50%)	Dry cough: 21(84%)
Sputum production	161/453(35.5%)	13(25.5%)	12(8.8%)	15(18.1%)	11(14%)	34(41.0)	NR	NR	NR	4(16%)
Dyspnea	109/447(24.4%)	4(7.8%)	18(13.3%)	9(10.8%)	7(9%)	7(8.4%)	23(14.3%)	1(1.0%)	5(50%)	NR
Shortness of breath	NR	NR	Chest tightness and shortness of breath: 12(8.8%)	NR	NR	19(22.9)	NR	NR	NR	NR
Fatigue	NR	2(3.9%)	Fatigue or myalgia: 44(32.5%)	NR	NR	25(30.1)	64(39.8%)	Fatigue or myalgia:	NR	7(28%)
Myalgia	55/438(12.6%)	8(15.7%)		15(18.1%)	13(16%)	12(14.5)	18(11.2%)	17(16.8%)	3(30%)	6(24%)
Headache	NR	NR	34(32.5%)	9(10.8%)	headache: 8(10%)	12(14.5)	12(7.5%)	NR	NR	NR
Dizziness	NR	NR	NR	NR	NR	5(6.0%)	NR	NR	2(20%)	NR
Hemoptysis	5/435(1.1%)	NR	4(3%)	NR	NR	1(1.2)	NR	NR	NR	NR
Chills	24/374(6.4%)	NR	14(10.3%)	NR	NR	9(10.8)	NR	NR	NR	NR
Chest pain	21/440(4.8%)	NR	NR	5(6%)	5(6%)	NR	NR	NR	NR	NR
Diarrhea	NR	5(9.8%)	18(13.3%)	Abdominal pain and	Abdominal pain and	5(6.0)	17(10.6%)	3(3.0%)	8(80%)	1(4%)

				diarrhea: 7(8.4%)	diarrhea: 7(9%)						
Inappetence	NR	NR	6(4.4%)	NR	NR	6(7.2%)	NR	NR	NR	NR	NR
Abdominal pain	NR	NR	NR	NR	NR	1(1.2%)	NR	NR	2(20%)	NR	NR
Respiratory rate	NR	NR	> 24/min: 12(8.9%)	20(20-22)	21.05(3.74)	NR	NR	NR	NR	NR	NR
Sore throat	35/433(8.1%)	3(5.9%)	24(17.7%)	NR	NR	14(16.9)	NR	12(11.9%)	5(50%)	3(12%)	
Pharyngeal discomfort	NR	NR	NR	6(7.2%)	9(11%)	NR	NR	NR	NR	NR	NR
Rhinorrhea	NR	NR	NR	NR	NR	NR	0	NR	2(20%)	NR	
Nausea or vomiting	NR	NR	Retching: 4(3.0%)	NR	NR	4(4.8)	Nausea: 6(3.7%)	2(2.0%)	Nausea: 5(50%)	NR	
Digestive symptoms:					Catarrh		More than one				
	49/446(11%);			Blood in	symptoms:		symptom:		Nasal		
Others	Neurological symptoms: 47/440(10.7%).		Palpitation 5(3.7%).	sputum 3(4%);	7(8.4); Thirst: 2(2.4); Chest	NR	67(66.3%); Asymptomatic	congestion: 2(20%).			
					distress: 8(9.6%)		infection: 2(2.0%).				

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported.

Table S20 Signs and symptoms on admission of the confirmed patients outside of former epicenter d

	Diao 2020	Gao 2020	Li 2020 C	Liang 2020 B	Lv 2020	Mao 2020 B	Wang 2020 D	Xiang 2020	Xu 2020 E
Fever	8(53.3%)	30(75%)	47(95.9%)	26(92.9%)	17(100%)	15(62.5%)	16(94.1%)	38(78.7%)	27(84.3%)
Highest temperature >39°C	NR	NR	NR	4(14.3%)	NR	1(4.2%)	NR	NR	NR
Cough	10(66.7%)	Dry cough: 3(7.5%)	37(75.5%)	14(50%)	15(88.2%)	22(91.66%); Dry cough: 9(37.5%)	Dry cough: 7(41.2%)	19(38.8%)	19(59.4%)
Sputum production	1(6.7%)	NR	19(38.8%)	5(17.9%)	NR	13(54.2%) A*	1(5.9%)	7(14.3%)	NR
Dyspnea	NR	NR	NR	3(10.7%)	4(23.5%)	6(25%)	4(23.5%)	NR	4(12.5%)
Fatigue	NR	NR	32(65.3%)	15(53.6%)	13(76.4%)	11(45.83%)	2(11.8%)	9(18.4%)	5(15.6%)
Myalgia	NR	NR	NR	7(25%)	1(5.9%)	NR	1(5.9%)	NR	12(37.5%)
Headache	1(6.7%)	1(2.5%)	NR	NR	NR	2(8.33%)	NR	6(12.2%)	4(12.5%)
Dizziness	NR	NR	NR	NR	NR	1(4.16%)	1(5.9%)	NR	NR
Chills	2(13.3%)	NR	NR	NR	NR	1(4.16%)	2(11.8%)	8(16.3%)	7(21.9%)
Chest pain	NR	NR	NR	NR	NR	NR	NR	NR	NR
Chest distress	2(13.3%)	NR	shortness of breath 31(63.2%)	9(32.1%)	NR	6(25%)	NR	4(8.2%)	NR
Diarrhea	NR	NR	4(8.2%)	1(3.6%)	NR	1(4.16%)	1(5.9%)	2(4.1%)	0
Respiratory rate	19.0(18.0 ~ 20.0)	NR	NR	NR	NR	NR	NR	20.6(14 ~ 32)	NR
Sore throat	1(6.7%)	2(5%)	NR	2(7.1%)	NR	3(12.5%)	2(11.8%)	Sore throat/Pharyngeal discomfort: 7(14.9%)	2(6.3%)
Rhinorrhea	NR	NR	NR	1(3.6%)	NR	4(16.7%)	NR	NR	1(3.1%)
Nausea or vomiting	NR	NR	NR	NR	NR	1(4.16%)	Nausea: 2(11.8%)	NR	NR
Asymptomatic infection	NR	4(10%)	NR	NR	NR	NR	NR	3(6.1%)	NR
Others	Other digestive symptoms: 1(6.7%);			Inappetence: 2(7.1%); Black stool: 2(7.1%)	Thirst: 1(5.9%)			Pneumonia: 31(96.9%);	

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. A*: White sputum 10(41.67%), yellow sputum 3(12.5%).

Table S21 Complications of the confirmed patients in/ outside of former epicenter/ nationwide

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020	Xu 2020 A	Guan 2020	Yang 2020	Chen 2020 C	Wan 2020	Xu 2020 D	Lo 2020	Feng 2020
ARDS	12(29%)	17(17%)		27(19.6%)	1(2%)	37(3.4%)	0	8(3.2%)	21(15.6%)	0	0	NR
Acute cardiac injury	5(12%)	NR		10(7.2%)	NR	NR	0	NR	10(7.4%)	NR	0	NR
Acute respiratory injury	NR	8(8%)	26(18.9%), and patients with underlying cardiovascular	NR	NR	NR	0	NR	NR	NR	0	NR
Acute kidney injury	3(7%)	3(3%) A*	diseases often demonstrated comorbid heart failure.	5(3.6%)	NR	6(0.5%)	0	NR	5(3.7%)	NR	0	NR
Shock	3(7%)	4(4%)		12(8.7%)	NR	12(1.1%)	0	NR	1(0.7%)	NR	0	NR
Secondary infection	4(10%)	NR		NR	NR	NR	NR	NR	7(17.5%)	NR	NR	35/410(8.5%)
Others	RNAemia: 6(15%)	Ventilator-associated pneumonia: 1(1%)		Arrhythmia: 23(16.7%)		Rhabdomyolysis: 2(0.2%); Disseminated intravascular coagulation: 1(0.1%)						

Categorical data are n(N%). ARDS, acute respiratory distress syndrome. A*: With renal function damage 7(7%). B*: Cycle threshold of RNAemia was 35.1(34.7–35.1) median(IQR).

Table S22 Radiologic findings of the confirmed patients in former epicenter a

	Huang 2020	Chen 2020	Liu 2020 A	Wang 2020	Huang 2020 B	Chen 2020 B	Zhang 2020 B
Bilateral involvement of chest radiological examination on admission	CT: 40 (98%)	CT and x-ray: 74 (75%)	CT: 116 (84·7%)	CT: 138 (100%)	27 (79·4%)		CT: 121/135 (89·6%)
Local patchy shadowing of chest radiological examination on admission	NR	CT and x-ray: 25 (25%)	CT:36 (31·0%)	CT: 0	3 (8·8%)		13/135 (9·6%)
Ground glass opacity of chest radiological examination on admission	A*	CT and x-ray: 14 (14%)	CT:55 (47·4%)	CT: 138 (100%) B*	NR		NR
Consolidation shadow of chest radiological examination on admission	D*	NR	CT:25 (21·6%)	NR	NR		NR
No abnormality of chest radiological examination on admission	CT: 0	CT and x-ray: 0	NR	NR	1 (2·9%)	NR	CT: 1/135 (0·7%)

Categorical data are n (N%). NR: not reported. A*: Huang2020 reported that most patients presented with bilateral ground-glass opacities on chest CT scans, but no certain frequency reported. B*: Ground glass opacity or patchy shadows with bilateral involvement. C*:Typical signs reported including: (1) local ground glass shadow; (2) multiple peripheral ground glass shadow; (3) patchy GGO with segmental consolidation; (4) paving stone sign; (5) diffuse ground glass shadow with bronchial sign; (6) large area consolidation shadow with interlobular thickening; D*: The typical findings of chest CT images of ICU patients on admission.

Table S23 Radiologic findings of the confirmed patients in former epicenter b

	Cao 2020	Li 2020 A	Wang 2020 B	Chen 2020 D	Din 2020	Wang 2020 C
Bilateral involvement of chest radiological examination on admission	CT and x-ray: 72(70.6%)		CT B*	CT: 60(93.8%)	HRCT: 53(94.6%)	CT: 89(92.7%)
Local patchy shadowing of chest radiological examination on admission	CT and x-ray: 30(29.4%)		CT C*	CT: 4(6.2%)	HRCT: 2(3.6%)	CT: 7(7.3%)
Ground glass opacity of chest radiological examination on admission	CT and x-ray: 18(17.6%)	CT A*	CT: 30(27.3%)	CT: 48(75%)	NR	NR
Consolidation shadow of chest radiological examination on admission	NR		CT: 30(27.3%)	D*	NR	NR
No abnormality of chest radiological examination on admission	NR	NR	CT: 3(2.6%)	NR	NR	NR
Others				Pericardial effusion: 8(14.3%); Mediastinal emphysema 2(3.6%); Pulmonary embolism 1(1.8%).		Bilateral pleural effusion (CT): 5(5.2%)
Categorical data are n(N%). NR: not reported. A*: Mild cases: single or multiple ground glass opacity(GGO) mainly in the dorsal or periphery part of the lung, local or bilateral patchy shadowing for most common cases/ Severe cases: rapidly increased size and density of lesions, and diffused damage covered both lungs, with air bronchogram and interstitial abnormalities, and “White lung” predicted very poor prognosis. B*: Multiple lobes of both lungs 80(72.7%), bilateral lower lungs 4(3.6%), bilateral middle and lower lungs 10(9.1%). C*: Single lobe of one lung 10(9.1%), multiple lobes of one lung 6(5.5%), patchy 56(50.1%), spherical 28(25.5%). D*: Patchy consolidation 7(10.9%), Large scale consolidation 8(12.5%).						

Table S24 Radiologic findings of the confirmed patients outside of former epicenter/ nationwide a

	Xu 2020 A	Guan 2020	Liu2020 B	Yang 2020	Wu 2020 A	Xu 2020 B
Bilateral involvement of chest radiological examination on admission	CT and x-ray: 52 (84%)	CT: 505/975 (51·8%); X-ray: 100/274 (36·5%)			CT: 36 (45·00%)	D*
Local patchy shadowing of chest radiological examination on admission	NR	CT: 409/975 (41·9%); X-ray: 77/274 (28·1%)			CT: 19 (23·75%)	E*
Ground glass opacity of chest radiological examination on admission	NR	CT: 550/975 (56·4%); X-ray: 55/274 (20·1%)	A*	B*	NR	21 (75·0%)
Interstitial abnormalities of chest radiological examination on admission	NR	CT: 143/975 (14·7%); X-ray: 12/274 (4·4%)			NR	NR
No abnormality of chest radiological examination on admission	CT and x-ray: 1 (2%)	CT: 135/ 975 (13·8%); X-ray: 112/274 (40·9%)	NR	17 (11·4%)	CT: 25 (31·25%)	NR
Categorical data are n (N%). NR: not reported. A*: Typical findings as bilateral multiple patchy ground glass and consolidation shadows. B*: Finding were reported in the total number of pulmonary segments. C*: 8 (47·1%) were patchy shadows or ground glass opacity; D*:15(53·6%) with bilateral upper lobes involved, and 12(42·9%) with bilateral lower lobes involved.						
E*: 30 (73·2%) with right upper lobe involved; 22 (53·7%) with right middle lobe involved; 39 (95·1%) with right lower lobe involved; 33 (80·5%) with left upper lobe involved; 36 (87·8%) with left lower lobe involved.						

Table S25 Radiologic findings of the confirmed patients outside of former epicenter b

	Huang 2020 C	Xu 2020 C	Liu 2020 D	Qian 2020	Chen 2020 C	Peng 2020	Liu 2020 C	Dai 2020	Xu2020 D	Wan 2020
Bilateral involvement of chest radiological examination on admission	CT: 21(60%)	CT: 53(59%)		CT: 61(67.03%)	CT or X-Ray: 203(81.5%)			CT: 192/219(87.7%)	CT: 39(76%)	CT: 135(100%)
Local patchy opacity of chest radiological examination on admission	CT: 19(54.28%)	CT: U*	B*	CT: 25(27.47%)	CT or X-Ray: 39(15.7%)	D*	E*	F*	CT: 8(15.7%), Unilateral pneumonia	NR
Ground glass opacity of chest radiological examination on admission	CT: 11(31.43%) A*	CT: 65(72%)		C*	NR			NR	CT: 4(7.8%) G*	NR
Consolidation	NR	CT: 12(13%)	NR	NR	NR	NR	CT: 8(11%)	NR	NR	NR
Crazy-paving pattern	NR	CT: 11(12%)	NR	NR	NR	NR	CT: 28(38.4%)	NR	NR	NR
Bronchial wall thickening	NR	NR	NR	NR	NR	NR	CT: 19(26%)	HRCT: 76/219(34.7%)	NR	NR
Interlobular septal thickening	NR	CT: 33(37%)	NR	NR	NR	NR	NR	HRCT: 205/219(93.6%)	NR	NR
Pleural effusion	NR	4(4%)	NR	NR	NR	NR	3(4.1%)	NR	NR	NR
Pleural thickening	NR	Adjacent pleura thickening, CT: 50(56%)	NR	NR	NR	NR	NR	HRCT: 170/219(77.6%)	NR	NR
Air bronchogram sign	NR	CT: 7(8%)	NR	NR	NR	NR	NR	HRCT: 184/219(84%)	NR	NR
No abnormality of chest radiological examination on admission	CT: 4(11.43%)	CT: 21(23.3%)	NR	CT: 5(5.49%)	CT and X-Ray: 6(2.41%)	NR	CT: 3(4.1%)	HRCT: 15(6.4%)	NR	0
Others	CT: H*							HRCT: J*		

Categorical data are n(N%). NR: not reported. A*: And cloud opacity 3(8.57%). U*: Periphery distribution 46(51%), multifocal involvement 62(69%), unifocal involvement 7(8%). B*: Bilateral involvement for most patients, and the ground glass opacity appeared in the outer zone of both lungs in the early stage. The density opacity of the two upper lobes is scattered in the flake ground glass, and the edge is fuzzy for mild patients on admission. Bilateral extrapulmonary bands are scattered in patchy, flocculent high-density opacities, with fuzzy edges and local pulmonary tissue consolidation for patients with severe condition on admission. For critical patients, bilateral lungs presented cord like fibrosis, fuzzy margin, distorted bronchi and local stenosis during treatment. C*: Patchy ground-glass opacities in lung as typical findings. D*: Were mainly patchy ground-glass opacities(GGO) and consolidation opacities distributed along the bronchovascular bundles and subpleural space, with a thickened leaflet interval and thickened lobular septum, showing “crazy-paving pattern” and vascular bundle sign. E*: Unilateral lung involvement 15(10.5%), bilateral lungs involvement 55(75.3%), unique ground-glass opacities 15(10.5%), multiple ground-glass opacities 50(68.5%), thickening of lung texture 65(89%). F*: Single lobe involved 16/219(7.31%), distributed in the lower lungs and/or the periphery of the lungs mainly 208/219(94.98%), irregular shape of the lesions mainly 193/219(88.13%), followed by small patches 189/219(86.3%), strip-like 152/219(69.41%), round-like 108/219(49.32%) and “anti-butterfly” 105/219(47.95%). G*: Multiple mottling and ground-glass opacity. H*: Linear opacities combined: 55(61%), cavitation: 0; pericardial effusion: 1(1%); lymphadenopathy: 1(1%); pulmonary emphysema: 0. I*: With VES 207/219(94.5%), with intralesional and/or perilesional bronchiectasis 173/219(79%), with solid nodules 138/219(63%), with reticular/mosaic sign 135/219(61.6%), with interlobar fissure displacement 124/219(56.6%), with minor pleural effusion and pericardial effusion 29/219(13.2%), with mediastinal lymphadenopathy 21/219(9.6%).

Table S26 Radiologic findings of the confirmed patients outside of former epicenter c

	Li 2020 B	Wu 2020 B	Tang 2020	Zheng 2020	Zhao 2020	Lo 2020	Feng 2020	Diao 2020	Gao 2020	Li 2020 C
Bilateral involvement of chest radiological examination on admission	CT: 79(95.2%)	CT: 53(59%)	CT: 70/75(93.3%)	CT: 89(55.3%)	CT: 83(82.2%)	CT: 8(80%)	CT: 373/442(84.4%)	HRCT: 9(60%)	CT: U*	CT: 34(69.4%)
Local patchy opacity of chest radiological examination on admission	NR	NR	NR	CT: 113(70.2%)	NR		NR	HRCT: 6(40%)	CT: 12(30%)	CT: 15(30.6%)
Ground glass opacity of chest radiological examination on admission	CT: 81(97.6%)	CT: 73(91%)	CT: 74/75(98.7%)	CT: 82(50.9%)	CT: 87(86.1%)		CT: 425/442(96.2%)	HRCT: 14(93.3%)	CT: U*	NR
Interstitial abnormalities of chest										
radiological examination on admission	NR	NR	CT: 8/75(10.7%)	CT: 2(1.2%)	NR	NR	NR	NR	NR	NR
Consolidation	CT: 53(63.9%)	CT: 50(63%)	CT: 34/75(45.3%)	NR	CT: 44(43.6%)	NR	CT: 87/442(19.7%)	HRCT: 6(40%)	NR	NR
Bronchial wall thickening	CT: 19(22.9%)	CT: 9(11%)	NR	NR	CT: 29(28.7)	NR	NR	NR	NR	NR
Interlobular septal thickening	CT: 52(62.7%)	CT: 47(59%)	CT: 36/75(48%)	NR	NR	NR	NR	NR	NR	NR
Pleural effusion	NR	CT: 5(6%)	CT: 3/75(4%)	NR	CT: 14(13.9%)	NR	CT: 25/442(5.7%)	NR	NR	NR
Lymph node enlargement	NR	CT: 3(4%)	Mediastinal lymph node, CT: 8/75(10.7%)	NR	Intrathoracic lymph node, CT: 1(1.0)	NR	NR	Mediastinal lymph node, HRCT:3(20%)	NR	NR
Crazy-paving pattern	CT: 30(36.1%)	CT: 23(29%)	NR	NR	NR	NR	NR	NR	NR	NR
Pleural thickening	NR	NR	Interlobular pleural, CT: 2/75(2.7%)	NR	NR	NR	CT: 238/442(53.8%)	NR	NR	NR
No abnormality of chest	CT: 4(5%)	0	NR	CT: 8(7.9%)	CT:	NR	NR	CT:	0	

radiological examination on admission	4(11.43%)			2(20%)		3(7.5%)
Others	CT: B*	CT: C*	CT: D*	CT: E*	CT: linear opacity: 129/442(29.2%).	HRCT: fibrotic lesion 3(20%).

Categorical data are n(N%). NR: not reported. A*: Bilateral distribution of patchy opacities or ground glass opacity 6(60%). B*: 54(65.1%) for linear opacities, 21(25.3%) for spider web sign, 17(20.5%) for subpleural curvilinear. C*: Spider web sign 20(25%), subpleural line 16(20%), pericardial effusion 4(5%), subpleural distribution 42(53%), diffuse distribution 7(9%), peribronchial distribution 3(4%), mixed distribution 24(30%). D*: patchy opacity 72/75(96%), flake opacity 46/75(61.3%), nodular opacity 11/75(14.7%), stripe opacity 51/75(68%), subpleural line 27/75(36%), gridding opacity 11/75(14.7%), mixing density 34/75(45.3%), air bronchogram 23/75(30.7%), thickening of blood vessels in ground glass opacity 5/75(6.7%), bronchiectasia 11/75(14.7%)., E*: Mixed ground-glass opacities and consolidation 65(64.4), centrilobular nodules 23(22.8), architectural distortion 22(21.8), reticulation 49(48.5), subpleural bands 28(27.7) traction bronchiectasis 53(52.5), vascular enlargement 72(71.3). U*: subpleural strip opacity and ground glass opacities 3(7.5%), bilateral gridding and ground glass opacities 5(12.5%), bilateral multiple ground glass opacities 17(42.5%).

Table S27 Radiologic findings of the confirmed patients outside of former epicenter d

	Liang 2020 B	Lv 2020	Mao 2020 B	Wang 2020 D	Xiang 2020	Xu 2020 E	Yu 2020 A	Yu 2020 B
Bilateral involvement of chest radiological examination on admission				CT: 14(82.4%)		CT: 26(81.3%)		NR
Local patchy opacity of chest radiological examination on admission	CT(Typical radiologic findings of COVID-19): 28(100%)	CT: A*	CT: B*		CT: D*	CT: E*	CT: F*	NR
Ground glass opacity of chest radiological examination on admission				CT: C*			CT: 26(80.3%)	NR
Consolidation	NR	NR	NR	NR	NR	CT: 14(43.8%)	NR	NR
Pleural effusion	NR	NR	NR	NR	NR	CT: 4(12.5%)	NR	NR
Pleural thickening	NR	NR	NR	NR	NR	CT: 7(21.9%)	NR	NR
No abnormality of chest radiological examination on admission	CT: 0	CT: 1(5.9%)	NR	CT: 3(17.6%)	CT: 2(4.1%)	CT: 1(3.1%)	CT: 18(72%)	CT: 9(9.3%)

Categorical data are n(N%). NR: not reported. A*: Ground glass opacity, mixed ground glass opacity and crazy-paving pattern mainly. B*: Bilateral ground glass opacity 22(91.67%), bilateral ground glass opacity with unilateral pleural effusion 2(8.33%), bilateral ground glass opacity with slight pericardial effusion 1(4.17%), lung texture increased and thickened 1(4.17%). C*: Reported as bilateral patchy, ground glass opacity, pulmonary consolidation and interstitial lesions mainly; D*: Single or scattered patchy ground glass density opacities 47(95.9%), and the lesions involved a wide range with an average of 2.8 lobes. E*: Patchy opacity 27(84.6%), nodular opacity 8(23.1%), sector opacity 12(36.5%), irregular opacity 15(48.1%), ground glass opacity with consolidation 20(62.5%), tubercle opacity 7(21.9%), interlobular septal thickening 23(71.9%), bronchovesicular bundle thickening 22(68.8%), crazy-paving pattern 14(43.8%), air bronchogram 12(37.5), cavity 9(28.1%), halo sign 8(25.0%), reversed halo sign 6(18.8%), tree-in-bud 4(12.5%), fibrosis 6(18.8%), “White lung” 1(3.1%), mediastinal lymphadenopathy 1(3.1%). F*: Patchy exudative opacities and interstitial abnormalities 7(28%), bilateral pneumonia 2(8%), unilateral pneumonia 5(20%).

Table S28 Laboratory findings of the confirmed patients in former epicenter a

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020 A	Huang 2020 B	Chen 2020 B	Zhang 2020 B	Mao 2020 A
White blood cell count, $\times 10^9/\text{L}$	6·2 (4·1–10·5)	7·5 (3·6)	NR	4·5 (3·3–6·2)	NR	NR	4·7 (3·7–6·7)	4·9 (0·1–20·4)
White blood cell count $> 10 \times 10^9/\text{L}$	12/40 (30%)	24 (24%)	26 (19·0%)	NR	Increased: 4 (11·8%)	6 (21%)	$> 9\cdot5 \times 10^9/\text{L}$: 17/138 (12·3)	
White blood cell count $< 4 \times 10^9/\text{L}$	10/40 (25%)	9 (9%)	51 (37·2%)	NR	Decreased: 6 (17·6%)	6 (21%)	$< 3\cdot5 \times 10^9/\text{L}$: 27/138 (19·6%)	
Neutrophil count, $\times 10^9/\text{L}$	5·0 (3·3–8·9)	5·0 (3·3–8·1)	NR	3·0 (2·0–4·9)	Increased: 4 (11·8%)	NR	NR	3·0 (0·0–18·7)
Monocyte count, $10^9/\text{L}$	NR	10/L: 38 (38%)	NR	0·4 (0·3–0·5)	NR	NR	NR	NR
Lymphocyte count, $\times 10^9/\text{L}$	0·8 (0·6–1·1)	NR	NR	0·8 (0·6–1·1)	NR	NR	0·8 (0·6–1·1)	1·1 (0·1–2·6)
	$< 1 \times 10^9/\text{L}$: 26 (63%)	$< 1 \times 10^9/\text{L}$: 10/L: 35 (35%)	$< 1 \times 10^9/\text{L}$: 99 (72·3%)		Decreased: 17 (50·0%)	10/L: 6 (21%)	$< 1 \times 10^9/\text{L}$: 104/138 (75·4%)	
Haemoglobin, g/L	126·0 (118·0–140·0)	129·8 (14·8)	NR	NR	NR	NR	NR	NR
	$< 130\text{g/L}$: 50 (51%)				Decreased: 13 (38·2%)	$< 130\text{g/L}$: 12(41%)		
Platelet count, $\times 10^9/\text{L}$	164·5 (131·5–263·0)	213·5 (79·1)	NR	163 (123–191)	NR	NR	NR	209·0 (18·0–583·0)
	$< 100 \times 10^9/\text{L}$: 2/40 (5%)	$< 125 \times 10^9/\text{L}$: 10/L: 12 (12%)			Decreased: 9 (26·5%)	$< 125 \times 10^9/\text{L}$: 5(17%)		
	$> 350 \times 10^9/\text{L}$							

				10%L: 4 (4%)				
Prothrombin time, s	11·1 (10·1–12·4)	11·3 (1·9)	NR	13·0 (12·3– 13·7)	NR	NR	NR	NR
	< 10·5 s: 30 (30%)				Decreased: 1 (2·9%)			
	> 13·5 s: 5 (5%)				Increased: 17 (50·0%)			
Activated partial thromboplastin time, s	27·0 (24·2–34·1)	27·3 (10·2)	NR	31·4 (29·4– 33·5)	NR	NR	NR	NR
	< 21 s: 16 (16%)							
	> 37 s: 6 (6%)							
D-dimer, mg/L	0·5 (0·3–1·3)	0·9 (0·5– 2·8)	NR	203 (121– 403) µg/L	NR	NR	0·2 (0·1–0·5)	0·5 (0·1– 20·0)
	> 1·5mg/L: 36 (36%)				Increased: 5 (14·7%)		> 0·243mg/L: 35/81 (43·2%)	
Albumin, g/L	31·4 (28·9–36·0)	31·6 (4·0)	NR	NR	NR	NR	NR	NR
	< 40g/L: 97 (98%)				Decreased: 25 (73·5%)	< 35g/L: 15(52%)		
Alanine aminotransferase, U/L	32·0 (21·0–50·0)	39·0 (22·0– 53·0)	NR	24 (16–40)	NR	NR	NR	26·0 (5·0– 1933·0)
	> 50 U/L: 28 (28%)				Increased: 8 (23·5%)	> 41 U/L: 5(17%)		
Aspartate aminotransferase, U/L	34·0 (26·0–48·0)	34·0 (26·0– 48·0)	NR	31 (24–51)	NR	NR	NR	26·0 (8·0– 8191·0)
	> 40 U/L: 15 (37%)	> 40 U/L: 35 (35%)			Increased: 7 (20·6%)	> 40 U/L: 7(24%)		
Total bilirubin, mmol/L	11·7 (9·5–13·9)	15·1 (7·3)	NR	9·8 (8·4– 14·1)	NR	NR	NR	NR

	> 21					> 26		
	mmol/L: 18 (18%)				Increased: 3 (8·8%)	mmol/L: 1(3%)		
Potassium, mmol/L	4·2 (3·8–4·8)	NR	NR	NR	Decreased: 4 (11·8%); Increased: 2 (5·9%)	NR	NR	NR
Sodium, mmol/L	139·0 (137·0– 140·0)	NR	NR	NR	NR	NR	NR	NR
Serum creatinine, µmol/L	74·2 (57·5–85·7)	75·6 (25·0)	NR	72 (60-87)	NR	NR	NR	68·2 (35·9– 9435·0)
	> 133 µmol/L: 4 (10%)	> 111 µmol/L: 3 (3%)			Increased: 6 (17·6%)	> 104 µmol/L: 2(7%)		
	< 57 µmol/L: 51 (52%)				Decreased: 7 (20·6%)			
Creatine kinase-MB, U/L	NR	NR	NR	14 (10-18)	NR	NR	NR	NR
Creatine kinase, U/L	132·5 (62·0– 219·0)	85·0 (51·0– 184·0)	NR	92 (56-130)	NR	NR	72·5 (52·2-115)	64·0 (8·8– 12216·0)
	> 185 U/L:	> 310 U/L: 13/40 (33%)			Increased: 1/12 (8·3%)			
	≤185 U/L: 27/40	< 50 U/L: (68%)				> 200 U/L: 4/60 (6·7)		
Lactate dehydrogenase, U/L	286·0 (242·0– 408·0)	336·0 (260·0– 447·0)	NR	261 (182– 403)	NR	NR	NR	241·5 (2·2– 908·0)
	> 245 U/L:	> 250 U/L: 29/40 (73%)				> 225 U/L: 20(69%)		
Hypersensitive troponin I, pg/mL	3·4 (1·1–9·1)	NR	NR	6·4 (2·8– 18·5)	NR	NR	NR	NR
	> 28 pg/mL				Increased: 1/15 (6·7%)			

(99th percentile):

5 (12%)

Procalcitonin, ng/mL	0·1 (0·1–0·1)	0·5 (1·1)	NR	NR	NR	NR	0·07 (0·04–0·1)	NR
	> 5·0			≥0·5				
≥0·5 ng/mL:	ng/mL: 6		ng/mL: 49		Increased: 13/31 (41·9%)		> 0·1 ng/mL: 41/118 (34·7%)	
3/39 (8%)	(6%)		(35·5%)					
< 0·1 ng/mL:								
27/39 (69%)								
Blood urea nitrogen, mmol/L	NR	5·9 (2·6)	NR	4·4 (3·4-5·8)	NR	NR	NR	4·1 (1·5-48·1)
	> 9·5				> 8			
mmol/L: 6					mmol/L:			
(6%)					5(17%)			
< 3·6								
mmol/L: 17								
(17%)								
C-reactive protein, mg/L	NR	51·4 (41·8)	NR	NR	NR	NR	34·2 (12·5–67·4)	12·2 (0·1–212·0)
	> 5 mg/L:	Elevated:			≥5·0			
63/73 (86%)	115 (83·9%)				mg/L:	> 3 mg/L: 125/136 (91·9%)		
					27(93%)			
Others	NR	NR	NR	NR	Myoglobin: Increased 3/12 (25·0%); Erythrocyte sedimentation rate (ESR): Increased 13/22 (59·1%); Interleukin Increased 9/9 (100·0%); Brain natriuretic peptide (BNP): Increased 1/4 (25·0%)	NR	Lymphocyte percentage, %: 16·9 (9·2–26·0); Eosinophils, ×10 ⁹ /L: 0·01 (0·0–0·05), decreased: 73/138 (52·9); Serum amyloid A (SAA), mg/L: 92·53 (44·6–161·3), increased: 46/51 (90·2%)	NR

Continuous data are median (IQR) or mean (SD); Categorical data are n (N%). NR: not reported.

Table S29 Laboratory findings of the confirmed patients in former epicenter b

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020 A	Huang 2020 B	Chen 2020 B	Zhang 2020 B	Mao 2020 A
White blood cell count, $\times 10^9/\text{L}$	6·2 (4·1–10·5)	7·5 (3·6)	NR	4·5 (3·3–6·2)	NR	NR	4·7 (3·7–6·7)	4·9 (0·1–20·4)
White blood cell count $> 10 \times 10^9/\text{L}$	12/40 (30%)	24 (24%)	26 (19·0%)	NR	Increased: 4 (11·8%)	6 (21%)	$> 9\cdot5 \times 10^9/\text{L}$: 17/138 (12·3)	
White blood cell count $< 4 \times 10^9/\text{L}$	10/40 (25%)	9 (9%)	51 (37·2%)	NR	Decreased: 6 (17·6%)	6 (21%)	$< 3\cdot5 \times 10^9/\text{L}$: 27/138 (19·6%)	
Neutrophil count, $\times 10^9/\text{L}$	5·0 (3·3–8·9)	5·0 (3·3–8·1)	NR	3·0 (2·0–4·9)	Increased: 4 (11·8%)	NR	NR	3·0 (0·0–18·7)
Monocyte count, $10^9/\text{L}$	NR	10/L: 38 (38%)	NR	0·4 (0·3–0·5)	NR	NR	NR	NR
Lymphocyte count, $\times 10^9/\text{L}$	0·8 (0·6–1·1)	NR	NR	0·8 (0·6–1·1)	NR	NR	0·8 (0·6–1·1)	1·1 (0·1–2·6)
	$< 1 \times 10^9/\text{L}$: 26 (63%)	$< 1 \times 10^9/\text{L}$: 10/L: 35 (35%)	$< 1 \times 10^9/\text{L}$: 99 (72·3%)		Decreased: 17 (50·0%)	10/L: 6 (21%)	$< 1 \times 10^9/\text{L}$: 104/138 (75·4%)	
Haemoglobin, g/L	126·0 (118·0–140·0)	129·8 (14·8)	NR	NR	NR	NR	NR	NR
	$< 130\text{g/L}$: 50 (51%)				Decreased: 13 (38·2%)	$< 130\text{g/L}$: 12(41%)		
Platelet count, $\times 10^9/\text{L}$	164·5 (131·5–263·0)	213·5 (79·1)	NR	163 (123–191)	NR	NR	NR	209·0 (18·0–583·0)
	$< 100 \times 10^9/\text{L}$: 2/40 (5%)	$< 125 \times 10^9/\text{L}$: 10/L: 12 (12%)			Decreased: 9 (26·5%)	$< 125 \times 10^9/\text{L}$: 5(17%)		
	$> 350 \times 10^9/\text{L}$							

				10%L: 4 (4%)				
Prothrombin time, s	11·1 (10·1–12·4)	11·3 (1·9)	NR	13·0 (12·3– 13·7)	NR	NR	NR	NR
	< 10·5 s: 30 (30%)				Decreased: 1 (2·9%)			
	> 13·5 s: 5 (5%)				Increased: 17 (50·0%)			
Activated partial thromboplastin time, s	27·0 (24·2–34·1)	27·3 (10·2)	NR	31·4 (29·4– 33·5)	NR	NR	NR	NR
	< 21 s: 16 (16%)							
	> 37 s: 6 (6%)							
D-dimer, mg/L	0·5 (0·3–1·3)	0·9 (0·5– 2·8)	NR	203 (121– 403) µg/L	NR	NR	0·2 (0·1–0·5)	0·5 (0·1– 20·0)
	> 1·5mg/L: 36 (36%)				Increased: 5 (14·7%)		> 0·243mg/L: 35/81 (43·2%)	
Albumin, g/L	31·4 (28·9–36·0)	31·6 (4·0)	NR	NR	NR	NR	NR	NR
	< 40g/L: 97 (98%)				Decreased: 25 (73·5%)	< 35g/L: 15(52%)		
Alanine aminotransferase, U/L	32·0 (21·0–50·0)	39·0 (22·0– 53·0)	NR	24 (16–40)	NR	NR	NR	26·0 (5·0– 1933·0)
	> 50 U/L: 28 (28%)				Increased: 8 (23·5%)	> 41 U/L: 5(17%)		
Aspartate aminotransferase, U/L	34·0 (26·0–48·0)	34·0 (26·0– 48·0)	NR	31 (24–51)	NR	NR	NR	26·0 (8·0– 8191·0)
	> 40 U/L: 15 (37%)	> 40 U/L: 35 (35%)			Increased: 7 (20·6%)	> 40 U/L: 7(24%)		
Total bilirubin, mmol/L	11·7 (9·5–13·9)	15·1 (7·3)	NR	9·8 (8·4– 14·1)	NR	NR	NR	NR

	> 21					> 26		
	mmol/L: 18 (18%)				Increased: 3 (8·8%)	mmol/L: 1(3%)		
Potassium, mmol/L	4·2 (3·8–4·8)	NR	NR	NR	Decreased: 4 (11·8%); Increased: 2 (5·9%)	NR	NR	NR
Sodium, mmol/L	139·0 (137·0– 140·0)	NR	NR	NR	NR	NR	NR	NR
Serum creatinine, µmol/L	74·2 (57·5–85·7)	75·6 (25·0)	NR	72 (60-87)	NR	NR	NR	68·2 (35·9– 9435·0)
	> 133 µmol/L: 4 (10%)	> 111 µmol/L: 3 (3%)			Increased: 6 (17·6%)	> 104 µmol/L: 2(7%)		
	< 57 µmol/L: 51 (52%)				Decreased: 7 (20·6%)			
Creatine kinase-MB, U/L	NR	NR	NR	14 (10-18)	NR	NR	NR	NR
Creatine kinase, U/L	132·5 (62·0– 219·0)	85·0 (51·0– 184·0)	NR	92 (56-130)	NR	NR	72·5 (52·2-115)	64·0 (8·8– 12216·0)
	> 185 U/L:	> 310 U/L: 13/40 (33%)			Increased: 1/12 (8·3%)			
	≤185 U/L: 27/40	< 50 U/L: (68%)				> 200 U/L: 4/60 (6·7)		
Lactate dehydrogenase, U/L	286·0 (242·0– 408·0)	336·0 (260·0– 447·0)	NR	261 (182– 403)	NR	NR	NR	241·5 (2·2– 908·0)
	> 245 U/L:	> 250 U/L: 29/40 (73%)				> 225 U/L: 20(69%)		
Hypersensitive troponin I, pg/mL	3·4 (1·1–9·1)	NR	NR	6·4 (2·8– 18·5)	NR	NR	NR	NR
	> 28 pg/mL				Increased: 1/15 (6·7%)			

(99th percentile):

5 (12%)

Procalcitonin, ng/mL	0·1 (0·1–0·1)	0·5 (1·1)	NR	NR	NR	NR	0·07 (0·04–0·1)	NR
	> 5·0			≥0·5				
≥0·5 ng/mL:	ng/mL: 6		ng/mL: 49		Increased: 13/31 (41·9%)		> 0·1 ng/mL: 41/118 (34·7%)	
3/39 (8%)	(6%)		(35·5%)					
< 0·1 ng/mL:								
27/39 (69%)								
Blood urea nitrogen, mmol/L	NR	5·9 (2·6)	NR	4·4 (3·4- 5·8)	NR	NR	NR	4·1 (1·5- 48·1)
	> 9·5				> 8			
mmol/L: 6					mmol/L:			
(6%)					5(17%)			
< 3·6								
mmol/L: 17								
(17%)								
C-reactive protein, mg/L	NR	51·4 (41·8)	NR	NR	NR	NR	34·2 (12·5-67·4)	12·2 (0·1- 212·0)
	> 5 mg/L:	Elevated:			≥5·0			
63/73 (86%)	115 (83·9%)				mg/L:	> 3 mg/L: 125/136 (91·9%)		
					27(93%)			
Others	NR	NR	NR	NR	Myoglobin: Increased 3/12 (25·0%); Erythrocyte sedimentation rate (ESR): Increased 13/22 (59·1%); Interleukin Increased 9/9 (100·0%); Brain natriuretic peptide (BNP): Increased 1/4 (25·0%)	NR	Lymphocyte percentage, %: 16·9 (9·2-26·0); Eosinophils, ×10 ⁹ /L: 0·01 (0·0-0·05), decreased: 73/138 (52·9); Serum amyloid A (SAA), mg/L: 92·53 (44·6-161·3), increased: 46/51 (90·2%)	NR

Continuous data are median (IQR) or mean (SD); Categorical data are n (N%). NR: not reported.

Table S30 Laboratory findings of the confirmed patients outside of former epicenter/ nationwide a

	Xu 2020 A	Chang 2020	Guan 2020	Liu 2020 B	Yang 2020	Wu 2020 A	Xu 2020 B
White blood cell count, $\times 10^9/L$	4.7(3.5-5.8)	5.83(2.32)	4.7(3.5– 6.0)	4.71(3.72-5.77)	4.56(2.48)	4.1(3.2-5.7)	NR
White blood cell count $> 10 \times 10^9/L$	1(2%)		58/978(5.9%)		$> 9.5 \times 10^9/L: 2(1.34\%)$	$> 9.5 \times 10^9/L: 5(6.25\%)$	
White blood cell count $< 4 \times 10^9/L$	19(31%)		330/978(33.7%)		$< 3.5 \times 10^9/L: 33(24.16\%)$	$< 3.5 \times 10^9/L: 36(45.00\%)$	Normal or decreased: 49(98%)
Neutrophil count, $\times 10^9/L$	2.9(2.0-3.7)	3.67(1.71)	NR	3.29(2.17-4.06)	2.60(2.03)	4.3(2.3-5.9)	NR
					$> 6.3 \times 10^9/L: 6(4.03\%)$	$> 6.3 \times 10^9/L: 20(25.00\%)$	
					$< 1.8 \times 10^9/L: 34(22.82\%)$		
Monocyte count, $10^9/L$	NR	0.526(0.208)	NR	NR	NR	0.5(0.3-0.7)	NR
						$> 0.6 \times 10^9/L: 15(18.75\%)$	
Lymphocyte count, $\times 10^9/L$	1.0(0.8-1.5)	1.58(0.653)	1.0(0.7– 1.3)	1.17(0.87-1.35)	1.21(0.68)	0.6(0.4-1.0)	NR
	$< 1 \times 10^9/L:$ 26(42%)		$< 1.5 \times 10^9/L:$ 731/890(82.1%)		$< 1.1 \times 10^9/L: 53(35.57\%)$	$< 1.1 \times 10^9/L: 26(32.50\%)$	Decreased: 14(28%)
Hemoglobin, g/L	137.0(128.8-152.3)	147(12.1)	134.0(119.0–148.0)	NR	NR	125.3(13.4)	NR
						$< 130g/L: 29(36.25\%)$	
Platelet count, $\times 10^9/L$	176.0(135.8-215.5)	199(72.5)	168.0(132.0–207.0)	NR	174.5(78.25)	155(116-188)	NR
	$< 100 \times 10^9/L:$ 3(5%)		$< 150 \times 10^9/L:$ 315/869(36.2%)		$< 125 \times 10^9/L: 20(13.42\%),$ $> 350 \times 10^9/L: 8(5.37\%)$	$< 125 \times 10^9/L: 11(13.75\%)$	
Prothrombin time, s	NR	NR	NR	NR	12.20(1.53) $> 13.5 s: 17(11.41\%)$ $< 10 s: 4(2.68\%)$	10.8(9.3-13.2) $< 10.5 s: 3(3.75\%)$	NR

Activated partial thromboplastin time, s	NR	NR	NR	NR	33.29(4.98)	18.6(17.2-28.6)	NR
					> 36 s: 40(26.85%)	< 21 s: 2(2.50%)	
D-dimer, mg/L	0.2(0.2-0.5)	NR	NR	NR	0.22(0.28)	0.9(0.4-2.4)	NR
			> 0.5mg/L		> 0.55mg/L: 21(14.09%)	> 1.5 mg/L: 3(3.75%)	
			260/560(46.4%)				
Albumin, g/L	NR	NR	NR	39.00(36.20-44.20)	41.65(5.48)	38.3(37.0-46.2)	NR
					> 57 g/L: 3(2.01%)		
					< 35 g/L: 9(6.04%)	< 40 g/L: 2(2.50%)	
Alanine aminotransferase, U/L	22(14-34)	NR	NR	26.98(16.88-46.09)	20(20.5)	24(12-38)	NR
				> 40 U/L:			
			158/741(21.3%)		> 64 U/L: 18(12.08%)	> 50 U/L: 3(3.75%)	
Aspartate aminotransferase, U/L	26(20-32)	NR	NR	24.75(18.71-31.79)	23(15.75)	30(19-39)	NR
				> 40 U/L:			
			10(16.1%)	168/757(22.2%)	> 40 U/L: 27(18.12%)	> 40 U/L: 3(3.75%)	
Total bilirubin, mmol/L	NR	NR	NR	16.40(11.34-21.15)	9.9(5.95)	6.6(5.4-12.0)	NR
				> 17.1 mmol/L:			
				76/722(10.5%)	> 24 mmol/L: 4(2.68%)	> 12 mmol/L: 1(1.25%)	
Potassium, mmol/L	3.7(3.5-3.9)	NR	3.8(3.5-4.2)	NRN	NR	NR	NR
Sodium, mmol/L	139(127-141)	NR	138.2(136.1-140.3)	NR	NR	NR	NR
Serum creatinine, $\mu\text{mol/L}$	72.0(61.0-84.0)	NR	NR	NR	66.07(14.79)	78(60-90)	NR
			> 133 $\mu\text{mol/L}$:				
			3(5%)	12/752(1.6%)	> 73 $\mu\text{mol/L}$: 43(28.86%)	> 111 $\mu\text{mol/L}$: 2(2.50%)	
					< 41 $\mu\text{mol/L}$: 1(0.67%)		
Creatine kinase-MB, U/L	NR	NR	NR	NR	NR	22(15-25)	NR
						16(20.00%)	

Creatine kinase, U/L	69.0(40.5-101.0)	NR	NR	NR	76.5(53.5)	99(61-191)	NR
> 185 U/L: 5(8%)		> 200 U/L: 90/657(13.7%)			> 200 U/L: 12(8.05%) < 40 U/L: 19(12.75%)		> 310 U/L: 18(22.50%)
Lactate dehydrogenase, U/L	205.0(184.0-260.5)	NR	NR	NR	210(94.5)	226(182-308)	NR
> 245 U/L: 17(27%)		≥ 250 U/L: 277/675(41.0%)			> 250 U/L: 45(30.20%)		> 250 U/L: 17(21.25%)
Procalcitonin, ng/mL	0.04(0.03-0.06)	0.187(0.0633)	NR	NR	NR	1.3(0.4-2.6)	NR
≥0.1 ng/mL: 7(11%)		≥0.5 ng/mL: 35/633(5.5%)				≥5.0 ng/mL: 1(1.25%)	
Blood urea nitrogen, mmol/L	NR	NR	NR	NR	3.8(1.4) < 2.6 mmol/L: 17(11.41%)	4.9(3.4-5.9) > 9.5 mmol/L: 2(2.50%)	NR
C-reactive protein, mg/L	NR	14.7(10.2)	NR	NR	7.25(23)	6.6(5.3-12.3)	NR
Others	NR	NR	≥10 mg/L: 481/793(60.7%)	> 10 mg/L: 13(40.63%)	> 6 mg/L: 82(55.03%)	> 5 mg/L: 62(77.50%)	Increased: 26(52%)
				Neutrophil percentage, %: 63.80(58.10-72.55); Lymphocyte percentage, %: 25.20(19.33-33.05)	Glucose, mmol/L: 5.83(1.97), > 6.1 mmol/L: 59(39.60%), < 3.9 mmol/L: 1(0.67%)	Glucose, mmol/L: 6.8(4.6-7.7), > 6.1 mmol/L: 19(23.17%); Erythrocyte sedimentation rate, mm/h: 11.9(9.0-17.2), > 15 mm/h: 59(73.75%)	

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported.

Table S31 Laboratory findings of the confirmed patients outside of former epicenter/ nationwide b

	Huang 2020 C	Chang 2020	Liu 2020 D	Qian 2020	Chen 2020 C	Peng 2020	Xu 2020 D
White blood cell count, $\times 10^9/L$	NR	NR	(2.3-8.1), range	4.99(4.25-5.69)	4.71(3.80-5.86)	6.41(1.57), mean \pm SD	A*
White blood cell count $> 10 \times 10^9/L$	NR	NR	0	$> 9.5 \times 10^9/L$: 3(32.97%)	NR	NR	NR
White blood cell count $< 4 \times 10^9/L$	Decreased: 11(31.43%)	NR	17(40.5%)	$< 3.5 \times 10^9/L$: 14(15.39%)	NR	NR	17(33.3%)
Neutrophil count, $\times 10^9/L$	NR	NR	NR	2.91(2.3-3.58)	NR	NR	NR
			$> 5.8 \times 10^9/L$:	$> 6.3 \times 10^9/L$: 3(3.30%)			
			1(2.4%)				
			$< 2 \times 10^9/L$:	$< 1.8 \times 10^9/L$: 10(10.99%)			
			12(28.6%)				
Monocyte count, $10^9/L$	NR	NR	NR	0.4(0.3-0.58), $> 0.6 \times 10^9/L$: 18(19.78%)	NR	NR	NR
Eosinophils count, $10^9/L$	NR	NR	NR	0.01(0.01-0.05); $< 0.02 \times 10^9/L$: 47(51.65)	NR	0.02(0.03)	
Basophils count, $10^9/L$	NR	NR	NR	0.01(0.01-0.02), $> 0.06 \times 10^9/L$: 1(1.10)	NR	0.0007(0.03)	
Lymphocyte count, $\times 10^9/L$	NR	NR	NR	1.35(0.98-1.66)	1.12(0.79-1.49)	1.43(0.60), mean \pm SD	B*
	Decreased: 22(62.86%)		$< 1.1 \times 10^9/L$	$< 1.1 \times 10^9/L$: 28(30.77%)			

				10 ⁹ /L: 22(52.4%)			
Hemoglobin, g/L	NR	147(12.1)	NR	135(125-145) < 115g/L: 33(36.26%)	NR	NR	NR
Platelet count, × 10⁹/L	NR	199(72.5)	NR	196(142-238) Decreased: 3(8.57%) < 125× 10 ⁹ /L: 10(10.99%) > 350× 10 ⁹ /L: 3(3.30%)	NR	NR	NR
D-dimer, mg/L	NR	NR	NR	0.22(0.28) > 243ng/L: 22(24.18%)	NR	NR	NR
Albumin, g/L	NR	NR	NR	40(37.85-42) < 40 g/L: 43(47.25)	40.8(37.9-43.0)	NR	NR
Fibrinogen, g/L	NR	NR	NR	3.4(2.7-4.04) Increased 12(34.29%) > 4g/L: 22(24.18%) < 2g/L: 3(3.30)	NR	NR	NR
Alanine aminotransferase, U/L	NR	NR	NR	18(13-28) Increased: 7(16.7%) > 50 U/L: 7(7.69%)	23(15-33)	NR	C*
Aspartate aminotransferase, U/L	NR	NR	NR	21(17-28) Increased: 9(21.4%) > 50 U/L: 9(9.89)	25(20-33)	NR	D*
Total bilirubin, mmol/L	NR	NR	NR	NR Increased: 5(11.9%)	NR	NR	NR
Potassium, mmol/L	NR	NR	NR	4.04(3.72-4.23) Decreased: 9(25.71%) Decreased: < 3.5mmol/L: 7(7.69%)	NR	NR	NR

				6(14.3%)				
Sodium, mmol/L	NR	NR	NR	139(137.25-141) < 137mmol/L: 16(17.58)	NR	NR	NR	NR
Serum creatinine, µmol/L	NR	NR	NR	66(57.75-77) > 73 µmol/L: 3(3.30%) < 57 µmol/L: 21(23.08%)	NR	NR	NR	NR
Creatine kinase, U/L	NR	NR	NR	NR	NR	NR	NR	NR
			Increased: 3(7%)					
Lactate dehydrogenase, U/L	NR	NR	NR	NR	229(195-291)	NR	NR	NR
			Increased: 14(33.3%)					
Procalcitonin, ng/mL	NR	0.187(0.0633)	NR	0.02(0-0.04) All in normal range	NR	NR	NR	NR
C-reactive protein, mg/L	NR	14.7(10.2)	NR	6.81(1.87-15.30)	12(4.4-29.4)	7.66(7.33), mean±SD	E*	
	Increased: 22(62.86%)	NR	> 8 mg/L: 22(52.4%)	> 5 mg/L: 49(53.85%)				
Others	Chloride: Decreased 15(42.86%);			Red blood cell, ×10 ¹² /L: 4.49(4.11-4.81), < 3.8×10 ¹² /L:		Erythrocyte sedimentation rate,		
	CD3+: Decreased 28(80%);			10(10.99%); Thrombocytocrit, %: 0.2(0.15-0.24), > 0.36%:		mm/h: 54(33-90); Lactate, mmol/L:		
	CD4+: Decreased 28(80%);			4(4.40%), < 0.19%: 39(42.86%); Urea, mmol/L: 3.95(3.3-4.49),		1.4(1.1-2.1); Estimated glomerular	F*, G*,	
	CD8+: Decreased 19(54.29%);			< 3.1mmol/L: 19(20.88%); Ca2+, mmol/L: 2.16(2.06-2.25), >		filtration rate, mL/min/1.73m ² :	H*, I*	
	CD4+/CD8+: Decreased 7(20%);			2.52mmol/L: 1(1.10%), < 2.11mmol/L: 11(12.09); Cl-, mmol/L:		109.2(95.3-127.2); CD4 T cells		
	Arterial partial pressure of			103(100.55-105), > 110mmol/L: 1(1.10%), < 99mmol/L:		counts, cells/µL: 431(299-637);		

oxygen: Decreased 9(25.71%).

8(8.79%); PaO₂, mmHg: 75.6(53.5-90.38), > 108mmHg:
6(17.65%), < 83mmHg: 18(52.94%); PaCO₂, mmHg: 36.5(28-41),
> 48mmHg: 1(2.94%), < 35mmHg: 2(5.88%); Lactic acid, mmol/L:
1.4(1.1-1.93), > 1.6mmol/L: 19(55.88%); PH: 7.44(7.40-7.46), >
7.45: 10(29.41%).

CD4/CD8: 1.68(1.24-1.33).

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. A*: 5.2(4.6-6.3) for imported cases(n=15), 4.8(3.4-6.2) for secondary cases(n=17) and 3.9(3.1-5.7) for tertiary cases(n=19). B*: 1.5(0.9-2.1) for imported cases(n=15), 1.1(1.0-1.9) for secondary cases(n=17) and 1.3(0.9-1.6) for tertiary cases(n=19). C*: 22.9(16.6-31.0) for imported cases(n=15), 13.5(11.6-21.1) for secondary cases(n=17) and 25.2(11.7-36.2) for tertiary cases(n=19). D*: 19.0(17.0-31.0) for imported cases(n=15), 17.0(12.5-19.5) for secondary cases(n=17) and 22.0(17.0-34.0) for tertiary cases(n=19). E*: 4.4(1.3-11.2) for imported cases(n=15), 2.2(1.0-16.2) for secondary cases(n=17) and 7.0(0.8-20.0) for tertiary cases(n=19). F*: CD3+ T lymphocyte, %: 69.9(62.9-78.2) for imported cases(n=15), 65.9(60.0-72.9) for secondary cases(n=17) and 72.2(65.8-76.1) for tertiary cases(n=19). G*: CD4+ T lymphocyte, %: 39.9(38.2-45.7) for imported cases(n=15), 37.5(32.2-43.9) for secondary cases(n=17) and 37.4(32.6-40.4) for tertiary cases(n=19). H*: CD8+ T lymphocyte, %: 28.7(22.7-33.9) for imported cases(n=15), 26.7(20.8-31.9) for secondary cases(n=17) and 30.3(26.0-34.0) for tertiary cases(n=19). I*: B lymphocyte, %: 13.9(9.8-18.1) for imported cases(n=15), 11.4(8.4-16.1) for secondary cases(n=17) and 9.1(7.5-10.9) for tertiary cases(n=19).

Table S32 Laboratory findings of the confirmed patients outside of former epicenter c

	Wan 2020	Li 2020 B	Wu 2020 B	Zheng 2020 A	Lo 2020	Feng 2020	Diao 2020	Gao 2020	Li 2020 C
White blood cell count, $\times 10^9/L$	5.4(4.1-7.8)	5.30(4.2-6.80)	5.40(4.20-6.95)	4.36(3.33, 5.42)	5.0(4.4-5.4)	5.29(4.22-7.02)	5.49(4.97-6.48)	NR	NR
White blood cell count $> 10 \times 10^9/L$	$> 9.5 \times 10^9/L:$ 9(6.7%)	Increased: 9(10.8%)	Increased: 10(10%)	3(1.9%)	NR	49/475(10.3%)	NR	NR	
White blood cell count $< 4 \times 10^9/L$	$< 3.5 \times 10^9/L:$ 28(20.7%)	Decreased: 10(12%)	Decreased: 7(9%)	66(41.0%)	Leukopenia: 2(20%)	91/475(19.2%)	Decreased: 1(6.7%)	9(22.5%)	15(30.6%)
Neutrophil count, $\times 10^9/L$	3.5(2.6-4.4)	3.61 A*	3.74(2.67-5.20)	NR	2.6(2.3-3.6)	3.56(2.61-5.42)	3.48(3.23-4.92)	NR	NR
		Increased: 17(20.5%) A*	Increased: 16(20%)					Neutrophil percentage $> 75\%:$ 27(55.1%)	
		Decreased: 5(6%) A*	Decreased: 5(6%)		Neutropenia: 1(10%)		Decreased: 1(6.7%)		
Monocyte count, $10^9/L$	NR	0.39(0.27-0.53) B*	0.41(0.27-0.53)	NR	0.5(0.5-0.6)	NR	NR	NR	NR
		Increased: 12(14.5%) B*	Increased: 8(10%)						
Lymphocyte count, $\times 10^9/L$	1.1(0.7-1.5)	1.05(0.75-1.32)	1.15(0.76-1.40)	1.07(0.77-1.43)	1.3(1.0-1.7)	1.03(0.7-1.45)	1.24(1.00-1.76)	NR	NR
	$< 1.1 \times 10^9/L:$ 68(50.4%)	Decreased: 44(53%)	Decreased: 34(43%)	$< 0.8 \times 10^9/L:$ 42(26.1%)	Lymphopenia: 7(70%)	$< 1 \times 10^9/L:$ 225(47.3%)	Decreased: 5(33.3%)	$< 1 \times 10^9/L:$ 18(45%)	$< 1 \times 10^9/L:$ 30(61.2%)
Hemoglobin, g/L	133(122-147)	NR	NR	130(120-141)	13.1(12.5-14.0)	132(121-144)	NR	NR	NR
				$< 110g/L:$ 13(8.1%)					

Platelet count, × 10⁹/L	158(131-230)	NR	NR	168(131-220)	178(163.5-206.8)	184(145-238)	NR	NR	NR
< 125× 10 ⁹ /L:				< 100× 10 ⁹ /L:					< 100× 10 ⁹ /L: 5(10.2%)
23(17%)				11(6.8%)					
Prothrombin time, s	10.9(10.5-11.4)	NR	NR	NR	12.2(11.7-12.8)	NR	NR	NR	11.9(2), M(QR)
Activated partial thromboplastin time, s	26.9(24.7-29)	NR	NR	NR	34.5(32.4-37.2)	NR	NR	NR	28.5(4.7), M(QR)
D-dimer, mg/L	0.4(0.2-0.6)	NR	NR	NR		0.58(0.35-1.48)	NR	NR	0.66(0.99), M(QR)
Albumin, g/L	40.5(37-43.4)	NR	NR	NR	NR	37.87(32.8-41.84)	NR	NR	35.9(10.8), M(QR)
Alanine aminotransferase, U/L	26(12.9-33.15)	NR	NR	20.3(15.0, 24.5)	24(19.3-35.3)	26(16-41)	NR	NR	NR
				> 40 U/L: 13(8.1%)					≥40 U/L: 13(26.5%)
Aspartate aminotransferase, U/L	33.4(27.8-43.7)	NR	NR	25.1(19.9, 32.8)	20(9.0-42.5)	28(21-39)	NR	NR	NR
	> 40 U/L: 30(22.2%)			> 40 U/L: 22(13.7%)					≥35U/L: 11(22.4%)
Total bilirubin, mmol/L	8.6(5.9-13.7)	NR	NR	10.9(8.37-15.43)	6(4.0-7.0)	10.1(7.5-14)	NR	NR	NR
				> 20.5 mmol/L: 9(5.6%)					
Potassium, mmol/L	4(3.55-4.41)	NR	NR	NR	NR	3.9(3.6-4.2)	NR	NR	NR
Sodium, mmol/L	139(137-141)	NR	NR	NR	NR	139(137-141)	NR	NR	NR

	141)								
Serum creatinine, µmol/L	66(57.8- 74.5)	NR	NR	48.2(38.9, 58.2) > 87 µmol/L: 2(1.2%)	56(46.3-70.8)	66.77(53.66-78.6)	NR	NR	NR
									≥84 µmol/L: 8(16.3%)
Creatine kinase- MB, U/L	NR	NR	NR	NR	NR	13(10.49-16.74)	NR	NR	NR
Creatine kinase, U/L	82.2(56.3- 146.3)	NR	NR	NR	87(60.8-138.5)	82(55-148)	NR	NR	NR
						Increased: 10(7.4%)			
Lactate dehydrogenase, U/L	320.5(248.5- 385.3)	NR	NR	177.1(141.0- 221.9)	228(206.5- 240.5)	259(202-356)	NR	NR	NR
						Increased: 58(43%)			≥214 U/L: 43(87.8%)
Procalcitonin, ng/mL	0.11(0.08- 0.16)	0.048(0.032- 0.085)	0.04(0.03-0.07)	NR	0.03(0.03- 0.04)	0.05(0.02-0.08)	NR	NR	0.02(0.02), M(QR)
						Increased: 1(0.7%)			
						Increased: 44(53%)			
						Increased: 32(40%)			
Blood urea nitrogen, mmol/L	NR	NR	NR	NR	NR	NR	NR	NR	4.7(1.6), M(QR)
C-reactive protein, mg/L	10.5(2.7- 51.2)	16.7(3.58-60.87)	12.39(2.71-50.61)	17.9(8.1- 36.7)	0.4(0.1-0.7), mg/dL	18.8(5.23-57)	NR	NR	NR
Others	Oxyhemoglobin saturation, %:	SaO ₂ , % room air: 97%(96%-98%);	Oxygenation index:	Urea, mmol/L: 3.8(3.0-4.3);	Direct bilirubin, µmol/L: 4(3.1-5.5); Urea, mmol/L: 4.8(3.67-5.89);	Eosinophils percentage, %: Decreased, 9(60.0%);	Serum amyloid A	IL-6, ng/L: 47.9(67.3), M(QR).	

97(95.1-98);	PH value:	366(316-	eGFR, ml/min/1.73m ² : 106(87-125);	Eosinophils count, ×10 ⁹ /L:	≥10mg/L:
Decreased:	7.45(0.02);	393);	Calcium, mmol/L: 2.04(1.96-2.15);	0.01(0.00 ~ 0.04); Neutrophil-	29(72.5%)
16(19.3%)	PaCO ₂ , mm Hg:	39.21(7.25);	Myohemoglobin, ng/ml: 18.85(4.8-51.48); Troponin increased,no. /total:	to-lymphocyte ratio: 2.81(1.69 ~ 4.53); Lymphocyte	
	PaO ₂ , mm Hg:	85.73(22.11)	86/384(22.4%); ESR, mm/h: 48(30-80); BNP, pg/ml: 40.85(21.64-79.37); Lactic acid, mmol/L:	percentage, %: Decreased, 5(33.3%); Lymphocyte	
			2.75(2.23-3.27); Fibrinogen, g/L: 4.4(3.65-5.41);	percentage, %: 23.40(16.80 ~ 32.60).	

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. A*: Neutrophil ratio, %: 71.52(11.31), increased: 25(30.1%), decreased: 1(1.2%); B*: Monocyte ratio, %: 7.17(2.93), increased: 15(18.1%);

Table S33 Laboratory findings of the confirmed patients outside of former epicenter d

	Liang 2020 B	Mao 2020 B	Wang 2020 D	Xiang 2020	Xu 2020 E	Yu 2020 A	Yu 2020 B
White blood cell count, $\times 10^9/L$	NR	NR	NR	5.52±3.50	NR	5. 17±1. 55,(3.32-8.68, range)	NR
White blood cell count $> 10 \times 10^9/L$	Increased: 1(3.6%)	Increased: 2(8.33%)	NR	NR	NR	NR	5(5.7%)
White blood cell count $< 4 \times 10^9/L$	Decreased: 7(25%)	Decreased: 4(16.67%)	Decreased: 3(17.6%)	NR	Decreased: 20(62.5%)	Decreased: 3(12%)	16(18.4%)
Neutrophil count, $\times 10^9/L$	NR	NR	NR	3.84±2.94	NR	NR	NR
			Decreased: 2(11.8%)				
Monocyte count, $10^9/L$	NR	NR	NR	0.36±0.17	NR	NR	NR
Lymphocyte count, $\times 10^9/L$	NR	NR	NR	1.16±0.71	NR	1.39±0.75,(range, 0.75-3.76)	NR
	Decreased: 17(60.7%)	Decreased: 14(58.33%)	Decreased: 7(41.2%)		Decreased: 21(65.6%)	Decreased: 8(32%)	< 1 $\times 10^9/L$: 30(34.5%)
Hemoglobin, g/L	NR	NR	NR	143.3±18.2	NR	NR	NR
Platelet count, $\times 10^9/L$	NR	NR	NR	163.9±65.7	NR	NR	NR
							< 125 $\times 10^9/L$: 10(17.2%)
Prothrombin time, s	NR	NR	NR	12.76±1.49	NR	NR	NR
Activated partial thromboplastin time, s	NR	NR	NR	32.68±13.41	NR	NR	NR
ESR, mm/h	NR	NR	NR	47.00±26.50	NR	13. 89±10. 61,(range,	NR

2-85)

				Increased, 7(41.2%)				Increased: 6(24%)
D-dimer, mg/L	NR	NR	NR		2.51±12.99		NR	NR
				Increased: 1(5.9%)				
Albumin, g/L	NR	NR	NR		42.9±5.08		NR	NR
Alanine aminotransferase, U/L	NR	NR	NR		22.7±12.4		NR	NR
Aspartate aminotransferase, U/L	NR	NR	NR		27.4±12.3		NR	NR
				Increased: 2(11.8%)				
Total bilirubin, mmol/L	NR	NR	NR		8.23±3.76		NR	NR
Potassium, mmol/L	NR	NR	NR		3.83±0.55		NR	NR
Sodium, mmol/L	NR	NR	NR		136.3±3.5		NR	NR
Serum creatinine, µmol/L	NR	NR	Decreased: 2(11.8%)		68.8±23.6		NR	NR
Creatine kinase-MB, U/L	NR	NR	NR		NR		NR	NR
				Increased: 3(17.6%)				
Creatine kinase, U/L	NR	NR	NR		138.2±137.7		NR	NR
				Increased: 2(11.8%)				
				Decreased: 2(11.8%)				
Lactate	NR	NR	NR		276.7±123.1		NR	NR

dehydrogenase, U/L

			Increased: 3(17.6%)					
Procalcitonin, ng/mL	NR	NR	0.04-0.157	0.06±0.08	NR	NR	NR	NR
			Increased: 1(4.17%)					
Blood urea nitrogen, mmol/L	NR	NR	NR	NR	NR	NR	NR	NR
			Decreased: 1(5.9%)					
Urea, mmol/L	NR	NR	NR	4.44±1.59	3.8(3.0-4.3)	NR	NR	NR
C-reactive protein, mg/L	NR	NR	NR	27.77±38.67	NR	NR	NR	NR
			Increased: 7(41.2%)		Increased: 23(71.9%)			
	Increased: 9(37.5%)					> 10mg/L: 48(55.2%)		
Others	Hypoproteinemia: 13(54.17%)			Red blood cell, $\times 10^{12}/L$: 4.56±0.53; Hematocrit, L/L: 0.41±0.05; Eosinophils (Absolute value), $\times 10^9/L$: 0.15±0.89; Globulin, g/L: 27.74±4.56; Direct bilirubin, $\mu\text{mol}/L$: 2.84±1.40; Alkaline phosphatase, U/L: 65.2±22.9; Uric acid, umol/L : 251.4±75.9; Triglycerides, mmol/L: 1.14±0.96; Total cholesterol, mmol/L: 3.69±0.74; High-density lipoprotein, mmol/L: 1.05±0.31; Low density lipoprotein, mmol/L: 2.35±0.72; Amylase, U/L: 65.2±33.6; Cl^- , mmol/L: 97.5±15.3; Ca^{2+} , mmol/L: 2.0±0.1; Serum amyloid protein A, mg/L: 113.05±90.82; Fibrinogen, g/L: 3.84±2.05.	IL-6, pg/mL: 18. 66± 14. 86,(range, 4. 52- 55. 5); IL-6 increased: 20(80. 0%).			

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported.

Table S34 Treatment of the confirmed patients in former epicenter

	Huang 2020 A	Chen 2020 A	Liu 2020 A	Wang 2020 A	Huang 2020 B	Cao2020	Bin 2020
Oxygen therapy	27(66%)	75(76%)	85(62.0%)	106(76.81%)	25(73.5%)	76(74.5%)	NR
Invasive mechanical ventilation	2(5%)	4(4%)	0	17(12.32%)	3(8.8%)	14(13.7%)	NR
Non-invasive mechanical ventilation	10(24%)	13(13%)	34(24.8%)	15(10.9%)	2(5.9%) A*	5(4.9%)	NR
CRRT	3(7%)	9(9%)	NR	2(1.45%)	NR	6(5.9%)	NR
ECMO	2(5%)	3(3%)	0	4(2.9%)	NR	3(2.9%)	NR
Antibiotic treatment	41(100%)	70(71%)	119(86.9%)	B*	31(91.2%)	101(99%)	NR
Antiviral treatment	38(93%)	75(76%)	105(76.6%)	124(89.9)	32(94.1%) C*	100(98%)	55(100%)
Corticosteroid therapy	9(22%)	19(19%)	40(29.2%)	62(44.9)	21(61.8%)	51(50%)	17(30.9%)
Intravenous immunoglobulin therapy	NR	27(27%)	44(32.1%)	NR	NR	11(10.8%)	NR
Antifungal treatment	NR	15(15%)	NR	NR	NR	NR	NR
ICU	13(32%)	23(23%)	NR	36(26.1%)	8(23.5%)	18(17.6%)	NR
Others	NR	NR	NR	Vasopressors: 13(9.4%)	NR	Chinese medicine treatment: 3(2.9%).	Chinese patent medicine: 46(83.6%) D*

Categorical data are n(N%). NR: not reported. CRPT: continuous renal replacement therapy. ECMO: extracorporeal membrane oxygenation. ICU: intensive unit care; A*: Non-invasive ventilation or high flow nasal cannula; B*: Wang2020 reported that many patients received antibacterial therapy(moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]); C*: Other drugs but not lopinavir/ritonavir, and antiviral therapy switched to lopinavir/ritonavir later: 9(26.5%). D*: Oral Lianhua Qingwen capsule;

Table S35 Treatment of the confirmed patients outside of former epicenter a

	Qian 2020	Chen 2020 C	Dai 2020	Xu 2020 D	Wan 2020	Lo 2020	Feng 2020	Gao 2020	Li 2020 C
Oxygen therapy	NR		NR	NR	90(66.7%)	4(40%)	B*	1(2.5%)	
Invasive mechanical ventilation	NR		NR	0	1(0.7%)	0	39(8.2%)	NR	M*
Non-invasive mechanical ventilation	NR		11(4.7%)	0	34(25.2%) A*	0	34(7.1%)	NR	
ECMO	NR	NR	NR	NR	0	NR	4(0.8%)	NR	NR
Antibiotic treatment	NR		118(50.4%)	NR	59(43.7%)	10(100%)	319(67%)	25(62.5%)	32(65.3%)
Antiviral treatment	91(100%)		234(100%)	NR	135(100%)	10(100%)	286(60.1%)	40(100%)	30 (62.1%) D*
Corticosteroid therapy	9(9.9%)		34(14.5%)	NR	36(26.7%)	3(30%)	127(26.7%)	6(15%)	29(59.2%)
Intravenous immunoglobulin therapy	NR		34(14.5%)	NR	NR	NR	NR	NR	24(49%)
Antifungal treatment	NR		NR	NR	NR	0	8(1.7%)	NR	NR
Hemofiltration therapy	NR	NR	NR	NR	R	NR	NR	1(2.5%)	2(4.1%)
Interferon therapy	NR	NR	NR	NR	NR	3(30%)	NR	Aerosol inhalation of α interferon: 40(100%)	Aerosol inhalation: 37(75.5%)
Traditional Chinese medicine	NR	NR	NR	NR	124(91.8%)	NR	NR	NRN	Chinese patent medicine:42(85.7%)
ICU	9(9.89%)	22(8.8%)	0	NR	NR	NR	NR	NR	NR
Others					Continuous renal replacement therapy: 5(3.7%);				

Categorical data are n(N%). NR: not reported. ECMO: extracorporeal membrane oxygenation. ICU: intensive unit care; A*: Non-invasive ventilation or high-flow nasal cannula. B*: Nasal cannula or no oxygen therapy 368(77.3%), and high-flow nasal cannula 31(6.5%). C*: Air suction 6(12.2%), intranasal oxygen inhalation 17(34.7%), oxygen therapy / assisted ventilation 26(53.1%). D*: One antiviral drug alone 30(62.1%), combined two antiviral drugs 19(38.8%).

Table S36 Treatment of the confirmed patients outside of former epicenter/ nationwide b

	Wang 2020 D	Yu 2020 A	Xu 2020 A	Guan 2020	Yang 2020	Wu 2020 A
Oxygen therapy	NR	NR	NR	454(41.3%)	134(89.93%)	35(43.75%)
Invasive mechanical ventilation	NR	NR	NR	25(2.3%)	0	0
Non-invasive mechanical ventilation	NR	NR	NR	56(5.1%)	2(1.34%)	0
ECMO	NR	NR	NR	5(0.5%)	NR	0
Antibiotic treatment	NR	NR	28(45%)	637(58.0%)	34(22.82%)	73(91.25%)
Antiviral treatment	NR	25(100%)	55(89%)	393(35.8%)	140(93.96%)	80(100.00%)
Corticosteroid therapy	NR	2(8%)	16(26%)	204(18.6%)	5(3.36%)	NR
Intravenous immunoglobulin therapy	NR	NR	NR	144(13.1%)	19(12.75%)	16(20.00%)
Antifungal treatment	NR	NR	NR	31(2.8%)	0	NR
Interferon therapy	NR	Recombinant human interferon α 2B injection: 25(100%)	NR	NR	144(96.64%)	NR
Traditional Chinese medicine	17(100%)	NR	NR	NR	NR	3(3.75%)
ICU	NR	NR	1(2%)	55(5%)	0	NR
Others				CRRT: 9(0.8%)		Hormone therapy: 12(14.63%).

Categorical data are n(N%). NR: not reported. CRPT: continuous renal replacement therapy. ECMO: extracorporeal membrane oxygenation. ICU: intensive unit care.

Table S37 Percentages of epidemiological and clinical characteristics among the confirmed patients: Non-severe/severe (median, IQR)

Subject	Non-severe, %	Severe, %	p
Epidemiological characteristics and comorbidities			
Male	51(40-59)	57(52-69)	0.04
Age>45-60, y	48(31-55)	78(58-78)	0.017
Current smoker	8.1(3.8-10)	3.4(1.3-15)	1
Former smoker	3.7(1.3-17)	6.9(5.2-25)	0.4
Exposure former epicenter	62(49-83)	59(18-85)	0.721
Exposure to confirmed patients	44(19-68)	41(13-70)	1
Medical staff	3.7(0-62)	0(0-22)	0.7
Cluster/ gathering infection	37(16-54)	32(8.2-58)	0.886
Death	0(0-0.9)	6.5(1.3-17)	0.056
Any comorbidities	21(17-35)	50(41-64)	0.003
Hypertension	9.4(5.2-21)	32(11-40)	0.007
Cardiovascular disease	1.8(1.2-4.5)	6.7(4-14)	0.026
Cerebrovascular disease	2.3(1.2-2.3)	3.3(2.3-7.3)	0.2
Cardio-cerebrovascular disease	6.3(1-19)	11(8-15)	0.7
COPD	1.7(0-3.1)	10(3.5-16)	0.002
Other chronic respiratory disease	4.8(0-9.5)	11(2.5-20)	1
Diabetes	3.8(0-11)	16(11-23)	0.001
Chronic liver disease	4.1(1.5-13)	1.3(0-5.8)	0.343
Immunodeficiency/HIV	0.4(0.2-0.6)	2(0-4)	1
Hepatitis B infection	1.2(0-2.4)	5.9(0.6-11)	1
Malignancy	1.2(0.85-5.1)	5.7(2.7-7.1)	0.2
Chronic kidney disease	0.55(0.13-2.6)	2(1.6-3.1)	0.2
Signs, symptoms and complications			
Fever	84(72-91)	87(69-96)	0.724

Highest temperature > 39°C	4.9(3.4-6.2)	3.5(2.4-4.5)	0.343
Chills	11(6.6-12)	15(8.6-25)	0.222
Cough	67(61-71)	70(57-87)	0.381
Sputum production	23(8.8-35)	44(26-57)	0.063
Dyspnea	7.7(2.4-15)	33(23-57)	0.001
Chest tightness	9.3(8.6-10)	7.7(0-15.4)	0.222
Chest pain	2.8(1.7-3.9)	11.8(7.6-16)	0.333
Hemoptysis	0.8(0.6-1.3)	2.6(0.58-6.4)	0.343
Fatigue	36(20-55)	33(30-79)	0.436
Myalgia	15(9.4-22)	17(11-34)	0.436
Headache	10(6.3-16)	13(8.4-19)	0.546
Sore throat	17(7.9-18)	8.7(0-13)	0.053
Diarrhea	11(5.2-20)	11(1.7-24)	0.863
Nausea or vomiting	4.6(3.9-35)	5.2(0-10)	0.818
Abdominal pain	2.8(1.65-7.25)	7.4(1.7-9.88)	0.686
Dizziness	11.1(7.1-15.1)	9.65(0-19.3)	1
Inappetence	11(3.55-26.8)	15(10.85-36.95)	0.421
ARDS	1.1(1.1-1.1)	32.8(15.6-50)	0.333
Acute cardiac injury	8.4(8.4-8.4)	5(5-5)	1
Acute kidney injury	2.05(0.1-4)	2.7(2.5-2.9)	1
Shock	0.05(0-0.1)	4.45(2.5-6.4)	0.333
Secondary infection	1.95(0-3.9)	19.9(17.5-22.3)	0.333
Radiological and laboratory findings			
Bilateral involvement	79.3(46.8-90.15)	93(89.5-100)	0.011
Local patchy opacity	39.2(11.5-71.8)	55.1(7-63.3)	1
Ground glass opacity	6.55(0.8-12.3)	99.1(66.7-100)	0.259
Consolidation	31.4(15.6-49.65)	45.2(27.23-73.9)	0.31
Pleural effusion	2.35(0-7.9)	15.4(12.88-29.93)	0.002
Interlobular septal thickening	59.25(43.5-75)	69.2(96.2-69.2)	1
Crazy-paving pattern	29.1(27.6-30.6)	55.1(54.2-56)	0.333

Bronchial Wall Thickening	5.2(4.1-21.3)	64(42.8-70.8)	0.1
Air bronchogram	40.5(27.4-53.6)	50(46.2-53.8)	1
Lymph node enlargement	1.8(0-6.98)	15.2(1.78-26.83)	0.343
Upper lobes involvement	64.7(18.58-83.6)	92.3(23.08-95.08)	0.343
Lower lobes involvement	75(45.98-97.5)	96.15(60.58-100)	0.486
No abnormality	7.65(2.5-15.73)	0(0-2.18)	0.057
White blood cell count > 9.5-10 × 10 ⁹ /L	6.6(4.8-8.6)	16(7.5-23.2)	0.209
White blood cell count < 3.5-4 × 10 ⁹ /L	25(19.1-31.3)	16.1(11.1-30)	0.383
Lymphocyte count < 1-1.5×10 ⁹ /L	38(16-79.3)	82.1(71.8-88.9)	0.073
Platelet count < 100-150 g/L	11.6(6.1-31.6)	30(10-57.7)	0.7
D-dimer > 0.5 mg/L	35.9(28.6-43.2)	59.45(59.3-59.6)	0.333
Alanine aminotransferase > 40 U/L	12.95(6.1-19.8)	22.4(16.7-28.1)	1
Aspartate aminotransferase >40 U/L	16(7.2-18.2)	39.4(37.5-40)	0.1
LDH > 225-250 U/L	33.1(20.45-46.8)	62.4(52.03-72.93)	0.029
Total bilirubin > 21-26 mmol/L	7.25(4.6-9.9)	11.65(10-13.3)	0.333
Creatine kinase >190-200 U/L	4.55(2.85-10.9)	18.25(13.38-27.25)	0.057
Serum creatinine > 87-97 μmol/L	1.9(0.8-3)	5.4(3.3-7.5)	0.333
Procalcitonin > 0.5 ng/mL	3.7(0-39.7)	13.7(2.5-84)	0.7
C-reactive protein > 10 mg/L	56.3(41.3-62.95)	81.5(46.9-96)	0.151
Treatment			
Oxygen therapy	48.35(8.93-90.25)	48.05(15.93-77.78)	1
Invasive mechanical ventilation	0(0-0)	14.5(2.5-31.5)	0.267
Non-invasive mechanical ventilation	0(0-7.4)	32.4(27.4-67.5)	0.267
CRRT	0.5(0-1)	7.6(5.2-10)	0.333
ECMO	0(0-0)	2.9(0-3.2)	0.2
Antibiotic treatment	53.8(25-59.4)	87.5(80.3-88.7)	0.1
Antiviral treatment	68.25(39.48-95)	79.55(52.2-97.23)	0.686
Corticosteroid therapy	13.7(13.4-15.8)	52.5(44.5-64.5)	0.1
Intravenous immunoglobulin therapy	9.3(9.3-9.3)	33.5(33.5-33.5)	1
Antifungal treatment	1.25(0.6-1.9)	6.15(4.8-7.5)	0.333

TCM	83.55(75.6-91.5)	90.7(88.9-92.5)	1
Percentage of patients in severe condition or not of each subject is in median and interquartile ranges (IQR). COPD: Chronic obstructive pulmonary disease; ARDS: Acute respiratory distress syndrome; LDH: Lactate dehydrogenase; CRRT: Continuous renal replacement therapy; ECMO: Extracorporeal membrane oxygenation; TCM: Traditional Chinese medicine.			

Table S38 Epidemiological and clinical characteristics of the confirmed patients with severe condition or not

	Non severe	Severe
	Epidemiological characteristics	
	Total	
Guan 2020	926/1099(84.3%)	173/1099(15.7%)
Mao 2020 A	126(58.9%)	88(41.1%)
Zhang 2020 B	82(58.6%)	58(41.4%)
Xu 2020 B	37(74%)	13(26%)
Tian 2020	216(42.4%)	46(17.6%)
Li 2020 A	16(64%)	9(36%)
Qian 2020	82(90.1%)	9(9.9%)
Liu 2020 C	49(67.1%)	24(32.9%)
Wan 2020	95(70.4%)	40(29.6%)
Li 2020 B	58(69.9%)	25(30.1%)
Tang 2020	70(84.3%)	13(15.7%)
Zheng 2020	131(81.4%)	30(18.6%)
Zhao 2020	87(86.1%)	14(13.9%)
Lo 2020	6(60%)	4(40%)
Feng 2020	352(73.9%)	124(26.1%)
Bin 2020	45(81.8%)	9(16.4%)

Wang 2020 C	42(43.8%)	54(56.2%)
Li 2020 C	22(44.9%)	27(55.1%)
Lv 2020	13(76.5%)	4(23.5%)
Xiang 2020	40(81.6%)	9(18.4%)
Male		
Guan 2020	537/923(58.2%)	100(57.8%)
Mao 2020 A	43(34.1%)	44(50.0%)
Zhang 2020 B	38(46.3%)	33(56.9%)
Xu 2020 B	22(59.5%)	7(53.8%)
Tian 2020	101(46.8%)	26(56.5%)
Li 2020 A	6(37.5%)	6(66.7%)
Liu 2020 C	31(63.3%)	10(41.7%)
Wan 2020	52(54.7%)	21(52.5%)
Li 2020 B	29(50%)	15(60%)
Zheng 2020	66(50.4%)	14(46.7%)
Zhao 2020	48(55.2%)	8(57.1%)
Lo 2020	2(33%)	1(25%)
Feng 2020	190(54%)	81(65.3%)
Bin 2020	23(51.1%)	7(77.8%)
Wang 2020 C	15(35.7%)	31(57.4%)
Li 2020 C	9(40.9%)	19(70.4%)
Lv 2020	8(61.5%)	4(100%)
Xiang 2020	25(62.5%)	8(88.9%)
Female		
Guan 2020	386/923(41.8%)	73(42.2%)
Mao 2020 A	83(65.9%)	44(50.0%)
Zhang 2020 B	44(53.7%)	25(43.1%)
Xu 2020 B	15(40.5%)	6(46.2%)
Tian 2020	115(53.2%)	20(43.5%)
Li 2020 A	10(62.5%)	3(33.3%)
Liu 2020 C	18(36.7%)	14(58.3%)

Wan 2020	43(45.3%)	19(47.5)
Li 2020 B	29(50%)	10(40%)
Zheng 2020	65(49.6%)	16(53.3%)
Zhao 2020	39(44.8%)	39(44.8%)
Lo 2020	4(67%)	3(75%)
Feng 2020	162(46%)	43(34.7%)
Bin 2020	22(48.9%)	2(22.2%)
Li 2020 C	13(59.1%)	8(29.6%)
Lv 2020	5(38.5%)	0
Xiang 2020	15(37.5%)	1(11.1%)
Age, Median(IQR)		
Guan 2020	45.0(34.0–57.0)	52.0(40.0–65.0)
Zhang 2020 B	51.5, range: 26-78	64, range: 25-87
Xu 2020 B	40.7, range: 3-62	57.2, range: 34-85
Tian 2020	44.5, range: 1-93	61.4, range: 1-94
Wan 2020	44(33-49)	56(52-73)
Zheng 2020	40(31-51)	57(46.5-66)
Feng 2020	51(37-63)	Severe: 58(48-67), n=54; Critical: 61(49-68), n=70
Li 2020 C, M(QR)	31.5(17.5)	54(23.5)
Age, ≥50(y)		
Guan 2020	350/848(54.7%)	95/163(58.3%)
Mao 2020 A	60(47.6%)	64(72.7%)
Zhang 2020 B	50(61%)	48(82.8%)
>50, Xu 2020 B	10(27%)	5(38.5%)
≥45, Tian 2020	103(47.7%)	36(78.2%)
> 51, Li 2020 A	5(31.3%)	7(77.8%)
≥65, Feng 2020	73(20.7%)	45(36.3%)
> 60, Wang 2020 C	17(40.5%)	42(77.8%)
Age, Mean(SD)		
Mao 2020 A	48.9(14.7)	58.2(15.0)
Qian 2020	49(35.3-56)	66(54-80)

Liu 2020 C	Mild: 29.2(10.9); Common: 33.4(12.2)	Severe: 44.2(12.0); Critical: 63.0(21.2)
Li 2020 B	41.9(10.6)	53.7(12.3)
Tang 2020	43.7(15)	57.4(11.8)
Zhao 2020	42.94(11.7)	53.71(12.6)
Lo 2020	37(19)	61(5)
Bin 2020	52.1(17.6)	64.4(9.9)
Lv 2020	53.4(12.5)	47.8(8.3)
Xiang 2020	40.6(14.3)	53(14)
Current smoker		
Guan 2020	108/913(11.8%)	29/172(16.9%)
Zhang 2020 B	0	2(3.4%)
Wan 2020	8(8.4%)	1(2.5%)
Feng 2020	27/333(8.1)	17/121(14%)
Xiang 2020	3(7.5%)	0
Former smoker		
Guan 2020	12/913(1.3%)	9/172(5.2%)
Zhang 2020 B	3(3.7%)	4(6.9%)
Lo 2020	1(17%)	1(25%)
Never smoking		
Guan 2020	793/913(86.9%)	134/172(77.9%)
Li 2020 A	14(87.5%)	4(44.4%)
BMI		
>24kg/m², Wang 2020 C	14(33.3%)	30(55.6%)
Xiang 2020	24.55±4.04	26.17±3.93
Exposure to the former epicenter		
Xu 2020 B	24(48%)	6(12%)
Tian 2020	48(22.2%)	5(10.9%)
Liu 2020 C	33(67.3%)	21(87.5%)
Wan 2020	56(58.9%)	15(37.5%)
Zheng 2020	84(64.1%)	20(66.7%)
Feng 2020	312(88.6)	113(91.1%)

Li 2020 C	11(50%)	14(51.9%)
Xiang 2020	39(97.5%)	7(77.7%)
Exposure to confirmed patients		
Wan 2020	18(18.9%)	5(12.5%)
Li 2020 C	15(68.2%)	19(70.4%)
Contact with wildlife		
Guan 2020	10/559(1.8%)	3/128(2.3%)
Onset of symptoms to hospital admission(d)		
Zhang 2020 B	8(5-11)	7(6-12)
Tian 2020	4.4(3.5)	5.2(4.6)
Li 2020 B	6(3-8.5)	8(6-12)
Zheng 2020	6(3-8)	6(3.75-8)
Feng 2020	6(3-10)	Severe: 7(4-10), n=54; Critical: 9(7-13), n=70
Incubation period		
Guan 2020	4.0(2.8-7.0)	4.0(2.0-7.0)
Tian 2020	2.1(1.9)	2.1(1.6)
Li 2020 C, M(QR)	7(3)	6(2.5)
Xiang 2020	4.7(4.4)	4.5(0.7)
Medical staff		
Zhang 2020 B	3(3.7%)	0
Li 2020 A	10(62%)	2(22.2%)
Lo 2020	0	0
Familiar/cluster/ Close contact infections		
Zhang 2020 B	11(13.4)	4(6.9)
Xu 2020 B	12(24%)	6(12%)
Tian 2020	109(50.5%)	24(52.2%)
Li 2020 C	12(54.5%)	16(59.3%)
Clinical outcomes		
Discharge		
Guan 2020	50(5.4%)	5(2.9%)
Tian 2020	43(19.9%)	2(4.3%)

Wan 2020	10(1.05%)	5/(12.5%)
Feng 2020	334(94.9%)	69(55.6%)
Staying in hospital		
Guan 2020	875(94.5%)	154(89.0%)
Tian 2020	173(80.1%)	41(89.1%)
Wan 2020	85(89.5%)	35(87.5%)
Feng 2020	6(1.7%)	17(13.7%)
Death		
Guan 2020	1(0.1%)	14(8.1%)
Tian 2020	0	3(6.5%)
Wan 2020	0	1/(2.5%)
Lo 2020	0	0
Feng 2020	6(1.7%)	32(25.8%)
Comorbidity		
Any comorbidity		
Guan 2020	194(21.0%)	67(38.7%)
Mao 2020 A	41(32.5%)	42(47.7%)
Zhang 2020 B	44(53.7%)	46(79.3%)
Wan 2020	15(16.3%)	28(70%)
Li 2020 B	4(6.9%)	11(44%)
Tang 2020	12(17.1%)	4(30.8%)
Zhao 2020	23(26.4%)	7(50%)
Lo 2020	1(17%)	2(50%)
Feng 2020	133(37.8%)	72(58.1%)
Hypertension		
Guan 2020	124(13.4%)	41(23.7%)
Mao 2020 A	19(15.1%)	32(36.4%)
Zhang 2020 B	20(24.4%)	22(37.9%)
Li 2020 A	1(6%)	1(11.1%)
Wan 2020	9(9.4%)	4(10%)
Li 2020 B	3(5.2%)	2(8%)

Zheng 2020	10(7.6%)	12(40%)
Feng 2020	73(20.7%)	40(32.3%)
Wang 2020 C	15(35.7%)	35(64.8%)
Li 2020 C	1(4.5%)	8(29.6%)
Xiang 2020	2(5%)	4(44.4%)
Diabetes		
Guan 2020	53(5.7%)	28(16.2%)
Mao 2020 A	15(11.9%)	15(17.0%)
Zhang 2020 B	9(11.0%)	8(13.8%)
Li 2020 A	0	1(11.1%)
Wan 2020	3(3.1%)	9(22.5%)
Li 2020 B	0	7(28%)
Zheng 2020	5(3.8%)	2(6.7%)
Feng 2020	32(9.1%)	17(13.7%)
Wang 2020 C	6(14.3%)	19(35.2%)
Li 2020 C	0	1(3.7%)
Xiang 2020	0	2(22.2%)
Cardiovascular disease		
Feng 2020	21(6%)	17(13.7%)
Li 2020 C	1(4.5%)	4(14.8%)
Guan 2020 (Coronary heart disease)	17(1.8%)	10(5.8%)
Zhang 2020 B (Coronary heart disease)	3(3.7%)	4(6.9%)
Li 2020 B (Coronary heart disease)	0	1(4%)
Zheng 2020 (Coronary heart disease)	2(1.5%)	2(6.7%)
Zhang 2020 B (Aorta sclerosis)	1(1.2%)	1(1.7%)
Cerebrovascular disease		
Guan 2020	11(1.2%)	4(2.3%)
Zheng 2020	3(2.3%)	1(3.3%)
Feng 2020	8(2.3%)	9(7.3%)
Cardio cerebrovascular disease		
Mao 2020 A	8(6.3)	7(8.0)

Li 2020 A	3(18.8%)	1(11.1%)
Wan 2020	1(1%)	6(15%)
Chronic gastritis and gastric ulcer		
Zhang 2020 B	5(6.1%)	2(3.4%)
Cholelithiasis		
Zhang 2020 B	2(2.4%)	4(6.9%)
Hyperlipidemia		
Zhang 2020 B	5(6.1%)	2(3.4%)
COPD		
Guan 2020	6(0.6%)	6(3.5%)
Zhang 2020 B	0	2(3.4%)
Li 2020 A	1(6%)	4(44.4%)
Wan 2020	0	4(10%)
Li 2020 B	1(1.7%)	4(16%)
Zheng 2020	4(3.1%)	2(6.7%)
Feng 2020	8(2.3%)	14(11.3%)
Malignancy		
Guan 2020	7(0.8%)	3(1.7%)
Mao 2020 A	8(6.3%)	5(5.7%)
Wan 2020	1(1%)	3(7.5%)
Feng 2020	5(1.4%)	7(5.6%)
Chronic kidney disease		
Guan 2020	5(0.5%)	3(1.7%)
Mao 2020 A	4(3.2%)	2(2.3%)
Zhang 2020 B	0	2(3.4%)
Feng 2020	2(0.6%)	2(1.6%)
Chronic liver disease		
Wan 2020	1(1%)	1(2.5%)
Zheng 2020	4(3.1%)	0
Xiang 2020	6(15%)	0
Zhang 2020 B (Fatty liver and abnormal liver function)	4(5.0%)	4(6.9%)

Immunodeficiency/HIV		
Guan 2020	2(0.2%)	0
Feng 2020(Immunosuppression)	2(0.6%)	5(4%)
Hepatitis B infection		
Guan 2020	22(2.4%)	1(0.6%)
Li 2020 C	0	3(11.1%)
Arrhythmia		
Zhang 2020 B	1(1.2%)	4(6.9%)
Thyroid diseases		
Zhang 2020 B	1(1.2%)	4(6.9%)
Electrolyte imbalance		
Zhang 2020 B	0	4(6.9%)
Urolithiasis		
Zhang 2020 B	2(2.4%)	1(1.7%)
Stroke		
Zhang 2020 B	1(1.2%)	2(3.4%)
Aorta sclerosis		
Zhang 2020 B	1(1.2%)	1(1.7%)
Secondary pulmonary tuberculosis		
Zhang 2020 B	0	2(3.4%)
Other pulmonary disease		
Wan 2020	0	1(2.5%)
Wang 2020 C	4(9.5%)	11(20.4%)
Signs and symptoms on admission		
Fever		
Guan 2020	391/910(43%)	82/171(48%)
Mao 2020 A	92(73.0%)	40(45.5%)
Zhang 2020 B	59/67(88.1%)	51/53(96.2%)
Xu 2020 B	33(66%)	10(20%)
Tian 2020	178(82.4%)	37(80.4%)
Li 2020 A	15(93.8%)	9(100%)

Liu 2020 C	45(91.8%)	23(95.8%)
Wan 2020	86(90.1%)	34(85%)
Li 2020 B	50(86.2%)	22(88%)
Tang 2020	61(87.1%)	11(84.6%)
Zheng 2020	93(71%)	29(96.7%)
Feng 2020	277/337(82.2%)	113/117(91.1%)
Wang 2020 C	30(71.4%)	41(75.9%)
Li 2020 C	22(100%)	25(92.6%)
Lv 2020	13(100%)	4(100%)
Xiang 2020	32(80%)	6(66.7%)
Fever during hospitalization		
Guan 2020	816/926(88.1%)	159/173(91.9%)
Highest temperature > 39°C		
Guan 2020	30/910(3.3%)	8/171(4.7%)
Xu 2020 B	3(6%)	2(4%)
Tian 2020	8(3.7%)	1(2.2%)
Wan 2020	6(6.3%)	1(2.9%)
Highest temperature > 39°C during hospitalization		
Guan 2020	88/774(11.4%)	26/152(17.1%)
Highest temperature < 37.5°C		
Guan 2020	519/910(57.0%)	89/171(52.0%)
<37.3°C, Xu 2020 B	7(19%)	3(23%)
<37.3°C, Tian 2020	38(17.6%)	9(19.6%)
<37.3°C, Li 2020 A	1(6.2%)	0
<37.3°C, Wan 2020	11(11.6%)	5(14.3%)
Highest temperature < 37.5°C during hospitalization		
Guan 2020	79/774(10.2%)	13/152(8.6%)
Cough		
Guan 2020	623(67.3%)	122(70.5%)
Mao 2020 A(dry cough)	77(61.1%)	30(34.1%)
Zhang 2020 B	45/67(67.2%)	45/53(84.9%)

Xu 2020 B	14(28%)	6(12%)
Tian 2020	95(44.0%)	25(54.3%)
Li 2020 A	11(68.8%)	6(66.7%)
Liu 2020 C	40(81.6%)	20(83.3%)
Wan 2020	67(70.5%)	35(87.5%)
Li 2020 B	41(70.7%)	24(96%)
Tang 2020	50(71.4%)	10(76.9%)
Zheng 2020	80(61.1%)	21(70%)
Feng 2020(Dry cough)	220/336(65.5%)	49/117(39.5%)
Wang 2020 C	26(61.9%)	44(81.5%)
Li 2020 C	19(86.4%)	18(66.7%)
Lv 2020	11(84.6%)	4(100%)
Xiang 2020	13(32.5%)	6(66.7%)
Sputum production		
Guan 2020	309(33.4%)	61(35.3%)
Xu 2020 B	5(10%)	2(4%)
Liu 2020 C	23(46.9%)	16(66.7%)
Wan 2020	5(5.3%)	7(17.5%)
Li 2020 B	6(10.3%)	9(36%)
Tang 2020	26(37.1%)	8(61.5%)
Feng 2020	100/336(29.8%)	61/117(52.1%)
Li 2020 C	5(22.7%)	14(51.9%)
Xiang 2020	3(7.5%)	4(44.4%)
Dyspnea		
Guan 2020	140(15.1%)	65(37.6%)
Zhang 2020 B	20/67(29.9%)	24/53(45.3%)
Xu 2020 B(chest tightness or dyspnea)	0	4(8%)
Tian 2020	3(1.4%)	15(32.6%)
Li 2020 A	12(75%)	8(88.9%)
Wan 2020	0	18(18.9%)
Li 2020 B	2(3.4%)	7(28%)

Tang 2020	3(4.3%)	4(30.8%)
Tang 2020(气促)	11(15.7%)	8(61.5%)
Zheng 2020	14(10.7%)	9(30%)
Feng 2020	50/335(14.9%)	59/112(52.7%)
Li 2020 C	1(4.5%)	3(11.1%)
Lv 2020	1(7.7%)	3(75%)
Fatigue		
Guan 2020	350(37.8%)	69(39.9%)
Xu 2020 B	2(4%)	6(12%)
Tian 2020	54(25.0%)	15(32.6%)
Li 2020 A(fatigue or muscular soreness)	13(81.3%)	4(44.4%)
Liu 2020 C	35(71.4%)	20(83.3%)
Tang 2020	21(30%)	4(30.8%)
Zheng 2020	49(37.4%)	15(30%)
Li 2020 C	8(36.4%)	24(88.9%)
Lv 2020	10(76.9%)	3(75%)
Xiang 2020	6(15%)	3(33.3%)
Myalgia		
Guan 2020(myalgia or arthralgia)	134(14.5%)	30(17.3%)
Mao 2020 A	6(4.8%)	17(19.3%)
Zhang 2020 B	51/67(76.1%)	39/53(73.6%)
Xu 2020 B	4(8%)	4(8%)
Wan 2020(myalgia or arthralgia)	25(26.3%)	19(47.5%)
Li 2020 B	10(17.2%)	5(20%)
Tang 2020	11(15.7%)	1(7.7%)
Zheng 2020	14(10.7%)	4(13.3%)
Feng 2020	38/333(11.4%)	17/105(16.2%)
Headache		
Guan 2020	124(13.4%)	26(15.0%)
Mao 2020 A	15(17.0%)	13(10.3%)
Xu 2020 B	3(6%)	2(4%)

Tian 2020	14(6.5%)	3(6.5%)
Wan 2020	23(24.2%)	11(27.5%)
Li 2020 B	6(10.3%)	3(12%)
Tang 2020	10(14.3%)	2(15.4%)
Zheng 2020	8(6.1%)	4(13.3%)
Xiang 2020(headache/dizziness)	4(10%)	2(22.2%)
Hemoptysis		
Guan 2020	6(0.6%)	4(2.3%)
Wan 2020	1(1%)	3(7.5%)
Tang 2020	1(1.4%)	0
Feng 2020	2/332(0.6%)	3/103(2.9%)
Diarrhea		
Guan 2020	32(3.5%)	10(5.8%)
Mao 2020 A	28(22.2%)	13(14.8%)
Zhang 2020 B	9/82(11.0%)	9/57(15.8%)
Li 2020 A	4(25%)	1(11.1%)
Wan 2020	5(5.3%)	13(32.5%)
Tang 2020	5(7.1%)	0
Zheng 2020	16(12.2%)	1(3.3%)
Li 2020 C	4(18.2%)	27(100%)
Xiang 2020	2(5%)	0
Gastrointestinal reaction		
Xu 2020 B	1(2%)	0
Feng 2020(Digestive symptoms)	39/336(11.6%)	10/110(9.1%)
Sore throat		
Guan 2020	130(14.0%)	23(13.3%)
Mao 2020 A	21(16.7%)	10(11.4)
Xu 2020 B	3(6%)	1(2%)
Wan 2020	24(25.3%)	0
Tang 2020	12(17.1%)	2(15.4%)
Feng 2020	26/330(7.9%)	9/103(8.7%)

Xiang 2020	7(17.5%)	0
Respiratory rate		
Tian 2020	123.7(14.4)	126.1(16.4)
Wan 2020(> 24/min)	3(3.2%)	9(22.5%)
Li 2020 B	20(20-22)	21(19.5-24.5)
Xiang 2020	20.0±2.4	23.2±6.2
Nausea or vomiting		
Guan 2020	43(4.6%)	12(6.9%)
Zhang 2020 B(nausea)	19/82(23.2%)	5/57(8.8%)
Zhang 2020 B(vomiting)	5/82(6.1%)	2/57(3.5%)
Wan 2020(retching)	4(4.2%)	0
Tang 2020	2(2.9%)	2(15.4%)
Zheng 2020	6(4.6%)	0
Chill		
Guan 2020	100(10.8%)	26(15.0%)
Wan 2020	7(7.4%)	7(17.5%)
Tang 2020	8(11.4%)	1(7.7%)
Feng 2020	17/300(5.7%)	7/74(9.5%)
Xiang 2020	5(12.5%)	3(33.3%)
Dizziness		
Mao 2020 A	19(15.1%)	17(19.3%)
Tang 2020	5(7.1%)	0
Anorexia		
Mao 2020 A	47(37.3%)	21(23.9%)
Zhang 2020 B	9/82(11.0%)	8/57(14.0%)
Liu 2020 C	8(16.3%)	12(50%)
Wan 2020	0	6(15%)
Tang 2020	5(7.1%)	1(7.7%)
Abdominal pain		
Mao 2020 A	4(3.2%)	6(6.8%)
Zhang 2020 B	2/82(2.4%)	6/57(10.5%)

Li 2020 B (Abdominal pain/ Diarrhea)	5(8.6%)	2(8%)
Tang 2020	1(1.4%)	0
	Tonsil swelling	
Guan 2020	17(1.8%)	6(3.5%)
	Nasal congestion	
Guan 2020	47(5.1%)	6(3.5%)
	Conjunctival congestion	
Guan 2020	5(0.5)	4(2.3)
	Enlargement of lymph nodes	
Guan 2020	1(0.1%)	1(0.6%)
	Impaired consciousness	
Mao 2020 A	3(2.4%)	13(14.8%)
	Acute cerebrovascular disease	
Mao 2020 A	1(0.8%)	5(5.7%)
	Ataxia	
Mao 2020 A	0	1(1.1%)
	Seizure	
Mao 2020 A	0	1(1.1%)
	Taste impairment	
Mao 2020 A	9(7.1%)	3(3.4%)
	Smell impairment	
Mao 2020 A	8(6.3%)	3(3.4%)
	Vision impairment	
Mao 2020 A	1(0.8%)	2(2.3%)
	Nerve pain	
Mao 2020 A	1(0.8%)	4(4.5%)
	Neurological symptoms	
Feng 2020	35/334(10.5%)	12/106(11.3%)
	Rash	
Guan 2020	0	2(1.2%)
	Throat congestion	

Guan 2020	17(1.8%)	2(1.2%)
Belching		
Zhang 2020 B	4/82(4.9%)	3/57(5.3%)
Chest operation history		
Li 2020 A	6(37.5%)	7(77.8%)
Palpitation		
Wan 2020	2(2.1%)	3(7.5%)
Chest tightness and shortness of breath		
Wan 2020	9(9.5%)	3(7.5%)
Diastolic pressure, mm Hg		
Wan 2020	76(71-86)	76(70-80)
Xiang 2020	80.7±12.7	69.1±10.8
Systolic pressure, mm Hg		
Wan 2020	119(111-128)	121(112-133)
Xiang 2020	123.8±14.9	122.1±16.9
Median arterial pressure(mmHg)		
Li 2020 B	93.3(87.2-103.3)	91(84.3-100.5)
Pharyngeal discomfort		
Li 2020 B	4(6.9%)	2(8%)
Chest pain		
Li 2020 B	1(1.7%)	4(16%)
Feng 2020	13/335(3.9%)	8/105(7.6%)
Tang 2020(Chest distress)	6(8.6%)	2(15.4%)
Xiang 2020(Chest distress)	4(10%)	0
Others		
Tang 2020(Catarrhal symptoms)	7(10%)	0
Tang 2020(Thirst)	1(1.4%)	1(7.7%)
Xiang 2020(Asymptomatic infection)	3(7.5%)	0
Complications		
ARDS		
Guan 2020	10(1.1%)	27(15.6%)

Wan 2020	1(1.1%)	20(50%)
Acute kidney injury		
Guan 2020	1(0.1%)	5(2.9%)
Wan 2020	4(4%)	1(2.5%)
Acute cardiac injury		
Wan 2020	8(8.4%)	2(5%)
Shock		
Guan 2020	1(0.1%)	11(6.4%)
Wan 2020	0	1(2.5%)
Rhabdomyolysis		
Guan 2020	2(0.2%)	0
Disseminated intravascular coagulation		
Guan 2020	0	1(0.6%)
Pneumonia		
Guan 2020	800/894(89.5%)	172(99.4%)
Secondary infection		
Wan 2020	0	7(17.5%)
Feng 2020	12/307(3.9%)	23/103(22.3%)
Main radiological findings		
Bilateral involvement of chest CT on admission		
Guan 2020	368/808(45.5%)	137/167(82.0%)
Zhang 2020 B	68/78(87.2%)	53/57(93.0%)
Xu 2020 B(Bilateral upper lobes)	15(53.6%)	12(92.3%)
Xu 2020 B(Bilateral lower lobes)	12(42.9%)	13(100.0%)
Liu 2020 C	31(63.3%)	24(100%)
Li 2020 B	54(93.1%)	25(100%)
Tang 2020	58/62(93.5%)	12(92.3%)
Zheng 2020	63(48.1%)	26(86.7%)
Zhao 2020	69(79.3)	14(100)
Feng 2020	266/327(81.3%)	107/115(93%)
Li 2020 C	7(31.8%)	27(100%)

Local patchy shadowing of chest CT on admission		
Guan 2020	317/808(39.2%)	92/167(55.1%)
Zhang 2020 B	9/78(11.5%)	4/57(7%)
Zheng 2020	94(71.8%)	19(63.3%)
Number of lobs involved of chest CT on admission		
≤ 3: Xu 2020 B	11(39.3%)	1(7.7%)
4-5: Xu 2020 B	17(60.7%)	12(92.3%)
Li 2020 B	5(3-5)	5(5-5)
Feng 2020	5(3-5)	Severe: 5(5-5), n=54; Critical: 5(5-5), n=61
Xiang 2020	2.5±1.4	3.4±1.8
Ground glass opacity of chest CT on admission		
Guan 2020	449/808(55.6%)	101/167(60.5%)
Xu 2020 B	21(75.0%)	9(69.2%)
Liu 2020 C(Unique)	12(24.5%)	3(12.5%)
Liu 2020 C(Multiple)	31(63.3%)	19(79.2%)
Li 2020 B	56(96.6%)	25(100%)
Tang 2020	61/62(98.4%)	13(100%)
Zheng 2020	62(47.3%)	20(66.7%)
Zhao 2020	73(83.9%)	14(100%)
Feng 2020	311/327(95.1%)	114/115(99.1%)
Interstitial abnormalities of chest CT on admission		
Guan 2020	99/808(12.3%)	44/167(26.3%)
Zheng 2020	1(0.8%)	1(3.3%)
No abnormality of chest CT on admission		
Guan 2020	157/877(17.9%)	5/173(2.9%)
Zhang 2020 B	1/78(1.3%)	0
Liu 2020 C	3(6.1%)	0
Zhao 2020	8(9.2%)	0
Paving Stone Sign		
Liu 2020 C	15(30.6%)	13(54.2%)
Li 2020 B	16(27.6%)	14(56%)

Consolidation		
Liu 2020 C	0	8(33.3%)
Li 2020 B	31(53.4%)	22(88%)
Tang 2020	30(48.4%)	4(30.8%)
Zhao 2020	36(41.4%)	8(57.1%)
Feng 2020	68/327(20.8%)	19/115(16.5%)
Xu 2020 B	6(21.4)	9(69.2)
Bronchial Wall Thickening		
Liu 2020 C	2(4.1%)	17(70.8%)
Li 2020 B	3(5.2%)	16(64%)
Zhao 2020	22(25.3%)	6(42.8%)
Intrathoracic lymph node enlargement		
Xu 2020 B(Mediastinal nodes)	1(3.6)	0
Zhao 2020	0	1(7.1)
Tang 2020(Mediastinal nodes)	5(8.1%)	3(23.3%)
Li 2020 B	0	7(28%)
Pleural Effusion		
Liu 2020 C	0	3(12.5%)
Li 2020 B	0	7(28%)
Tang 2020	1/62(1.6%)	2(15.4%)
Feng 2020	10/327(3.1%)	15/115(13%)
Xu 2020 B	2(7.1%)	2(15.4%)
Zhao 2020	9(10.3%)	5(35.7%)
Interlobular septa thickening		
Xu 2020 B	21(75.0%)	9(69.2%)
Tang 2020	27(43.5%)	9(69.2%)
Air bronchogram		
Xu 2020 B	15(53.6)	7(53.8)
Tang 2020	17(27.4)	6(46.2)
Upper lobes involvement		
Xu 2020 B	15(53.6)	12(92.3)

Zhao 2020	6(6.9)	0
Tang 2020	47(75.8)	12(92.3)
Li 2020 B	50(86.2%)	24(96%)
Lower lobes involvement(CT)		
Xu 2020 B	12(42.9)	13(100.0)
Zhao 2020	48(55.2)	7(50)
Tang 2020	61(98.4)	12(92.3)
Li 2020 B	55(94.8%)	25(100%)
Main laboratory findings		
White blood cell count, × 10⁹/L		
Guan 2020	4.9(3.8–6.0)	3.7(3.0–6.2)
Mao 2020 A	4.5(1.8-14.0)	5.4(0.1-20.4)
Zhang 2020 B	4.5(3.5-5.9)	5.3(4.0-9.0)
Qian 2020	4.97(4.02-5.65)	5.23(4.74-6.8)
Wan 2020	5.5(4.0-8.0)	5.2(4.9-6.9)
Li 2020 B	5.27(4.2-6.3)	5.5(4.1-7.7)
Zheng 2020	4.17(3.33-5.24)	4.76(3.18-5.74)
Lo 2020	4.51(1.18)	5.57(1.99)
Feng 2020	5.15(4.17-6.54)	Severe: 5.42(3.69-8.17); Critical: 7.19(4.61-11.19)
Bin 2020	4.94±1.49	4.62±1.77
Li 2020 C, M(QR)	5.21(2.54)	5.74(5.17)
Xiang 2020	4.61±1.88	9.56±6.01
White blood cell count > 10 × 10⁹/L		
Guan 2020	39/811(4.8%)	19/167(11.4%)
Zhang 2020 B(> 9.5 × 10⁹/L)	4/82(4.9%)	13/56(23.2%)
Li 2020 A(> 9.5 × 10⁹/L)	9(56.3%)	4(44.5%)
Wan 2020(> 9.5 × 10⁹/L)	6(7%)	3(7.5%)
Li 2020 B(Increased)	5(8.6%)	4(16%)
Zheng 2020	3(2.3%)	0
Feng 2020	23/351(6.6%)	26(21%)
White blood cell count < 4× 10⁹/L		

Guan 2020	228/811(28.1%)	102/167(61.1%)
Zhang 2020 B(<3.5× 10⁹/L)	18/82(22.0%)	9/56(16.1%)
Li 2020 A	5(31.3%)	1(11.1%)
Wan 2020(<3.5× 10⁹/L)	24(25%)	4(10%)
Li 2020 B(Decreased)	6(10.3%)	4(16%)
Zheng 2020	57(43.5%)	9(30%)
Feng 2020	67/351(19.1%)	24/124(19.4%)
Neutrophil count, × 10⁹/L		
Mao 2020 A	2.6(0.7-11.8)	3.8(0.0-18.7)
Qian 2020	2.8(2.18-3.49)	3.32(3-5.82)
Wan 2020	3.6(3.0-3.9)	4.1(3.1-5.7)
Li 2020 B	3.5(2.64-4.46)	4.36(2.87-6.48)
Lo 2020	2.49(0.9)	3.82(1.81)
Feng 2020	3.39(2.5-4.64)	Severe: 3.6(2.59-5.99); Critical: 5.99(3.47-9.55)
Li 2020 C(Percentage), M(QR)	68.7(15.1%)	83.1(8%)
Xiang 2020	2.96±1.41	7.76±4.61
Eosinophils, × 10⁹/L		
Zhang 2020 B	0.02(0.008-0.05)	0.01(0.0-0.06)
Xiang 2020	0.02±0.07	0.70±2.08
Eosinophils <0.02 × 10⁹/L		
Zhang 2020 B	39/82(47.6%)	34/56(60.7%)
Eosinophils percentage, %		
Zhang 2020 B	0.5(0.08-1.0)	0.2(0.0-0.8)
Qian 2020	0.02(0.01-0.06)	0.01(0-0.01)
Basophil		
Qian 2020	0.01(0.01-0.02)	0(0-0.01)
Lymphocyte count, × 10⁹/L		
Guan 2020	1.0(0.8-1.4)	0.8(0.6-1.0)
Mao 2020 A	1.3(0.4-2.6)	0.9(0.1-2.6)
Zhang 2020 B	0.8(0.6-1.2)	0.7(0.5-1.0)
Qian 2020	1.4(1.05-1.75)	0.9(0.7-1.3)

Wan 2020	1.2(0.8-1.6)	0.8(0.6-1.0)
Li 2020 B	1.23(0.93-1.42)	0.7(0.44-0.95)
Zheng 2020	1.12(0.84, 1.45)	0.85(0.69, 1.06)
Lo 2020	1.4(0.54)	1.18(0.49)
Feng 2020	1.13(0.79-1.53)	Severe: 0.78(0.52-1.08); Critical: 0.82(0.49-1.08)
Bin 2020	1.25±0.43	0.83±0.32
Li 2020 C, M(QR)	1.17(0.31)	0.59(0.24)
Xiang 2020	1.26±0.69	0.72±0.66
Lymphocyte percentage, %		
Zhang 2020 B	20.0(12.5-28.4)	12.7(7.7-22.0)
Lymphocyte count < 1.5× 10⁹/L		
Guan 2020	584/736(79.3%)	147/154(95.5%)
Zhang 2020 B(< 1.1× 10⁹/L)	58/82(70.7%)	46/56(82.1%)
Xu 2020 B(Decreased)	8(16%)	6(12%)
Li 2020 A(< 1.1× 10⁹/L)	14(87.5%)	8(88.9%)
Wan 2020	36(38%)	32(80%)
Li 2020 B(Decreased)	22(37.9%)	22(88%)
Zheng 2020(< 0.8× 10⁹/L)	29(22.1%)	13(43.3%)
Feng 2020(< 1× 10⁹/L)	136(38.6%)	89(71.8%)
Mononuclear leucocyte count, ×10⁹/L		
Qian 2020	0.4(0.3-0.59)	0.35(0.3-0.7)
Li 2020 B	0.42(0.29-0.53)	0.34(0.15-0.51)
Li 2020 B(Increased)	10(17.2%)	2(8%)
Li 2020 B(Decreased)	0	2(8%)
Xiang 2020	0.35±0.14	0.37±0.25
Red blood cell		
Qian 2020	4.49(4.17-4.81)	4.26(3.8-4.82)
Xiang 2020	4.56±0.55	4.55±0.41
Hemoglobin, g/L		
Guan 2020	135.0(120.0–148.0)	128.0(111.8–141.0)
Qian 2020	135(126-147)	130(118-142)

Wan 2020	134(124-147)	130(120-143)
Feng 2020	133(121-144)	Severe: 132(123-144); Critical: 131(118-143)
Xiang 2020	143.0±19.3	144.8±12.6
Hemoglobin < 110 g/L		
Zheng 2020	11(8.4%)	2(6.7%)
Oxyhemoglobin saturation, %		
Li 2020 B	97(96-98)	95.1(92.9-97.45)
Li 2020 B(Decreased)	5(8.6%)	11(44%)
Platelet count, × 10⁹/L		
Guan 2020	172.0(139.0–212.0)	137.5(99.0–179.5)
Mao 2020 A	219.0(42.0 - 583.0)	204.5(18.0 - 576.0)
Qian 2020	198(144-248)	152(127-208)
Wan 2020	170(136-234)	147(118-213)
Zheng 2020	171(137,221)	160(133,214)
Feng 2020	185(146-238)	Severe: 184(138-216); Critical: 181(135-246)
Li 2020 C, M(QR)	172(81)	153(173)
Xiang 2020	161.3±67.7	175.4±57.9
Platelet count < 150× 10⁹/L		
Guan 2020	225/713(31.6%)	90/156(57.7%)
Wan 2020(< 125× 10⁹/L)	11(11.6%)	12(30%)
Zheng 2020(< 100× 10⁹/L)	8(6.1%)	3(10%)
Prothrombin time, s		
Wan 2020	10.8(10.4-11.3)	11.3(10.7-11.8)
Li 2020 C, QR	12.8(2)	11.5(1.6)
Xiang 2020	12.47±0.66	14.02±2.98
Activated partial thromboplastin time,s		
Wan 2020	26.6(24.5-28.8)	29.7(226.2-39.4)
Li 2020 C, M(QR)	29.6(5.3)	28.1(6.1)
Xiang 2020	30.86±3.80	40.57±30.04
Thrombocytocrit		
Qian 2020	0.21(0.16-0.25)	0.16(0.13-0.21)

Fibrinogen		
Qian 2020	3.36(2.64-4.08)	3.8(3.71-4.15)
Xiang 2020	3.71±2.16	4.38±1.51
Feng 2020	4.31(3.55-5.33)	Severe: 4.78(4.33-5.74); Critical: 4.71(3.89-5.74)
Albumin, g/L		
Liu 2020 B	39.70(36.50-46.10)	35.75(28.68-42.00)
Qian 2020	40.2(38-42.4)	38.55(36.33-39.25)
Wan 2020	49.9(37.4-43.6)	36(33-38.5)
Feng 2020	39.14(35.15-42.7)	Severe: 35.93(32.05-39.56); Critical: 32.25(27.88-34.35)
Li 2020 C, M(QR)	41.7(3.4)	30.8(5.4)
Xiang 2020	44.28±4.46	37.23±3.30
D-dimer, mg/L		
Mao 2020 A	0.4(0.2-8.7)	0.9(0.1-20.0)
Zhang 2020 B	0.2(0.1-0.3)	0.4(0.2-2.4)
Qian 2020	300(106-400)	450(160-485)
Wan 2020	0.3(0.2-0.5)	0.6(0.4-1.1)
Feng 2020	0.51(0.32-1.08)	Severe: 0.89(0.44-2.33); Critical: 1.11(0.51-4)
Li 2020 C, M(QR)	0.25(0.09)	0.98(3.35)
Xiang 2020	0.53±1.34	11.11±29.69
D-dimer > 0.5mg/L		
Guan 2020	195/451(43.2%)	65/109(59.6%)
Zhang 2020 B(> 0.243mg/L)	12/43(27.9%)	23/38(60.5%)
Wang 2020 C(Augmented)	12(28.6%)	32(59.3%)
Alanine aminotransferase, U/L		
Mao 2020 A	23.0(6.0-261.0)	32.5(5.0-1933.0)
Liu 2020 B	22.75(16.31-37.25)	60.25(40.88-68.90)
Qian 2020	18(13-29)	19.9(14-26)
Wan 2020	21.7(14.8-36.9)	26.6(14.5-33.3)
Zheng 2020A	19.3(14.6-17.8)	23.9(17.6, 35.3)
Feng 2020	23(15-38)	Severe: 32(21-47); Critical: 35(25-53)
Li 2020 C, M(QR)	27(34)	29(19)

Xiang 2020	20.7 ± 11.8	32.0 ± 11.2
Alanine aminotransferase > 40 U/L		
Guan 2020	120/606(19.8%)	38/135(28.1%)
Zheng 2020	8(6.1%)	5(16.7%)
Aspartate aminotransferase, U/L		
Mao 2020 A	23.0(9.0-244.0)	34.0(8.0-8191.0)
Liu 2020 B	23.63(18.71-26.50)	37.00(20.88-64.45)
Qian 2020	21(17-29)	27(23.75-27)
Wan 2020	22.4(16.9-30.5)	33.6(25.7-44.2)
Zheng 2020	23.4(19.0-28.8)	31.6(25.9-49.36)
Lo 2020	19(8)	24(9)
Feng 2020	25(19-34)	Severe: 34(26-53); Critical: 39(30-54)
Li 2020 C, M(QR)	23(11)	29(11)
Xiang 2020	25.1 ± 10.3	38.1 ± 15.7
Aspartate aminotransferase > 40 U/L		
Guan 2020	112/615(18.2%)	56/142(39.4%)
Wan 2020	15(16%)	15(37.5%)
Zheng 2020	10(7.6%)	12(40%)
Total bilirubin, mmol/L		
Liu 2020 B	15.95(11.34-20.83)	20.50(11.28-25.00)
Zheng 2020	10.7(8.18-15.3)	12.7(9.2-16.9)
Feng 2020	9.5(7.3-13.3)	Severe: 11.9(8.9-15.6); Critical: 12.2(8.6-16.7)
Xiang 2020	7.50 ± 3.35	11.48 ± 3.97
Wan 2020	8.6(5.6-14)	9.8(7.8-15.6)
Total bilirubin > 17.1 mmol/L		
Guan 2020	59/594(9.9%)	17/128(13.3%)
Zheng 2020	6(4.6%)	3(10%)
Potassium, mmol/L		
Guan 2020	3.9(3.6-4.2)	3.8(3.5-4.1)
Qian 2020	4.09(3.72-4.27)	3.82(3.76-3.89)
Wan 2020	4(3.7-4.5)	3.8(3.5-4.3)

Feng 2020	3.9(3.6-4.1)	Severe: 4(3.5-4.2); Critical: 4(3.7-4.6)
Xiang 2020	3.80±0.52	3.92±0.68
Sodium, mmol/L		
Guan 2020	138.4(136.6–140.4)	138.0(136.0–140.0)
Qian 2020	139.6(137.6-142)	137.85(135.3-139.38)
Wan 2020	139(137.2-141)	136.5(133-138)
Feng 2020	139(137-141)	Severe: 140(137-141); Critical: 140(137-142)
Xiang 2020	136.8±2.9	134.5±5.0
Qian 2020	139.6(137.6-142)	137.85(135.3-139.38)
Serum creatinine, µmol/L		
Mao 2020 A	65.6(39.4-229.1)	71.6(35.9-9435.0)
Qian 2020	66(57-76)	81.5(70.75-90.5)
Wan 2020	66(55-79)	63.5(51.5-74.3)
Zheng 2020	48.3(38.8, 57.9)	47.5(39.2, 64.2)
Lo 2020	66(15)	58(16)
Feng 2020	65.46(52.96-76.66)	Severe: 70.9(54.67-84.1); Critical: 67.95(55.23-81.28)
Li 2020 C, M(QR)	66.5(21.7)	69(26.5)
Xiang 2020	68.7±25.1	69.6±16.6
Serum creatinine ≥133 µmol/L		
Guan 2020	6/614(1.0%)	6/138(4.3%)
Wan 2020(> 97 µmol/L)	3(3%)	3(7.5%)
Zheng 2020(> 87 µmol/L)	1(0.8%)	1(3.3%)
Serum amyloid A, mg/L		
Zhang 2020 B	91.5(24.9-163.2)	108.4(54.1-161.6)
Xiang 2020	86.76±75.58	191.90±96.15
Serum amyloid A> 10 mg/L		
Zhang 2020 B	29/34(85.3%)	17/17(100.0%)
Creatine kinase, U/L		
Mao 2020 A	59.0(19.0- 1260.0)	83.0(8.8- 12216.0)

Zhang 2020 B	83.0(56.0-112.0)	66.0(38.5-144.0)
Wan 2020	57(36.5-86.5)	82(56.3-146.2)
Zheng 2020	68.7(43.2-111.3)	100.3(61.3-398.6)
Feng 2020	80(55-138)	Severe: 98(57-154); Critical: 93(52-246)
Xiang 2020	129.2±138.2	182.7±134.1
Creatine kinase > 200 U/L		
Guan 2020	67/536(12.5%)	23/121(19.0%)
Zhang 2020 B	1/35(2.8%)	3/25(12.0%)
Wan 2020	3(3%)	7(17.5%)
Zheng 2020(> 190U/L)	8(6.1%)	9(30%)
CK-MB, μL		
Feng 2020	12.75(10.07-15.95)	Severe: 14.11(11.31-19.25); Critical: 15.5(11.75-23)
Lactate dehydrogenase, U/L		
Mao 2020 A	215.0(2.5-908.0)	302.0(2.2-880.0)
Wan 2020	212(179.5-259)	309(253.8-408.3)
Zheng 2020	162.0(133.7, 208.5)	226.2(193.5, 315.1) -
Lo 2020	183(61)	238(52)
Feng 2020	236(192-314)	Severe: 307(228-401); Critical: 378(275-523)
Li 2020 C, M(QR)	231(54)	368(55)
Xiang 2020	237.5±72.6	467.3±144.3
Lactate dehydrogenase ≥ 250 U/L		
Guan 2020	205/551(37.2%)	72/124(58.1%)
Li 2020 A(Augmented)	8(50%)	6(66.7%)
Wan 2020(> 250 U/L)	28(29%)	30(75%)
Zheng 2020(> 225 U/L)	23(17.6%)	15(50%)
Procalcitonin, ng/mL		
Zhang 2020 B	0.05(0.03-0.1)	0.1(0.06-0.3)
Qian 2020	0.03(0-0.04)	0(0)
Wan 2020	0.04(0.03-0.06)	0.11(0.08-0.16)
Li 2020 B	0.038(0.028-0.068)	0.086(0.054-0.215)
Feng 2020	0.04(0.02-0.06)	Severe: 0.06(0.02-0.13); Critical: 0.07(0-0.18)

Li 2020 C, M(QR)	0.02(0.02)	0.03(0.03)
Xiang 2020	0.04±0.03	0.16±0.15
Procalcitonin ≥0.5 ng/mL		
Guan 2020	19/516(3.7%)	16/117(13.7%)
Zhang 2020 B(>0.1 ng/mL)	16/68(23.5%)	25/50(50.0%)
Wan 2020	0	1(2.5%)
Li 2020 B(Augmented)	23(39.7%)	21(84%)
Blood urea nitrogen, mmol/L		
Mao 2020 A	3.8(1.6-13.7)	4.6(1.5-48.1)
Li 2020 C, M(QR)	4.7(1.5)	4.8(2.1)
Urea, mmol/L		
Qian 2020	3.83(3.25-4.4)	5.19(4.66-6.14)
C-reactive protein, mg/L		
Mao 2020 A	9.4(0.4-126.0)	37.1(0.1-212.0)
Zhang 2020 B	28.7(9.5-52.1)	47.6(20.6-87.1)
Qian 2020	5.98(1.4-11.3)	30.63(12.5-103.4)
Wan 2020	7.7(1.9-31.1)	91(52.7-136.3)
Li 2020 B	9.59(2.07-29.89)	89.2(47.88-134.64)
Zheng 2020	15.4(5.8-24.9)	52.2(28.8-75.1)
Lo 2020	1.65(3.16)	2.63(3.12)
Xiang 2020	16.05±20.26	79.86±56.87
C-reactive protein ≥ 10 mg/L		
Guan 2020	371/658(56.4%)	110/135(81.5%)
Zhang 2020 B(>3mg/L)	72/81(88.9%)	53/55(96.4)
Xu 2020 B(Decreased)	18(36%)	8(16%)
Li 2020 A(Augmented)	9(56.3%)	7(77.8%)
Li 2020 B(Augmented)	27(46.6%)	23(92%)
Zheng 2020(> 8mg/L)	91(69.5%)	30(100%)
Others		
ESR, mm/h		
Li 2020 A(Augmented)	3(18.8%)	5(55.6%)

Feng 2020	48(27-83)	Severe: 45(33-79); Critical: 58(39-72)
Xiang 2020	41.23±23.24	75.25±24.45
BNP, pg/ml		
Feng 2020	34.53(21.15-67.1)	Severe: 52.5(16.93-113.3); Critical: 49.9(34.45-120.4)
Li 2020 A(AIncreased)	1(6.3%)	2(22.3%)
Urea, mmol/L		
Feng 2020	4.6(3.6-5.59)	Severe: 4.8(3.96-5.84); Critical: 5.65(4.3-7.73)
Xiang 2020	4.19±1.34	5.56±2.15
Ca2+, mmol/L		
Feng 2020	2.05(1.98-2.16)	Severe: 2.03(1.89-2.07); Critical: 1.95(1.87-2.06)
Qian 2020	2.17(2.07-2.25)	2.01(1.86-2.01)
Xiang 2020	2.0±0.1	1.8±0.1
Cl-, mmol/L		
Qian 2020	103.4(101.28-105.23)	101.4(99.28-104.5)
Xiang 2020	97.3±17.0	98.7±5.9
Direct bilirubin, µmol/L		
Feng 2020	3.9(3-5.5)	Severe: 4.5(3.4-6.7); Critical: 4.1(3.1-5.5)
Xiang 2020	2.48±0.98	4.42±1.91
Others		
Li 2020 A(Ferritin, Increased)	5(31.3%)	4(44.5%)
Li 2020 A(cTnI, Increased)	0	2(22.3%)
Li 2020 A(Transaminase, Increased)	8(50%)	5(55.6%)
Li 2020 A(Renal function damage)	1(6.3%)	2(22.3%)
Li 2020 A(Electrolyte disturbance)	7(43.8%)	7(77.8%)
Feng 2020(eGFR - ml/min/1.73m²)	108(92-128)	Severe: 102(89-118); Critical: 96(76-120)
Feng 2020(Methemoglobin, ng/ml)	11.7(3.65-40.2)	Severe: 28.04(10.07-51.5); Critical: 52.05(29.8-107.63)
Feng 2020(Troponin increased)	59/296(19.9%)	27/88(30.7%)
Feng 2020(Lactic acid, mmol/L)	2.73(2.22-3.22)	Severe: 3.09(2.37-3.62); Critical: 2.5(2.15-3.34)
Wang 2020 C(pH > 7.45)	17(40.5%)	30(55.6%)
Wang 2020 C(Partial pressure of oxygen < 80mmHg)	4(9.5%)	43(79.6%)

Li 2020 C, M(QR)(IL-6, ng/L)	17.9(25.2)	84(148)
Xiang 2020(Hematocrit, L/L)	0.41±0.04	0.41±0.03
Xiang 2020(Globulin, g/L)	26.95±3.35	31.25±7.29
Xiang 2020(Alkaline phosphatase, U/L)	15.7±15.7	80.1±40.7
Xiang 2020(Uric acid, umol/L)	254.0±74.9	240.2±83.9
Xiang 2020(Triglyceride, mmol/L)	1.17±1.04	1.01±0.48
Xiang 2020(Total cholesterol, mmol/L)	3.72±0.76	3.57±0.64
Xiang 2020(High density lipoprotein, mmol/L)	1.08±0.31	0.95±0.29
Xiang 2020(Low density lipoprotein, mmol/L)	2.36±0.73	2.30±0.64
Xiang 2020(Amylase, U/L)	61.6±21.8	112.0±105.1
Zheng 2020(oxygenation index)	373(345,400)	259(247,278)
Treatment		
Oxygen therapy		
Guan 2020	331(35.7%)	123(71.1%)
Wan 2020	58(61%)	32(80%)
Feng 2020(Nasal cannula or no oxygen therapy)	352(100%)	16(12.9%)
Feng 2020(High-flow nasal cannula)	0	31(25%)
Invasive mechanical ventilation		
Guan 2020	0	25(14.5%)
Wan 2020	0	1(2.5%)
Feng 2020	0	39(31.5%)
Non-invasive mechanical ventilation		
Guan 2020	0	56(32.4%)
Wan 2020(Non-invasive ventilation or high-flow nasal cannula)	7(7.4%)	27(67.5%)
Feng 2020	0	34(27.4%)
CRRT		
Guan 2020	0	9(5.2%)
Wan 2020	1(1%)	4(10%)
ECMO		
Guan 2020	0	5(2.9%)
Wan 2020	0	0

Feng 2020	0	4(3.2%)
Antibiotic treatment		
Guan 2020	498(53.8%)	139(80.3%)
Wan 2020	24(25%)	35(87.5%)
Feng 2020	209(59.4%)	110(88.7%)
Antiviral treatment		
Guan 2020	313(33.8%)	80(46.2%)
Wan 2020	95(100%)	40(100%)
Feng 2020	199(56.5%)	87(70.2%)
Bin 2020	23(80%)	8(88.9%)
Corticosteroid therapy		
Guan 2020	127(13.7%)	77(44.5%)
Wan 2020	15(15.8%)	21(52.5%)
Feng 2020	47(13.4%)	80(64.5%)
Intravenous immunoglobulin therapy		
Guan 2020	86(9.3%)	58(33.5%)
Antifungal treatment		
Guan 2020	18(1.9%)	13(7.5%)
Feng 2020	2(0.6%)	6(4.8%)
Traditional Chinese Medicine		
Wan 2020	87(91.5%)	37(92.5%)
Bin 2020	34(75.6%)	8(88.9%)

Continuous data are median(IQR) or mean(SD); Categorical data are n(N%). NR: not reported. ICU: intensive unit care; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; ARDS, acute respiratory distress syndrome; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation.

Table S39 Summary table of univariable risk factors significantly ($p < 0.05$) associated with severe condition/ICU admission

Epidemiological characteristics and comorbidities	
Subject	Numbers
Male	(4:0)/14
Middle and old age	(6:0)/2
Former smoker	(1:0)/2
Never smoking	(0:2)/0
Former epicenter exposure	(0:1)/7
Medical staff	(0:1)/2
Any comorbidity	(6:0)/3
Hypertension	(7:0)/4
Cardiovascular disease	(2:0)/5
Cerebrovascular disease	(1:0)/2
Cardio-cerebrovascular disease	(1:0)/2
Diabetes	(5:0)/6
COPD	(5:0)/2
Malignancy	(1:0)/3
Immunosuppression	(1:0)/1
Signs and symptoms on admission	
Fever	(1:1)/15
Highest temperature $> 39^{\circ}\text{C}$	(2:0)/2
Cough	(4:2)/10
Sputum production	(5:0)/4
Dyspnea	(10:0)/3
Respiratory rate $> 24/\text{min}$	(1:0)/
Fatigue	(2:0)/9
Myalgia	(2:0)/7
Hemoptysis	(1:0)/3
Nausea	(0:1)/5

Sore throat	(0:1)/6
Diarrhea	(2:0)/7
Anorexia	(2:1)/2
Rash	(1:0)/0
Conjunctival congestion	(1:0)/0
Impaired consciousness	(1:0)/0
Chest pain	(1:0)/3
Radiologic and laboratory findings on admission	
Bilateral involvement	(7:0)/4
Local patchy opacity	(1:0)/2
Interstitial abnormalities	(1:0)/1
≥4 lobes involved	(1:0)/0
Pleural effusion	(3:0)/3
Consolidation	(3:0)/3
Bronchial Wall Thickening	(2:0)/1
Interlobular septa thickening	(2:0)/0
Paving Stone Sign	(1:0)/1
Intrathoracic lymph node enlargement	(1:0)/3
Upper lobes involvement	(1:0)/3
Lower lobes involvement	(1:0)/3
No abnormality	(0:1)/3
WBC count > $10 \times 10^9/L$	(2:0)/2
WBC count > $9.5 \times 10^9/L$	(1:0)/2
WBC count < $4 \times 10^9/L$	(1:0)/4
WBC count < $3.5 \times 10^9/L$	(1:0)/1
Lymphocyte count < $1.5 \times 10^9/L$	(4:0)/2
Lymphocyte count < $0.8 \times 10^9/L$	(1:0)/0
Platelet count < $150 \times 10^9/L$	(1:0)/0
Platelet count < $125 \times 10^9/L$	(1:0)/0
Oxyhemoglobin saturation, % (Decreased)	(1:0)/0

PO ₂ < 80mmHg	(1:0)/0
ALT >40U/L	(1:0)/1
AST >40U/L	(3:0)/0
D-dimer > 0.5mg/L	(2:0)/0
D-dimer > 0.243mg/L	(1:0)/0
Total bilirubin > 17.1 mmol/L	(1:0)/1
Serum creatinine ≥ 133 µmol/L	(1:0)/0
Creatine kinase > 200 U/L	(2:0)/1
Lactate dehydrogenase ≥ 250 U/L	(2:0)/1
Lactate dehydrogenase > 225 U/L	(1:0)/0
Procalcitonin ≥ 0.5 ng/mL	(2:0)/0
Procalcitonin ≥ 0.1 ng/mL	(1:0)/0
C-reactive protein ≥ 10 mg/L	(2:0)/2

Univariable risk factors associated with ICU admission significantly (p < 0.05)

Subject	Numbers
Medical staff	(1:0)/0
Hospitalized patients	(1:0)/0
Any comorbidity	(1:0)/1
Hypertension	(1:0)/1
Cerebrovascular disease	(1:0)/0
Diabetes	(1:0)/1
Cough	(1:0)/1
Dyspnea	(2:0)/1
Sore throat	(1:0)/0
Dizziness	(1:0)/0
Respiratory rate >24/min	(1:0)/0
WBC count > 10 × 10 ⁹ /L	(1:0)/0
Hypersensitive troponin I > 28 pg/mL (99th percentile)	(1:0)/0
Procalcitonin ≥ 0.5 ng/mL	(2:0)/0

In "Numbers (a:b)/c" column, *a* is number of studies where the subject was estimated as risk factor significantly (p<0.05), *b* is number where the subject was estimated as

not risk factor (protective factor) significantly ($p<0.05$), and c is number of the other studies with no significant connection either ($p>0.05$). COPD: Chronic obstructive pulmonary disease; WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Table S40 Univariable risk factors significantly ($p < 0.05$) associated with severe condition

Study	OR	95% CI	P value
Epidemiological characteristics and clinical outcomes			
Male			
Mao 2020 A	1.93	[1.11-3.37]	0.02
Feng 2020	1.61	[1.05-2.46]	0.03
Li 2020 C	3.43	[1.05-11.22]	0.042
Wang 2020 C	2.43	[1.06-5.57]	0.036
Age ≥ 50 , y			
Guan 2020	1.99	[1.41,2.79]	0.0001
Mao 2020 A	2.93	[1.63,5.27]	0.0003
Zhang 2020 B	3.07	[1.36,6.93]	0.007
≥ 45 , Tian 2020	3.95	[1.87,8.36]	0.0003
≥ 65 , Feng 2020	2.18	[1.39-2.41]	< 0.001
Wang 2020 C (> 60)	5.15	[2.11-12.53]	< 0.001
Former smoker			
Guan 2020	4.15	[1.72,10.00]	0.002
Never smoking			
Guan 2020	0.53	[0.35-0.80]	0.003
Li 2020 A	0.11	[0.02-0.83]	0.032
Former epicenter exposure			
Wan 2020	0.42	[0.20-0.89]	0.024
Medical staff			
Li 2020 A	0.10	[0.02-0.51]	0.006
Comorbidity			
Any comorbidity			
Guan 2020	2.38	[1.69-3.37]	< 0.00001
Mao 2020 A	1.89	[1.08-3.31]	0.03
Zhang 2020 B	3.31	[1.53-7.15]	0.002

Feng 2020	2.28	[1.50-3.46]	< 0.001
Li 2020 B	10.61	[2.93-38.40]	< 0.001
Wan 2020	12.44	[5.20-29.78]	< 0.001
Hypertension			
Guan 2020	2.01	[1.35-3.99]	0.0006
Mao 2020 A	3.22	[1.67-6.18]	0.0005
Feng 2020	1.89	[1.20-2.97]	0.006
Li 2020 C	8.84	[1.01-77.40]	0.049
Wang 2020 C	3.32	[1.43-7.70]	0.005
Xiang 2020	15.20	[2.19-105.42]	0.006
Zheng 2020	8.07	[3.04-21.37]	< 0.001
Cardiovascular disease			
Guan 2020	3.28	[1.48-7.29]	0.004
Feng 2020	2.50	[1.27-4.92]	0.008
Cerebrovascular disease			
Feng 2020	3.37	[1.27-8.93]	0.015
Cardio cerebrovascular disease			
Wan 2020	16.59	[1.93-142.84]	0.011
Diabetes			
Guan 2020	3.18	[1.95-5.19]	< 0.00001
Li 2020 B	47.43	[2.58-870.76]	0.009
Wan 2020	8.90	[2.27-34.99]	0.002
Wang 2020 C	3.26	[1.16-9.11]	0.025
Xiang 2020	27	[1.17-620.53]	0.039
COPD			
Guan 2020	5.51	[1.76-17.29]	0.003
Feng 2020	5.47	[2.24-13.39]	< 0.001
Li 2020 A	12	[1.07-134.11]	0.044
Li 2020 B	10.86	[1.15-102.77]	0.038
Wan 2020	23.55	[1.24-448.35]	0.036
Malignancy			

Feng 2020	4.15	[1.29-13.33]	0.017
Immunosuppression			
Feng 2020	7.35	[1.41-38.40]	0.018
Signs and symptoms on admission			
Fever			
Mao 2020 A	0.31	[0.17-0.55]	< 0.0001
Feng 2020	6.12	[2.17-17.23]	< 0.001
Highest temperature > 39°C during hospital admission			
Guan 2020	1.61	[1.00-2.59]	0.05
Zheng 2020	11.85	[1.56-90.12]	0.17
Cough			
Mao 2020 A	0.33	[0.19-0.58]	0.0001
Zhang 2020 B	2.75	[1.11,6.82]	0.03
Feng 2020 (Dry cough)	0.64	[0.44-0.93]	0.019
Li 2020 B	9.95	[1.24-79.55]	0.03
Wan 2020	2.93	[1.04-8.24]	0.042
Wang 2020 C	2.71	[1.07-6.84]	0.035
Sputum production			
Feng 2020	2.57	[1.67-3.96]	< 0.001
Li 2020 C	3.66	[1.05-12.79]	0.042
Li 2020 B	4.88	[1.51-15.79]	0.008
Wan 2020	3.82	[1.13-12.87]	0.031
Xiang 2020	9.87	[1.69-57.60]	0.011
Dyspnea			
Guan 2020	3.38	[2.37-4.83]	< 0.00001
Xu 2020 B (chest tightness or dyspnea)	35.53	[1.76,718.74]	0.02
Tian 2020	34.35	[9.40,125.50]	< 0.00001
Feng 2020	6.35	[3.94-10.23]	< 0.001
Lv 2020	36	[1.71-757.79]	0.021
Li 2020 B	10.89	[2.07-57.20]	0.005
Tang 2020	9.93	[1.90-51.72]	0.006

Tang 2020	8.58	[2.36-31.16]	0.001
Wan 2020	157.04	[9.12-2704.97]	< 0.001
Zheng 2020	3.58	[1.37-9.33]	0.009
Respiratory rate > 24/min			
Wan 2020	8.90	[2.27-34.99]	0.002
Fatigue			
Xu 2020 B	15	[2.49,90.23]	0.003
Li 2020 C	14	[3.18-61.60]	< 0.001
Myalgia			
Mao 2020 AA*	4.79	[1.80-12.71]	0.002
Wan 2020	2.53	[1.17-5.47]	0.018
Hemoptysis			
Guan 2020	3.63	[1.01-13.00]	0.05
Nausea			
Zhang 2020 B	0.32	[0.11,0.91]	0.03
Sore throat			
Wan 2020	0.04	[0.002-0.61]	0.021
Diarrhea			
Li 2020 C	226.11	[11.48-4454.26]	< 0.001
Wan 2020	8.67	[2.83-26.50]	< 0.001
Anorexia			
Mao 2020 A	0.53	[0.29-0.97]	0.04
Liu 2020 C	5.13	[1.70-15.43]	0.004
Wan 2020	35.99	[1.97-655.75]	0.016
Rash			
Guan 2020	27.01	[1.29-565.10]	0.03
Conjunctival congestion			
Guan 2020	4.36	[1.16,16.40]	0.03
Impaired consciousness			
Mao 2020 A	7.11	[1.96-25.76]	0.003
Chest pain			

Li 2020 B	10.86	[1.14-102.77]	0.038
Radiologic and laboratory and findings			
Bilateral involvement of chest CT on admission			
Guan 2020	5.46	[3.59,8.30]	< 0.0001
Xu 2020 B (Bilateral upper lobes)	17.60	[2.06,150.03]	0.009
Xu 2020 B (Bilateral lower lobes)	55.08	[3.02,1003.70]	0.007
Feng 2020	3.07	[1.42-6.63]	0.004
Li 2020 C	113.67	[6.07-2127.89]	0.002
Liu 2020 C	28.78	[1.65-501.60]	0.021
Zheng 2020	7.02	[2.32-21.23]	< 0.001
Local patchy shadowing of chest CT on admission			
Guan 2020	1.90	[1.36,2.66]	0.0002
Interstitial abnormalities of chest CT on admission			
Guan 2020	2.56	[1.71,3.83]	< 0.0001
Number of lobs involved of chest CT on admission			
4-5: Xu 2020 B	14.12	[1.66,119.11]	0.02
Pleural Effusion			
Feng 2020	4.76	[2.07-10.92]	< 0.001
Li 2020 B	47.43	[2.58-870.76]	0.009
Zhao 2020	4.81	[1.32-17.54]	0.017
Consolidation			
Liu 2020 C	51	[2.79-932.53]	0.008
Li 2020 B	6.39	[1.72-23.72]	0.006
Xu 2020 B	11.63	[2.68-50.40]	0.001
Bronchial Wall Thickening			
Liu 2020 C	57.07	[10.78-302.11]	< 0.001
Li 2020 B	32.59	[7.88-134.88]	< 0.001
Interlobular septa thickening			
Tang 2020	3.58	[1.00-12.79]	0.049
Xu 2020 B	0.15	[0.06-0.39]	< 0.001
Paving Stone Sign			

Li 2020 B	3.34	[1.26-8.88]	0.016
Intrathoracic lymph node enlargement			
Li 2020 B	47.43	[2.58-870.76]	0.009
Upper lobes involvement			
Xu 2020 B	17.60	[2.06-150.03]	0.009
Lower lobes involvement			
Xu 2020 B	55.08	[3.02-1003.70]	0.007
No radiologic abnormality of chest CT on admission			
Guan 2020	0.31	[0.15,0.62]	0.001
White blood cell count > 10 × 10 ⁹ /L			
Guan 2020	2.54	[1.43-4.52]	0.002
Zhang 2020 B (> 9.5 × 10 ⁹ /L)	5.90	[1.81,19.20]	0.003
Feng 2020	3.78	[2.07-6.93]	< 0.001
White blood cell count < 4× 10 ⁹ /L			
Guan 2020	4.01	[2.84-5.68]	< 0.00001
Wan 2020 (< 3.5× 10 ⁹ /L)	34.13	[10.44-111.54]	< 0.001
Lymphocyte count < 1.5× 10 ⁹ /L			
Guan 2020	5.47	[2.51-11.91]	< 0.0001
Feng 2020	4.04	[2.59-6.31]	< 0.001
Li 2020 B	8.67	[2.28-32.87]	0.002
Wan 2020	6.56	[2.72-15.78]	< 0.001
Zheng 2020 (< 0.8× 10 ⁹ /L)	2.69	[1.17-6.18]	0.02
Platelet count < 150× 10 ⁹ /L			
Guan 2020	2.96	[2.07-4.22]	< 0.00001
Wan 2020 (< 125×10 ⁹ /L)	3.27	[1.30-8.24]	0.012
Oxyhemoglobin saturation, %			
Li 2020 B (Decreased)	8.33	[2.48-27.93]	< 0.001
PO ₂ < 80mmHg			
Wang 2020 C	37.14	[10.91-126.39]	< 0.001
Alanine aminotransferase > 40 U/L			
Guan 2020	1.59	[1.04-2.43]	0.03

		Aspartate aminotransferase > 40 U/L	
Guan 2020	2.92	[1.97-4.34]	< 0.00001
Wan 2020	3.20	[1.37-7.45]	0.007
Zheng 2020	8.07	[3.04-21.37]	< 0.001
		D-dimer > 0.5mg/L	
Guan 2020	1.94	[1.27-2.97]	0.002
Zhang 2020 B (> 0.243mg/L)	3.96	[1.56,10.05]	0.004
Wang 2020 C (Increased)	3.64	[1.54-8.61]	0.003
		Total bilirubin > 17.1 mmol/L	
Guan 2020	1.39	[0.78-2.47]	0.26
		Serum creatinine ≥ 133 μmol/L	
Guan 2020	4.61	[1.46-14.51]	0.009
		Creatine kinase > 200 U/L	
Wan 2020	6.51	[1.59-26.64]	0.009
Zheng 2020	6.59	[2.29-19.00]	< 0.001
		Lactate dehydrogenase ≥ 250 U/L	
Guan 2020	2.34	[1.57-3.47]	< 0.0001
Wan 2020 (> 250U/L)	7.18	[3.10-16.64]	< 0.001
Zheng 2020 (> 225 U/L)	4.70	[2.02-10.94]	< 0.001
		Procalcitonin ≥ 0.5 ng/mL	
Guan 2020	4.14	[2.06-8.33]	< 0.0001
Zhang 2020 B (> 0.1 ng/mL)	3.25	[1.48,7.15]	0.003
Li 2020 B	7.99	[2.43-26.30]	< 0.001
		C-reactive protein ≥ 10 mg/L	
Guan 2020	3.55	[2.22-5.66]	< 0.00001
Li 2020 B	13.20	[2.85-61.24]	0.001

OR=odds ratio. COPD=chronic obstructive pulmonary disease.

Table S41 Epidemiological and clinical characteristics of the confirmed patients with ICU admission or not

	Non-ICU admission		ICU admission	
	Huang 2020 A	Wang 2020 A	Huang 2020 A	Wang 2020 A
Epidemiological characteristics				
Total	28/41 (68.3%)	102/138 (73.9%)	13/41 (31.7%)	36/138 (26.1%)
Male	19 (68%)	53 (52.0%)	11 (85%)	22 (61.1%)
Female	9 (32%)	49 (48.0%)	2 (15%)	14 (38.9%)
Age	Median (IQR)	49 (41-57.5)	51 (37-62)	66 (57-78)
Huanan seafood market exposure	18 (64%)	7 (6.9%)	9 (69%)	5 (13.9%)
Current smoker	3 (11%)	NR	0	NR
Time from onset of symptoms to first hospital admission	NR	6.0 (3.0-7.0)	NR	8.0 (4.5-10.0)
Medical staff	NR	39 (38.2%)	NR	1 (2.8%)
Hospitalized patients	NR	8 (7.8%)	NR	9 (25.0%)
Clinical outcomes				
Discharge	21 (75%)	38 (37.3%)	7 (54%)	9 (25%)
Staying in hospital	6 (21%)	74 (72.5%)	0 (transferred to the general wards) 1 (8%) (still in ICU)	10 (27.8%) (transferred to the general wards) 11 (30.6%) (still in ICU)
Death	1 (4%)	0	5 (38%)	6 (16.7%)
Comorbidity				
Any comorbidity	8 (29%)	38 (37.3%)	5 (38%)	26 (72.2%)
Hypertension	4 (14%)	22 (21.6%)	2 (15%)	21 (58.3%)
Diabetes	7 (25%)	6 (5.9%)	1 (8%)	8 (22.2%)
Cardiovascular disease	3 (11%)	11 (10.8%)	3 (23%)	9 (25.0%)
Cerebrovascular disease	NR	1 (1.0%)	NR	6 (16.7%)
COPD	0	1 (1.0%)	1 (8%)	3 (8.3%)
Malignancy	1 (4%)	6 (5.9%)	0	4 (11.1%)

Chronic liver disease	1 (4%)	4 (3.9%)	0	0
Chronic kidney disease	NR	2 (2.0%)	NR	2 (5.6%)
Immunodeficiency/HIV	NR	2 (2.0%)	NR	0
Signs and symptoms on admission				
Fever	27 (96%)	100 (98.0%)	13 (100%)	36 (100%)
Highest temperature >39°C	11 (39%)	NR	3 (23%)	NR
Highest temperature <37.5°C	1 (4%)	NR	0	NR
Cough	11 (39%) (dry cough mostly)	61 (59.8%) (dry cough)	11 (85%) (dry cough mostly)	21 (58.3%) (dry cough)
Sputum production	11 (39%)	29 (28.4%)	5 (38%)	8 (22.2%)
Dyspnea	10/27 (37%)	20 (19.6%)	12 (92%)	23 (63.9%)
Fatigue	11 (39%) (fatigue or myalgia)	67 (65.7%)	7 (54%) (fatigue or myalgia)	29 (80.6%)
Myalgia		36 (35.3%)		12 (33.3%)
Headache	3/25 (12%)	6 (5.9%)	0	3 (8.3%)
Hemoptysis	1/26 (4%)	NR	1 (8%)	NR
Diarrhea	1/25 (4%)	8 (7.8%)	0	6 (16.7%)
Sore throat	NR	12 (11.8%)	NR	12 (33.3%)
Nausea or vomiting	NR	Nausea: 10 (9.8%); Vomiting: 2 (2.0%)	NR	Nausea: 4 (11.1%), Vomiting: 3 (8.3%)
Dizziness	NR	5 (4.9%)	NR	8 (22.2%)
Anorexia	NR	31 (30.4%)	NR	24 (66.7%)
Abdominal pain	NR	0	NR	3 (8.3%)
Time from onset of symptoms to shortness of breath	NR	2.5 (0.0-7.3)	NR	6.5 (3.0-10.8)
Time from onset of symptoms to shortness of ARDS	NR	8.0 (6.3-11.3)	NR	8.0 (6.0-12.0)
Respiratory rate	4 (14%) > 24/min	20 (19-21)	8 (62%) > 24/min	20 (16-25)
Complications				
ARDS	1 (4%)	5 (4.9%)	11 (85%)	22 (61.1%)
Acute cardiac injury	1 (4%)	2 (2.0%)	4 (31%)	8 (22.2%)
Acute kidney injury	0	2 (2.0%)	3 (23%)	3 (8.3%)
Shock	0	1 (1.0%)	3 (23%)	11 (30.6%)

Arrhythmia	NR	7 (6.9%)	NR	16 (44.4%)
RNAemia	4 (14%)	NR	2 (15%)	NR
Secondary infection	0	NR	4 (31%)	NR
Radiologic findings on admission				
Bilateral involvement of chest	27 (96%)	102 (100%)	13 (100%)	36 (100%)
CT on admission				
Local patchy shadowing of chest	NR	0	NR	0
CT on admission				
Ground glass opacity of chest	NR (bilateral ground-glass opacities on chest CT scans for most patients)	102 (100%)	NR (bilateral ground-glass opacities on chest CT scans for most patients)	36 (100%)
CT on admission				
Laboratory and findings on admission				
White blood cell count, $\times 10^9$/L	5.7 (3.1–7.6)	4.3 (3.3–5.4)	11.3 (5.8–12.1)	6.6 (3.6–9.8)
White blood cell count $> 10 \times 10^9/L$	5/27 (19%)	NR	7 (54%)	NR
White blood cell count $< 4 \times 10^9/L$	9/27 (33%)	NR	1 (8%)	NR
Neutrophil count, $\times 10^9/L$	4.4 (2.0–6.1)	2.7 (1.9–3.9)	10.6 (5.0–11.8)	4.6 (2.6–7.9)
Monocyte count, $10^9/L$	NR	0.4 (0.3–0.5)	NR	0.4 (0.3–0.5)
Lymphocyte count, $\times 10^9/L$	1.0 (0.7–1.1)	0.9 (0.6–1.2)	0.4 (0.2–0.8)	0.8 (0.5–0.9)
	< 1 $\times 10^9/L$: 15 (54%)		< 1 $\times 10^9/L$: 11 (85%)	
Hemoglobin, g/L	130.5 (120.0–140.0)	NR	122.0 (111.0–128.0)	NR
Platelet count, $\times 10^9/L$	149.0 (131.0–263.0)	165 (125–188)	196.0 (165.0–263.0)	142 (119–202)
	< 100 $\times 10^9/L$: 1/27 (4%)		< 100 $\times 10^9/L$: 1 (8%)	
	$\geq 100 \times 10^9/L$: 26/27 (96%)		$\geq 100 \times 10^9/L$: 12 (92%)	
Prothrombin time, s	10.7 (9.8–12.1)	12.9 (12.3–13.4)	12.2 (11.2–13.4)	13.2 (12.3–14.5)
Activated partial thromboplastin time, s	27.7 (24.8–34.1)	31.7 (29.6–33.5)	26.2 (22.5–33.9)	30.4 (28.0–33.5)
D-dimer, mg/L	0.5 (0.3–0.8)	166 (101–285)	2.4 (0.6–14.4)	414 (191–1324)
Albumin, g/L	34.7 (30.2–36.5)	NR	27.9 (26.3–30.9)	NR
Alanine aminotransferase, U/L	27.0 (19.5–40.0)	23 (15–36)	49.0 (29.0–115.0)	35 (19–57)

Aspartate aminotransferase, U/L	34.0 (24.0–40.5)	29 (21-38)	44.0 (30.0–70.0)	52 (30-70)
	> 40 U/L: 7 (25%)		> 40 U/L: 8 (62%)	
	≤40 U/L: 21 (75%)		≤40 U/L: 5 (38%)	
Total bilirubin, mmol/L	10.8 (9.4–12.3)	9.3 (8.2-12.8)	14.0 (11.9–32.9)	11.5 (9.6-18.6)
Potassium, mmol/L	4.1 (3.8–4.6)	NR	4.6 (4.0–5.0)	NR
Sodium, mmol/L	139.0 (137.5–140.5)	NR	138.0 (137.0–139.0)	NR
Serum creatinine, µmol/L	73.3 (57.5–84.7)	71 (58-84)	79.0 (53.1–92.7)	80 (66-106)
	> 133 µmol/L: 2 (7%)		> 133 µmol/L: 2 (15%)	
Creatine kinase-MB, U/L	NR	13 (10-14)	NR	18 (12-35)
Creatine kinase, U/L	133.0 (61.0–189.0)	87 (54-121)	132.0 (82.0–493.0)	102 (62-252)
	> 185 U/L 7/27 (26%)		> 185 U/L: 6 (46%)	
	≤185 U/L 20/27 (74%)		≤185 U/L: 7 (54%)	
Lactate dehydrogenase, U/L	281.0 (233.0–357.0)	212 (171-291)	400.0 (323.0–578.0)	435 (302-596)
	> 245 U/L: 17/27 (63%)		> 245 U/L: 12 (92%)	
	≤ 245 U/L: 10/27 (37%)		≤ 245 U/L: 1 (8%)	
Hypersensitive troponin I, pg/mL	3.5 (0.7–5.4)	5.1 (2.1-9.8)	3.3 (3.0–163.0)	11.0 (5.6-26.4)
	> 28 pg/mL (99th percentile): 1 (4%)		> 28 pg/mL (99th percentile): 4 (31%)	
Procalcitonin, ng/mL	0.1 (0.1–0.1)	NR	0.1 (0.1–0.4)	NR
	≥0.5 ng/mL: 0/27	≥0.5 ng/mL: 22 (21.6%)	≥0.5 ng/mL: 3/12 (25%)	≥0.5 ng/mL: 27 (75.0%)
	≥0.1 to <0.5 ng/mL: 6/27 (22%)		≥0.1 to <0.5 ng/mL: 3/12 (25%)	
Blood urea nitrogen, mmol/L	NR	4.0 (3.1-5.1)	NR	5.9 (4.3-9.6)
		Treatment		
Oxygen therapy	26 (93%)	102 (100%)	1 (8%)	4 (11.11%)
Invasive mechanical ventilation	0	0	2 (15%)	17 (47.22%)
Non-invasive mechanical ventilation	2 (7%)	0	8 (62%)	15 (41.7%)
CRRT	0	0	3 (23%)	2 (5.56%)
ECMO	2 (7%)	0	2 (15%)	4 (11.1%)
Antibiotic treatment	28 (100%)	NA	13 (100%)	NA

Antiviral treatment	26 (93%)	90 (88.2%)	12 (92%)	34 (94.4%)
Corticosteroid therapy	3 (11%)	36 (35.3%)	6 (46%)	26 (72.2%)

Continuous data are median (IQR) or mean (SD); Categorical data are n (N%). NR: not reported. ICU: intensive unit care; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; ARDS, acute respiratory distress syndrome; CRPT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation.

Table S42 Univariable risk factors significantly ($p < 0.05$) associated with ICU admission

Study	OR	95% CI	P value
Epidemiological characteristics and clinical outcomes			
Medical staff			
Wang 2020 A	0.05	[0.01-0.35]	0.003
Hospitalized patients			
Wang 2020 A	3.92	[1.38-11.13]	0.01
Comorbidity			
Any comorbidity			
Wang 2020 A	4.38	[1.90-10.07]	0.0005
Hypertension			
Wang 2020 A	5.09	[2.26-11.48]	<0.0001
Cerebrovascular disease			
Wang 2020 A	3.74	[2.42-5.79]	<0.00001
Diabetes			
Wang 2020 A	4.57	[1.46-14.28]	0.0009
Signs and symptoms on admission			
Cough			
Huang 2020 A	8.50	[1.57-45.92]	0.01
Dyspnea			
Huang 2020 A	20.40	[2.30-181.26]	0.007
Wang 2020 A	7.25	[3.14-16.76]	<0.00001
Sore throat			
Wang 2020 A	3.75	[1.50-9.39]	0.005
Dizziness			
Wang 2020 A	5.54	[1.68-18.29]	0.005
Respiratory rate >24 breaths/ min			
Huang 2020 A	9.60	[2.06-44.74]	0.004
Radiologic and laboratory and findings			
White blood cell count > 10 × 10⁹/L			

Huang 2020 A	5.13	[1.19-22.11]	0.03
Hypersensitive troponin I > 28 pg/mL (99th percentile)			
Huang 2020 A	12.00	[1.18-121.81]	0.04
Procalcitonin ≥ 0.5 ng/mL			
Huang 2020 A	20.26	[0.96-429.41]	0.05
Wang 2020 A	8.93	[3.83-20.78]	<0.00001

OR=odds ratio.